Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 1of 129Clinical Study Protocol
Study Intervention Cotadutide
Study Code D5671C00006
Version 3.0
Date 15May 2023
A Phase II Randomized, Double -blind, Placebo -controlled , Proof -
of-Concept Study to Evaluate the Safety and Efficacy of 
Cotadutide in Participants with Non -cirrhotic Non -alcoholic 
Steatohepatitis with Fibrosis
Sponsor  Name: [CONTACT_271160]: [COMPANY_008] AB, 151 85 Södertälje, Sweden
Local Sponsor: [COMPANY_008] K.K., 3- 1, Ofuka -cho, Ki ta-ku, Osaka 530 -0011, Japan
Regulatory Agency Identifier  Number(s)
EudraCT: 2021 -005484-53
IND: 139975
Clinicaltrials.gov: [STUDY_ID_REMOVED]
This Clinical Study  Protocol  has been subject to a peer review according to [COMPANY_008] 
Standard procedures. The Clinical Study Protocol is publicly registered and the results are 
disclosed and/or published according to the [COMPANY_008] Global Policy on Bioethics and in 
compliance wi th prevailing laws and regulat ions.
Protocol N umber: D5671C00006
Amendment Number: 2
Study Intervention: Cotadutide, placebo
Clinical Study Protocol - 3.0 [COMPANY_008]
Cotadutide - D5671C00006 15 May 2023
CONFIDENTIAL AND PROPRIETARY 2 of 129Study Phase: Phase II
Short Title: A study to evaluate the safety and efficacy of cotadutide given by [CONTACT_601046]-cirrhotic non -alcoholic steatohepatitis with fibrosis 
Acronym :PROXYMO-ADVANCE 
Study Physician Name [CONTACT_9352] [CONTACT_601047]-ordinating investigator: 
Virginia Commonwealth University
Richmond, VA 23298[COMPANY_003][COMPANY_003][COMPANY_003]
Clinic al Study  Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 3of 129PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE
DOCUMENT HISTORY
Document Date
CSP version 2 07-Nov -2022
CSP version 1 28-Jan -2022
CSP version 3: 15 May 2023
This amendment i s consi dered to be substant ial based on the cri teria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council o f the European Unio n
and in the EU Clinical Trial Regulat ion Article 2, 2 (13) .
Overall Rat ionale for the Amendment:
Text revisio ns result ing from this amendment are incorporated in the body  of Protocol  
Amendment 2. This study  was designed to evaluate the safet y and efficacy o f cotaduti de given 
by [CONTACT_601048] -proven NASH wi th fibrosis stage F2 or F3. 
After careful considerat ion, the sponsor has decided to discont inue the development of 
cotaduti de(a daily injectable GLP -1/glucagon co -agonist) to focus efforts on other, more 
convenient treatments for patients with NASH . Rando mized participants and participants in 
active screening (having signed the ICF) will be allowed to continue participation in the study  
as per protocol unless they  decide to wi thdraw from  the study . The Phase III (Part B) portion 
of the study  will nolonger be conducted. As a consequence of these change s, the number of 
participants in the study  will be significantly reduced. Therefore, the primary object ive for this 
study  will be safet y, and efficacy object ives will be considered exploratory. The prot ocol has 
been revised accordingly  to reflect these key  changes . 
Substant ial changes to the protocol are summarized below .
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 4of 129Section # and Name [CONTACT_601101] .
Section 1 ( Protocol Summary )
Section 3.2 (Objectives and 
Endpoints: Part B)
Section 3.3 (Estimands)
Section 4 ( Study Design)
Section 5.4 (Screen Failures)
Section 6.3.1 (Method for 
Assigning Treatment Groups)
Section 6.3.3 (Methods for 
Unblinding)
Section 7.1 (Discontinuation of 
Study Intervention)
Section 8 ( Study Assessments and 
Procedures )
Section 9 ( Statistical 
Consider ations)
Appendix F (Patient -Reported 
Outcomes)Rem oval of content related to Part B (Phase III) due to the decision to 
not conduct that part of the study , including, but not limited to, 
removal of: 
• General description of Part B throughout
• Endpoints that were only planned for Part B
• Part B study schema , SoA,sample siz e,and statistical analysis
• Descriptio n of dose adaptation decision process and 
implementation .
Section 1.1 (Synopsis)
Section 3.1 (Objectives and 
Endpoints: Part A)
Section 4.1 (Overall Design)
Section 4. 2.3(Rationale for 
Endpoints)
Section 8.1. 5(Exploratory 
Biomarker Assessments)
Section 9 (Statistical 
Considerations)Revised the study objectives and endpoints due to the decision to 
discontinue enrollment . The primary objective and endpoints for this 
study were updated to safety . Efficacy endpoi nts are all exploratory .
• Reduced t he number of histology -based endpoints for Part A .
• Eliminated t he objective s/endpoint sfor absolute change from 
baseline in body weight , eGFR, and uACR .
• Combined o bjectives related to glycemic control and lipid profile .
• Assessment of change from baseline in HbA1c will no longer be 
restricted to participants with T2DM .
The ratio nale for endpoints and statistical considerations were also 
updated , and “proof of concept ”was added to the study description.
Section 1.1 (Synop sis)
Section 3.3 (Estimands)
Section 9 (Statistical 
Considerations)Revised statistical analysis description to reflect the updated study 
design and objectives and endpoints. 
• Updated the statistical hypotheses and sample size description . 
• Rem oved analysis and adaptations descriptions for Part B .
• Rem oved the multiplicity plan .
• Revised the analysis of efficacy endpoints to use nominal p value.
• Simplified the primary estimand to usea treatment policy 
approach for intercurrent events .
• Added the Per Protocol population definition .
Section 1.1 (Synopsis)
Section 2.1 (Study Rationale)
Section 4.1 (Overall Design)Provided explanation for thechange in study design .
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 5of 129Section # and Name [CONTACT_601102] 1.1 (Synopsis)
Section 1.2 (Schema)
Section 4.1 (Overall Design)
Section 9.2 (Sample Size 
Determination)Updated the number of countries, screened participants, and 
randomized participants .
Section [IP_ADDRESS] (Part A Schedule of 
Activities: Treatment Period and 
Follow -up)Rem oved the requirement for ADA monitoring for participants who 
test positive at the follow -up visit. No safety concerns related to the 
development of ADAs have been identified in the cotadutide clinical 
development program to date. Because the cotadutide NASH clinical 
program has been terminated, further ADA monitoring after the 
follow -up visit is not needed.
Section 2.3.1 (Risk Assessment) Added gallbladder -related disorders to the potential risks to align with 
the IB. 
Section [IP_ADDRESS] (Part A Schedule of 
Activities: Treatment Period and 
Follow -up)
Section 3.1 (Objectives and 
Endpoints: Part A)
Section [IP_ADDRESS] (Rationale for 
Explo ratory  Endpoints)
Section 8.1.3 (FibroScan and 
FibroScan -derived Biomarkers)
Section 8.1. 5(Exploratory 
Biomarker Assessments)Clarified the FibroScan -derived biomarkers by [CONTACT_601049] 3+ 
endpoint (and components) and the components of FAST score . 
Section 6.5.2 (Prohibited 
Concomitant Medications)Added instructions to address use of any drugs with new regulatory 
approvals for the treatment of NASH with fibrosi s. Use o f the newly 
approved treatment can be considered after discussion with study 
physician, if the investigator deems it not to be safe for the participant 
to postpone the start of such treatment until study end.
Section 7.1 (Discontinuation of 
Study Interventio n)Changed the liver -related potential reason for discontinuation to 
“suspected or confirmed diagnosis of DILI” for consistency with 
Figure 2 and Figure 3 and added cross reference to the figures. 
Section 8.4.2 (Immunogenicity 
Assessments)
Section 9.4.4 (Analysis of 
Pharmacokinetics and 
Immunogenicity)Due to change in scope of the study:
• Revised text on assessment of cross -reactivity  to GLP -1 and 
glucagon from “will be performed” to “may be performed .”
• Rem oved the analysis of presence of ne utralizing ADAs and the 
effect of immunogenicity on biomarkers and efficacy .
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 6of 129Nonsubstant ial changes to the protocol are summarized below.
Section # and Name [CONTACT_601102] [IP_ADDRESS] (Part A Schedule of 
Activities: Treatment Period and 
Follow -up)Clarified text on requirement for follow -up visits after early 
discontinuation or end of treatment visits. 
Section 2.2.1 (Disease Background) Minor update to language on approved pharmacological therapi[INVESTIGATOR_601014] 2.3.2 (Benefit Assessment) .
Section 2.2.2 (Cotadutide 
Background)Updated the IB edition to 10.[ADDRESS_795907] recently approved IB. 
Section 3.1 (Objectives and 
Endpoints: Part A)Moved the definitions of NASH endpoints to the footnote of the 
objectives and endpoints table for clarity. 
Section 5.2 (Exclusion Criteria) Changed the units for platelets to match units used by [CONTACT_11378]. 
Section 5.4 (Screen Failures) Rem oved GGT from the list of central laboratory criteria for retesting 
to correct an administrative error. 
Section 6.5.2 (Pr ohibited 
Concomitant Medications)Added paracetamol to the description for clarity. 
Section 6.7 (Missed Dose) Clarified that 7-dayinterruptio nsof IP that constitute an important 
protocol deviation must be consecutive. 
Section 7.3 (Lost to Follow Up) Correction of text on participants who become unreachable .
Section 8.2.5 (Clinical Safety 
Laborato ry Assessments)Added eGFR to the list of safety assessments because it was removed 
from the efficacy assessments. 
All sections Minor typographical and administrative edits .
Clinical Study Protocol -3.[ADDRESS_795908] ivities: Screening ...................................................................... [ADDRESS_795909] ivities: Treatment Period and Fo llow-up ................................... 24
[IP_ADDRESS] Part A Schedule o f Act ivities: Treatment Period and Follow -up......................... 24
[IP_ADDRESS] Part B Schedule of Activities: Treatment Period and Follow -up........................ 28
1.3.3 Unscheduled Visits for Dose Modificat ion........................................................ 28
1.3.4 Unscheduled Visit for Safet y or Any Other Reason ........................................... 29
2 INTRODUCTION ............................................................................................ 29
2.1 Study  Rati onale ................................................................................................ 29
2.2 Background ...................................................................................................... 30
2.2.1 Disease Background ......................................................................................... 30
2.2.2 Cotadutide Background ..................................................................................... 31
2.3 Benefit/Risk Assessment ................................................................................... 32
2.3.1 Risk Assessment ............................................................................................... 32
2.3.2 Benefit Assessment ........................................................................................... 34
2.3.3 Overall Benefit: Risk Conclusio n...................................................................... [ADDRESS_795910] ives and Endpo ints: Part A...................................................................... [ADDRESS_795911] ives and Endpo ints: Part B ...................................................................... 38
3.3 Estimands ......................................................................................................... 39
4 STUDY  DESIGN ............................................................................................. 40
4.1 Overall De sign.................................................................................................. 40
4.1.1 Part A Overall Design ....................................................................................... 41
4.1.2 Part B Overall Design ....................................................................................... 41
4.2 Scientific Rationale for Study  Design ............................................................... 41
4.2.1 Rationale for Study  Popul ation......................................................................... 41
4.2.2 Rationale for Treatment Duration ...................................................................... 41
4.2.3 Rationale for Endpoints .................................................................................... 42
[IP_ADDRESS] Rationale for Primary/Safet y Endpoints ............................................................ [ADDRESS_795912] igational Products .................................................................................... 52
6.1.2 Medical Devices ............................................................................................... 53
6.2 Preparati on/Handling/Storage/Accountabilit y................................................... 53
6.3 Measures to Minimize Bias: Rando mizat ion and Blinding ................................ 54
6.3.1 Method for Assigning Treatment Groups ........................................................... 54
6.3.2 Methods to Ensure Blinding .............................................................................. 55
6.3.3 Methods for Unblinding .................................................................................... 55
[IP_ADDRESS] Unblinding for Analysis .................................................................................... 55
6.4 Study  Intervent ion Compliance ......................................................................... 55
6.5 Concomitant Therapy ........................................................................................ 56
6.5.1 Permi tted Concomitant Medications ................................................................. 56
6.5.2 Prohibited Conco mitant Medi cations................................................................ 57
6.5.3 Management of Nausea and V omiting............................................................... 58
6.5.4 Management of Type 2 Diabetes Mellitus ......................................................... 58
[IP_ADDRESS] Use of Medications Known to Cause Hypoglycemia in Type 2 Diabetes Mellitus
......................................................................................................................... 58
[IP_ADDRESS] Therapi[INVESTIGATOR_601015] T ype 2 Diabetes Mellitus .................................... 58
[IP_ADDRESS] Management of Hypoglycemia ......................................................................... 59
[IP_ADDRESS] Management of Hyperglycemia ........................................................................ 59
6.6 Dose Modificat ion............................................................................................ 60
6.7 Missed Dose ..................................................................................................... 60
6.8 Treatmen t of Overdose ...................................................................................... 61
6.9 Intervention After the End of the Study ............................................................. 61
7 DISCONTINUA TION OF STUDY  INTER VENTION AND PARTICIPANT 
DISCONTINUA TION/WITH DRA WAL........................................................... [ADDRESS_795913] to Follow Up ............................................................................................. 63
8 STUDY  ASSESSMENTS AND PROCEDURES .............................................. 63
8.1 Efficacy Assessments ........................................................................................ 64
8.1.1 Liver Bi opsy -based Histopathology .................................................................. 64
8.1.2 Artificial Intelligence -based Histopathology ..................................................... 64
8.1.3 FibroScan and FibroScan -derived Bi omarkers .................................................. 64
8.1.4 Height and W eight ............................................................................................ 65
8.1.5 Exploratory  Biomarker Assessments ................................................................. 65
8.2 Safety Assessments ........................................................................................... 65
8.2.1 Medical History ................................................................................................ 66
8.2.2 Physical Examinat ions...................................................................................... 66
8.2.3 Vital Signs ........................................................................................................ 66
8.2.4 Electrocardiograms ........................................................................................... 67
8.2.5 Clinical Safety  Laboratory  Assessments ............................................................ 68
8.2.6 Other Safet y Assessments ................................................................................. 70
[IP_ADDRESS] Assessment of Injection Sites ............................................................................ [ADDRESS_795914] .................................................................... 73
8.3.7 Adverse Events Related to Liver Biopsy ........................................................... 74
8.3.8 Hy’s Law .......................................................................................................... 74
8.3.9 Reporting of Serious Adverse Events ................................................................ 74
8.3.10 Clinical Events for Adjudication ....................................................................... 75
8.3.1 1 Pregnancy ......................................................................................................... 79
[IP_ADDRESS] Maternal Exposure ............................................................................................ 79
8.3.12 Medicat ion Error , Drug Abuse, and Drug Misuse .............................................. 79
[IP_ADDRESS] Timelines .......................................................................................................... 79
[IP_ADDRESS] Medicat ion Error ............................................................................................... 80
[IP_ADDRESS] Drug Abuse ....................................................................................................... 80
[IP_ADDRESS] Drug Mi suse ..................................................................................................... 80
[IP_ADDRESS] Reporting of Overdose ...................................................................................... [ADDRESS_795915] OF FIGURES
Figure 1 Study  Design ........................................................................................... 19
Figure 2 Stoppi[INVESTIGATOR_601016] f or Possible Hepatocellular 
DILI in Participants with Normal/Near Normal ALT at Baseline ............. [ADDRESS_795916] ives and Endpo ints: Part A ............................................................. [ADDRESS_795917] ivities in the Screening Period for Parti cipants wi th a 
Historical Bi opsy (Part A) ........................................................................ [ADDRESS_795918] ivities in the Screening Period for Participants 
Undergoing On -study  Biopsy  (Part A) ..................................................... [ADDRESS_795919] ivities for Part A: Treatm ent Peri od and Follow -up......... [ADDRESS_795920] ives and Endpo ints: Part A ............................................................. [ADDRESS_795921] OF APPENDICES
Appendix A Regulatory , Ethical , and Study  Oversight Consi derati ons......................... 89
Appendix B Adverse Events: D efinit ions and Procedures for Recording, Evaluating, 
Follow-up, and Reporting ........................................................................ 96
Appendix C Handling of Human Bio logical  Samples ................................................ 102
Appendix D Optional Genomics Ini tiative Sample ..................................................... 104
Appendix E Actions Required in Cases of Increases in Liver Biochemistry  and 
Evaluat ion of Hy’s Law ......................................................................... [ADDRESS_795922] (AUDIT) ................................ [ADDRESS_795923] Haven Criteria for Hepatic Encephalopathy .................................. 115
Appendix H Abbreviat ions........................................................................................ 116
Appendix I Protocol  Versi on History ....................................................................... 119
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 12of 1291 PROTOCOL SUMMARY
1.1 Synopsis 
Protocol Title :A Phase II, rando mized, double -blind, placebo -controlled, proof -of-concept
study  to eval uate the safet y and efficacy o f cotadutide in part icipants wi th non-cirrhoti c non -
alcoho lic steatohepatit is with fibrosis
Short Title: A study  to eval uate the safety  and efficacy  of cotaduti de given by [CONTACT_601050]-cirrhoti c non -alcoho lic steatohepatit is wit h fibrosis
Rationale: This study  was ori ginally a 2-part Phase IIb/III study  to evaluate the safety and 
efficacy of cotadutide in adults wit h biopsy -proven non -cirrhoti c NASH wi th fibrosis stage F2 
or F3. GLP -1 receptor mono -agonists reduce liver fat and improve histological features of 
NASH ( Armstrong et al 2016 , Petit et al 2017, Newsome et al 2021 )
.Cotadutide, an 
oxyntom odulin -like pept idewith targeted balanced GLP -[ADDRESS_795924] and significant histologic benefits, including 
reducti on in NASH disease activit y and improvement in fibrosis in animal models ( Boland et 
al 2020 ). In obese pat ients with T2DM, cotadutide had a robust and significant treatment 
effect on HFF ( Ambery  et al  2018 ) and other non -invasive measures of NAFLD 
(Nahra et al 
2021)
. In pati ents wi th biopsy-proven non -cirrhotic NASH with fibrosis (F1, F2, F3), 
cotaduti de has demo nstrated robust and significant improvements in HFF , liver enzymes, and 
non-invasive markers of NASH and fibrosis.
After careful considerat ion, forem ost being the i dentification of other, more convenient 
treatm ents in development for pati ents wi th NASH, the sponsor decided to discont inue 
development of cotadutide and recrui tmentinto this study . 
Randomized participants and 
participants in active screening in the Phase II (Part A)portion of  the study will be allowed to 
continue participation . The Phase III portion of the study  (Part B) will not be conducted. 
Given the reduced sample size, the primary goal of this study  is to evaluate the safet y of 
cotaduti de in part icipants wi th non- cirrhoti c NASH wi th fibrosis. All efficacy evaluations will 
be exploratory  object ives.  
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 13of 129Objectives and Endpoints: Part A
Table 1 Objectives and Endpoints: Part A
Objectives Endpoints
Primary /Safety
To evaluate the safety and tolerability of 
cotadutide as compared with placebo in 
participants with non -cirrhotic NASH with 
fibrosisSafety and tolerability will be evaluated in terms of AEs, 
vital signs, clinical and laboratory assessments, and ECG.
Assessments related to AEs c over:
• Occurrence/Frequency
• Relationship to IP as assessed by [CONTACT_093]
• Intensity
• Seriousness
• Death
• AEs leading to discontinuation of IP
• AEs leading to dose reduction of IP
• AEs of special interest 
• Adjudicated CV events including MACE, selected 
liver events, diabetic ketoacidosis, pancreatitis, 
pancreatic carcinoma, and thyroid carcinoma
Vital signs parameters include SBP, DBP, and pulse. 
Assessments cover:
• Observed value
• Absolute change from baseline values over time
• Abnormality at least once on treatment
Laborato ry parameters include Clinical Chemistry 
(including MELD score) and Hematology parameters as 
well as urinalysis. A complete list of parameters is 
presented in Section 8.2.5 . 
Assessments cover: 
• Observed value 
• Absolute change from baseline values over time
• Abnormality/Clinically significant abnormality in 
laborato ry parameters at least once on treatment  
• Treatment -emergent increase in hematuria, 
proteinuria, and glucose in urinalysis defined as 
change from negative/trace at baseline to ++, +++, or 
++++ at any visit after baseline or an increase of at 
least ++ 
Electrocardiogram measurements include heart rate, RR, 
PR, QRS, and QT intervals. Derived variables cover 
QTcF. 
Assessments cover:
• Observed value
• Absolute change from baseline values over time 
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 14of 129• ECG parameters fulfilling potentially clinically
significant criteria at any time during treatment,
includ ing QRS duration > 118 ms, PR interval > 210
ms, RR < 600 ms (resting heart rate > 100 bpm), and
RR > 1330 ms (resting heart rate < 45 bpm)
• QTcF exceeding 450, 480, and 500 ms at any  time
during treatment
• Change in QTcF at any time during treatment as
compared to baseline exceeding 30 ms and 60 ms
• To assess the immunogenicity of
cotadutide• Incidence of ADAs to cotadutide and titer during
treatment and follow -up
Explo ratory
• To determine whether cotadutide is
superior to placebo on resolution of NASH
without worsening of liver fibrosis in
participants with non -cirrhotic NASH with
fibrosis• Proportio n of participants with resolution of NASH
without worsening of liver fibrosis based on biopsy at
Week 48
• To assess the effect of cotadutide versus
placebo on improvement in fibrosis by [CONTACT_601051] o ne stage without worsening of
NASH• Proportio n of participants with improvement of liver
fibrosis by [CONTACT_601052] 48
• To assess the effect of cotadutide versus
placebo on resolution of NASH and
improvement in fibrosis• Proportio n of participants with both resolution of
NASH andimprovement in fibrosis by [CONTACT_601053] 48
• To assess the effect of cotadutide versus
placebo on improvement in fibrosis by [CONTACT_601051] o ne stage• Proportio n of participants with improvement in
fibrosis by [CONTACT_601054] 48
• To assess the effect of cotadutide versus
placebo on i mprovement in NAS• Proportio n of participants with improvement in NAS
based on biopsy at Week 48
• Change f rom baseline in NAS based on biopsy at
Week 48
• To assess the effect of cotadutide versus
placebo on change in fibrosis• Change f rom baseline in fibrosis stage based on
biopsy at Week 48
• Proportio n of participants with progression, no
change, o r regression in fibrosis stage based on
biopsy at Week 48
• To assess the effect of cotadutide versus
placebo on i mprovement in each key
histological feature of NASH• Proportio n of participants with improvement in key
histological features of NASH based on biopsy at
Week 48, including:
 Inflammation
 Steatosis
 Ballooning
• To characterize using AI -based histology
assessment the effect of cotadutide versus
placebo on NASH histology, including:
 Resolution of NASH without
worsening of liver fibrosis• AI-based histology assessment of:
 Proportio n of participants with resolution of
NASH without worsening of liver fibrosis based
on biopsy at Week 48
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 15of 129 Improvement of liver fibrosis by [CONTACT_12697] o ne stage without worsening of 
NASH
 Resolution of NASH and 
improvement in fibrosis
 Improvement in fibrosis by [CONTACT_601055]
 Improvement in NAS
 Change in fibrosis 
 Improvement in eac h key  histological 
feature of NASH Proportio n of participants with improvement of 
liver fibrosis by [CONTACT_601056] 48
 Proportio n of participants with both resolution 
of NASH and improvement in fibrosis by [CONTACT_12697] o ne stage based on biopsy at Week 48
 Proportio n of participants with improvement in 
fibrosis b y at least o ne stage based on biopsy at 
Week 48
 Proportio n of participants with improvement in 
NAS based on biopsy at Week 48
 Change f rom baseline in NAS based on biopsy 
at Week 48 
 Change f rom baseline in fibrosis stage based on 
biopsy at Week 48
 Proportio n of participants with progression, no 
change, o r regression in fibrosis stage based on 
biopsy at Week 48
 Proportio n of participants with improvement in 
histological features of NASH based on biopsy 
at Week 48, including:
Inflammation
Steatosis
Ballooning
• To assess the effect of cotadutide versus 
placebo on circulating markers of hepatic 
inflammation• Change f rom baseline in liver enzymes including 
ALT and AST through Week 48
• To assess the effect of cotadutide versus 
placebo on lipid profile and glycemic 
control• Change f rom baseline in triglycerides, LDL 
cholesterol, HDL cholesterol, non -HDL cholesterol, 
total cholesterol, and HbA1c through Week 48
• To summarize the PK profile of cotadutide • Cotadutide PK exposure will be summarized and 
compared with prior data for consistency
• To assess the effect of cotadutide versus 
placebo on liver stiffness • Change f rom baseline at Week 48 in:
 LSM as assessed by [CONTACT_21699]
 Percentage CAP as assessed by [CONTACT_21699]
• To assess the effect of cotadutide versus 
placebo on disease -specific biomarkers• Changes from baseline at Week 48 in non-invasive 
disease -specific biomarkers, including but not limited 
to:
 Collagen turnover (Pro -C3)
 ELF score
 FIB-4
 APRI
 NFS
 BARD score
 FAST score 
 Agile 3+ 
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 16of 129ADA, anti -drug antibody; AE, adverse event; AI, artificial intelligenc e; ALT, alanine aminotransferase; APRI, 
AST -to-platelet ratio index; AST, aspartate aminotransferase; BARD, body mass index, AST/ALT ratio, 
diabetes; BP, blood pressure; CAP, con trolled attenuation parameter; CV, cardiovascular; DBP, diastolic blood 
pressu re; ECG, electrocardiogram; ELF, enhanced liver fibrosis; FAST, FibroScan -AST; FIB -4, fibrosis -4; 
HbA1c, hemoglobin A1c; HDL, high -density lipoprotein; IP, investigational product; LDL, low -density  
lipoprotein; LSM, liver stiffness measurement; MACE, major adverse cardiovascular event(s); MELD, model for 
end-stage liver disease; NAS, non -alcoholic fatty liver disease activity score; NASH, non -alcoholic 
steatohepatitis; NFS, non -alcoholic fatty liver disease fibrosis score; PK, pharmacokinetic(s); QTcF, Frid ericia-
corrected QT interval; SBP, systolic blood pressure
Overall Design
This study  was ori ginally  designed as a 2 -part (Phase IIb/III) study . However, given the 
decisio n to terminate recruit ment, only Part A (Phase II) will be conducted. 
This is a Phase II, global, rando mized, parallel -group, doubl e-blind, placebo -controlled, 
multicenter , proof -of-concept study  to assess the safet y and efficacy of [ADDRESS_795925] ion administered vi a a 
multidose pen, in adults with non- cirrhotic NASH wi th fibrosi s stage F2 or F3. 
The study  will assess safet y of cotaduti de treatm ent. All efficacy endpo ints are exploratory
and include whether treatm ent wi th cotaduti de resul ts in a si gnificant improvement compared 
to placebo in the proporti on of  parti cipants wi th resol ution of NASH without worsening of 
liver fibrosis at W eek 48. Parti cipants who are eligible according to the inclusio n/exclusio n 
criteria will be rando mized in a 2:1:2:[ADDRESS_795926] acebo matching cotadutide 600 µg. 
Parti cipants will be ≥ 18 to ≤75 years of age (inclusive) with biopsy -proven NASH (historical 
biopsy performed ≤ 180 days from randomi zationor on -study  biopsy) dem onstrating a 
NAS ≥4 (wi th a score of at least 1 for each component: steatosis, lobular inflammat ion, and 
ballooning) and liver fibrosis stage F2 or F3. At rando mizat ion, parti cipants will be stratified 
by [CONTACT_207028]/absence of T2DM and by  [CONTACT_601057] s stage. Each cotadutide treatment group will 
be placebo -matched with respect to titration schedule and dose levels. Parti cipants will be 
screened inapproximately 20countri es.
All liver biopsies will be read by a central patho logy review committee.
An independent DMC will be established to monitor data on an ongoing basis to ensure safet y • To determine whether cotadutide is 
superior to placebo for weight reduction• Percent change from baseline in body weight at 
Week 48
• To assess the effect of cotadutide versus 
placebo on glucose, adiponectin, and 
C-peptide• Change f rom baseline in fasting plasma glucose, 
adipo nectin, and C -peptide at Week 48
• To determine whether treatment with 
cotadutide compared with placebo will 
result in a reduction of BP• Change f rom baseline in SBP through Week 48
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 17of 129of parti cipants enrolled in this study  and to ensure the integrit y of the study .
Disclosur e Statement : This is a parallel group treatment study  that is blinded to the 
participants and invest igators. The study  will include 4 treatment arms.  
Number of Participants:
Approximately 600participants will be screened/enro lled andapproximately  55are pl anned to 
berandomized to study  intervent ion.
Note : “Enro lled” means a parti cipant's, or thei r legally  acceptable representative ’s, agreement 
to parti cipate in a clinical study  following com pletion of the informed consent process. 
Potenti al parti cipants who are screened for the purpose of determining eligi bility for the study  
but are not randomly assigned/assigned in the study , are considered “screen failures. ” 
Intervention Groups and Duration:
Parti cipants will be in the study  for at l east approximately 1.2 y ears (60 weeks) , includ inga 
screening period of up to 8 weeks ,a 48-week treatment period , and a 4-week safet y follow-up 
period.
Parti cipants will undergo dose titration steps every 4 weeks to reach the target dose of 300 μg 
or 600 μg qd. Dose titration will start from 50 μg cotad utide (or matching placebo) qd and 
increase to [ADDRESS_795927] co mpleted the study  and database l ock 
has occurred, the study will be unblinded and analyzed . 
Data Monitoring Committee: Yes
Statistical Methods
The primary  analyses will  be of safety, and analyses will be perform ed using the safet y 
analysis set. Safet y data will be presented using descript ive statist ics unless otherwi se 
specified and will not be formally tested. Safet y events and findings will be summarized by  
[CONTACT_3227]. No formal hypothesis testin g will be performed. 
Exploratory  efficacy analyses will use no minal 2 -sided 5% si gnificance levels (equivalent to 
nominal 1 -sided 2.5% si gnificance levels) unless otherwise stated.
The primary estimand o f interest for the histological endpo ints will usethe treatment policy 
strategy .The treatm ent policy  approach will  applyto intercurrent events of treatment 
discontinuat ion, deviat ions from  the protocol  titration schedule, changes in background 
medicat ion,liver events, or use of prohibited medication or other protocol deviat ions. The 
Clinical Study Protocol -3.[ADDRESS_795928] ive of the treatment they  actually received. Analyses will be performed using the F AS 
and/or per protocol analysis sets, as appropriate. The F AS will include all r ando mized and 
treated participants who received at least one dose of IP irrespect ive o f their protocol  
adherence, addition or modificat ion of background medicat ions, discontinuation of study  
intervent ion or switches to alternat ive medicat ions, and continue d partici pation in the study .
For the exploratory  analysis o f binary  histol ogical  endpo int(s)using F AS, parti cipants wi th 
missing histology  data due to any  reason will  be imputed as non -responders. The binary  
endpo int(s) will be analyzed using a Cochran -Mantel -Haenszel test with stratificat ion by 
T2DM presence and F2/F3 fibrosis stages. The treatment effects will be summarized by [CONTACT_601058], 95% CI, and p -value. 
In Part A, 300 participants were originally planned to be randomized toprovide > 90% power 
for the test of each dose versus pooled placebo to detect a difference of 20% in NASH 
resol ution assuming a placebo response rate of 15 %.As a result of the decisio n to terminate 
recrui tment, approximately 55participants are planned to be randomized in the study .
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 19of 1291.2 Schema
Figure 1 Study Design 
Pbo, placebo; R, randomization

Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 20of 1291.3 Schedule of Activities
1.3.1 Schedule of Activities: Screening
The SoA  for parti cipants wi th a qualifying historical biopsy  is presented in Table2, and the 
SoA for parti cipants undergo ing an on -study  biopsy  for screening is presented in Table3.
Table2 Schedule of Activiti es in the Screening Period for Participants with a 
Historical Biopsy (Part A)
Screening 
(procedures may occur 
over more than one day)
Visit V1
Procedure/Study Day Day-56 to -1
Informed consent (Appendix A 3) X
Optional informed consent for Genomics Initiative research (Appendix D 2) X
Confirmation of fasting (Section 5.3.2 ) X
Inclusion and exclusion criteria (Sections 5.1and 5.2) X
Demography X
Full physical examination including height and weight (Secti on 8.2.2 ) X
Medical history (includes AUDIT questionnaire and substance usage) 
(Section 8.2.1)X
Historical liver biopsy (Section 8.1.1 ) aX
Serum pregnancy test (WOCBP only) (Section 8.2.5) X
Hepatitis B and C and HIV screening (Section 8.2.5 ) bX
Urinaly sis for drugs of abuse (Section 8.2.5) X
Clinical safety laboratory assessments, including eGFR and MELD score 
calculation (Section 8.2.5)X
Amylase and lipase (Section 8.2.5 ) X
Coagulation parameters (Section 8.2.5) X
12-lead ECG (Section 8.2.4) cX
Vital signs (Section 8.2.3 ) dX
Assessment of AEs (Section 8.3) eX
Concomitant medication (Section 6.5) X
Blood sampling for ELF (Section 8.1.5 ) X
FIB-4 computed score (Section 8.1.5) X
HbA1c (Section 8.1.5 ) X
Fasting serum lipid panel (Section 8.1.5 ) X
Calcitonin (Section 8.2.5) X
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 21of 129Table2 Schedule of Activiti es in the Screening Period for Participants with a 
Historical Biopsy (Part A)
Screening 
(procedures may occur 
over more than one day)
Visit V1
Procedure/Study Day Day-56 to -1
Check participant’s ability to self -administer SC injection fX
Demonstration of and training on self -administration of SC injection 
(Section 6.2) gX
Review diet and lifestyle advice (Section 5.3.1 ) X
Enrollment in IRT/RTSM X
Participants should withhold alcohol and refrain from intense exercise for 24 hours prior to each study site visit.
aReview of participant’s medical history, including historical biopsy procedure report and histopathological 
findings report that meet the inclusion and exclusion criteria in Section 5.1and 5.2. In the event the 
historical bio psy is deemed not evaluable and a participant screen fails, an on -study liver biopsy may be 
scheduled. Such an on-study biopsy, if considered, should only be performed on a date that is ≥180 days 
after the date of the historical biopsy and after all other eligibility criteria are met. Biopsy tissue and/or 
biopsy tissue block and/or slides should be sent for the central histopathology review laboratory to 
determine eligibility at least [ADDRESS_795929].
eAE/SAEs will be collected from the time of signatur e of informed consent, throughout the treatment period 
and the follow -up period. 
fAt screening, the investigator will judge if the participant is able to self -administer SC injection.
gActivities related to demonstration and training on SC administration ca n be conducted at Visit 1 and/or 
prior to randomization at Visit 2.
AE, adverse event; AUDIT, Alcohol Use Disorder Identification Test; ECG, electrocardiogram; eGFR, estimated 
glomerular filtration rate; ELF, enhanced liver fibrosis; FIB -4, Fibrosis -4; HbA1c, hemoglobin A1c; HbsAg, 
hepatitis B surface antigen; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IRT, interactive 
response technology; MELD, model for end -stage liver disease; PK, pharmacokinetic(s); RTSM, randomization 
and trial supply m anagement; SAE, serious adverse event; SC, subcutaneous; V, visit; WOCBP, women of 
childbearing potential
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 22of 129Table3 Schedule of Activities in the Screening Period for Participants
Undergoing On -study Biopsy (Part A)
Screening 
(procedures may occur over 
more than one day)
Visit V1
Procedure/Study Day Day -56 to -21 a
Informed consent (Appendix A 3) X
Optional informed consent for Genomics Initiative research (Appendix D 2) X
Confirmation of fasting (Section 5.3.2 ) X
Inclusion and exclusion criteria (Sections 5.1and 5.2) X
Demography X
Full physical examination including height and weight (Section 8.2.2 ) X
Medical history (includes AUDIT questionnaire and substance usage) 
(Section 8.2.1)X
Serum pregnancy test (WOCBP only) (Section 8.2.5) X
Hepatitis B and C and HIV screening (Section 8.2.5 ) bX
Urinaly sis for drugs of abuse (Section 8.2.5) X
Clinical safety laboratory assessments, including eGFR and MELD score 
calculation (Section 8.2.5)X
Amylase and lipase (Section 8.2.5 ) X
Coagulation parameters (Section 8.2.5) X
12-lead ECG (Section 8.2.4) cX
Vital signs (Section 8.2.3 ) dX
Assessment of AEs (Section 8.3) eX
Concomitant medication (Section 6.5) X
FibroScan (Section 8.1.3 ) fX
Blood sampling for ELF (Section 8.1.5 ) gX
Blood sampling for NIS4 g, hX
FIB-4computed score (Section 8.1.5)hX
FAST score (Section 8.1.3 )g, hX
HbA1c (Section 8.1.5 ) X
Fasting serum lipid panel (Section 8.1.5 ) X
Calcitonin (Section 8.2.5) X
Check participant’s ability to self -administer SC injection iX
Demonstration of and training on self -administration of SC injection 
(Section 6.2) jX
Clinical Study Protocol -3.0 [COMPANY_008]
Cota dutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 23of 129Table3 Schedule of Activities in the Screening Period for Participants
Undergoing On -study Biopsy (Part A)
Screening 
(procedures may occur over 
more than one day)
Visit V1
Procedure/Study Day Day -56 to -21 a
Review diet and lifestyle advice (Section 5.3.1 ) X
Enrollment in IRT/RTSM X
Liver biopsy for histology (Section 8.1.1 ) aX
Participants should withhold alcohol and refrain from intense exercise for 24 hours prior to each study site visit.
aFor participants without a historical biopsy, the screening liver biop sy procedure is to be performed after all 
other screening procedures are complete and after confirmation that the participant meets all other 
inclusion/exclusion criteria. The biopsy procedure may be conducted on a different day but is part of 
Visit 1. Sit es to ensure biopsy tissue block and/or slides are sent to the central histopathology review 
laborato ry to determine eligibility at least [ADDRESS_795930].
eAE/SAEs will be collected from the time of signature [CONTACT_43998], throughout the treatment period 
and the follow -up period.  
fIf a site has access to appropriate FibroScan equipment, as well as compatible software and probes, they 
must complete the assessments per the schedule for any participant who does not have a previous FibroScan 
assessment conducted within [ADDRESS_795931] of on -study liver biopsy, using a sequential combination of 
the following, namely, BMI, FIB -4, NIS4 (if available) , FAST score or FibroScan, ELF, is strongly 
recommended. Investigator may choose an alternative pre -biopsy screening strategy that may not include 
one or more of the above parameters. It isrecommend edthat investigators discuss the alternative pre -biopsy 
screening strategy with the spo nsor prior to conduct of on -study biopsy.
hFAST score will be calculated only at sites that have the required software.
iAt screening, the investigator will judge if the participant is able to self -administer SC injection. 
jActivities related to demonstration and training on SC administration can be conducted at Visit 1 and/or 
prior to randomization at Visit 2.
AE, adverse event; AUDIT, Alcohol Use Disorder Identification Test; BMI, body mass index; ECG, 
electrocardiogram; eGFR, estimated glomerul ar filtration rate; ELF, enhanced liver fibrosis; FAST, FibroScan -
AST; FIB -4, Fibrosis -4; HbA1c, hemoglobin A1c; HbsAg, hepatitis B surface antigen; HCV, hepatitis C virus; 
HIV, human immunodeficiency virus; IRT, interactive response technology; MELD, mode l for end -stage liver 
disease; NIS4, non -invasive diagnostic score 4; PK, pharmacokinetic(s); RTSM, randomization and trial supply 
management; SAE, serious adverse event; SC, subcutaneous; V, visit; WOCBP, women of childbearing potential
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 24of 1291.3.2 Schedule of Activities: Treatment Period and Follow -up
[IP_ADDRESS] Part A Schedule of Activities: Treatment Period and Follow -up
Table4 Schedule of Activities for  Part A: T reatment Period and Follow -up
Treatment Period
E/D
Visit bFollow -up
4 weeks after EOT 
or E/D ( ±5d) aWeek 0 4 8 12 16 20 24 32 40 48
Visit V2 V3 V4 V5 V6 V7 V8 V9 V10V11
(EOT)
Day
(visit window ± xdays) a129
±5d57
±5d85
±5d113
±5d141
±5d169
±5d225
±5d281
±5d337
±5d
Confirmation of fasting (Section 5.3.2 ) X X X
Demonstration of and training on self -
administration of SC injection (Section 6.2) cX
Review of adherence to diet and lifestyle advice 
(Section 5.3.1 )X X X X X X X X X X X X
Concomitant medication (Section 6.5) X X X X X X X X X X X X
12-lead dECG (Section 8.2.4 )dX X X X X X X X X X X X
Vital signs (Section 8.2.3 )eX fX X X X X X X X X X X
Abbreviated (symptom -directed) physical 
examination including weight (Section 8.2.2 , 
Section 8.1.4 )X X X X X X X X X X X X
Assessment of AEs and injection site reactions
(Section 8.3; Section [IP_ADDRESS] ) g, hX X X X X X X X X X X X
Clinical safety laboratory assessments, including 
eGFR and MELD score calculation 
(Section 8.2.5 )X X X X X X X X X X X
Amylase and lipase (Section 8.2.5 ) X X X X X X
Coagulation parameters (Section 8.2.5 ) X X X X X X
Calcitonin (Section 8.2.5 ) X X X
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 25of 129Table4 Schedule of Activities for  Part A: T reatment Period and Follow -up
Treatment Period
E/D
Visit bFollow -up
4 weeks after EOT 
or E/D ( ±5d) aWeek 0 4 8 12 16 20 24 32 40 48
Visit V2 V3 V4 V5 V6 V7 V8 V9 V10V11
(EOT)
Day
(visit window ± xdays) a129
±5d57
±5d85
±5d113
±5d141
±5d169
±5d225
±5d281
±5d337
±5d
Urine pregnancy test (WOCBP only) 
(Section 8.2.5 )X X X X X X
Liver biopsy for histology (Section 8.1.1 ) X iX j
FibroScan, LSM, CAP, FAST Score , Agile 3+
(Section 8.1.3 ) k, lX X X
Randomization in IRT/RTSM (Section 6.3) X
Study  intervention administration in clinicmX X X X X X X X X
Study  intervention dispensed for at home 
administrationX X X X X X X X X
Instructions for use dispensed X X X X X X X X X
Uptitration step for 300 µg cotadutide/placebo X X X
Uptitration step for 600 µg cotadutide/placebo X X X X X X
Study  intervention compliance (Section 6.4) X X X X X X X X X X
Urine for albumin and creatinine X X X X X
HbA1c ( Section 8.1.5 ) X X X X X
Fasting serum lipid panel ( Section 8.1.5 ) X X X
Pre-dose blood for PK analysis ( Section 8.4) X X X X X X X
Serum for immunogenicity (ADA) ( Section 8.4.2 ) 
nX X X X X X X
Blood sampling for ELF (Section 8.1.5 ) X X X
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 26of 129Table4 Schedule of Activities for  Part A: T reatment Period and Follow -up
Treatment Period
E/D
Visit bFollow -up
4 weeks after EOT 
or E/D ( ±5d) aWeek 0 4 8 12 16 20 24 32 40 48
Visit V2 V3 V4 V5 V6 V7 V8 V9 V10V11
(EOT)
Day
(visit window ± xdays) a129
±5d57
±5d85
±5d113
±5d141
±5d169
±5d225
±5d281
±5d337
±5d
Blood sampling for Pro -C3(Section 8.1.5 ) X X X
FIB-4 computed score (Section 8.1.5 ) X X X
Blood for fasting plasma glucose (Section 8.1.5 ) X X X
Blood for C -peptide (Section 8.1.5) X X X
Blood for adiponectin (Section 8.1.5 ) X X X
Genomics Initiative optional, exploratory genetic 
sample (Section 8.6, Appendix D) oX
Optional biomarker serum sample (for biomarker 
research) (Section 8.5.2 )X X X
Participants should withhold alcohol and refrain from intense exercise for 24 hours prior to each study site visit.
aVisit windows should be calculated from Day 1. Visit 2 (randomization) may be scheduled any day following confirmation that participant meets all 
eligibility criteria including eligibility reading from the central pathology review of the biopsy (historical or on -study) sample and laboratory report 
assessments from the central laboratory (eg, the screening period does not need to be a full 8 weeks). Follow -up visit conducted 4 weeks ( ± 5d) after EOT 
visit or E/D visit. For participants who discontinue study intervention permanently and do not continue with study visits, follow -up visit should be 
performed 4 weeks (± 5 d) after the E/D visit. For participants who discontinue study intervention early but continue with stud y visits, follow -up visit 
should be performed 4 weeks (± 5 d) after the EOT.
bPerformed in event of early discontinuation of study intervention or withdrawal from study. 
cActivities related to demonstration and training on SC administration can be conducted at Visit 1 and/or prior to randomization at Visit 2.
dECGs will be recorded in triplicate after a [ADDRESS_795932] dose of study intervention. 
gAE/SAEs will be collected from the time of signature [CONTACT_43998], throughout the treatment period and follow -up period. 
hAssessment of injection site reactions to be conducted af ter injection of study intervention. 
Clinical Study Protocol -3.[ADDRESS_795933] -baseline biopsy to occur within a window from -2 weeks prior to Visit 11 (Week 48) until 4 weeks after Visit 11 .
jBiopsy should only be conducted as part of the E/D visit activities in participants who have received study intervention for at least 36 weeks and who are 
unwilling or unable to wait until Week 48. For participants who continue the study after an E/D visit and have a biopsy at the E/D visit, an additional biopsy 
should not be collected at Week 48. Biopsy should be scheduled within -2 weeks prior to +4 weeks after the E/D visit. 
kIf a site has access to appropriate FibroScan equipment, as well as compatible software and probes, they must complete the assessments per the schedule 
with extended visit windows. For V2, FibroScan must be performed pre -dose within extended visit window of -14 days but only for participants who meet 
all inclusion/exclusion criteria (including histology central read) and are determined to be eligible for randomization. For all other visits, Fibroscan must be 
performed within extended visit window of ±[ADDRESS_795934] been collected.
nADA samples will be collected prior to administration of IP.
oGenomics sample: If for any reason, the sample is not drawn at Visit 2, it m ay be taken at any  visit until the last study visit. Only one sample should be 
collected per participant for genetics during the study. The optional informed consent for Genomics Initiative research must be signed prior to sample 
collection. Refer to Appendix Dfor inclusion/exclusion criteria specific to the Genomics Initiative and further details on the optional Genomics Initiative 
sample.
ADA, anti -drug antibody; AE, adverse event; CAP, controlled attenuation parameter; dECG, digital electrocardiogram; E/D, early study int ervention 
discontinuation; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; ELF, enhanced liver fibrosis; EOT, e nd of treatment; FAST, 
FibroScan -AST; FIB -4, fibrosis -4; HbA1c, hemoglobin A1c; IP, investigational product; IRT, interactive response technology; LSM, liver stiffness 
measurement; MELD, model for end -
stage liver disease; PK, pharmacokinetic(s); Pro-C3, re leased N -terminal propeptide of type III collagen; RTSM, 
randomization and trial supply management; SAE, serious adverse event; V, visit; WOCBP, women of childbearing potential
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 28of 1291.3.2.2 Part B Schedule of Activities: Treatment Period and Follow -up
Due to the decisio nto end recruit ment into the study , Part B of the study  will not be 
conducted. 
1.3.[ADDRESS_795935] igator feels a site visit is required for a participant to discuss dose modificat ion 
(Secti on 6.6), activit ies that should be conducted are presented in Table5. Further acti vities 
may be conducted as judged by [CONTACT_3170] .
Table5 Schedule of Activities for  Unscheduled Dose Modification Site V isit
Unscheduled Titration Visit
Review of adherence to diet and lifestyle advice (Section 5.3.1 ) X
Concomitant medication (Section 6.5) X
Vital signs (Section 8.2.3 ) aX
Abbreviated (symptom -directed) physical examination including weight 
(Section 8.2.2 ; Section 8.1.4 )X
Assessment of AEs and injection site reactions (Section 8.3; Section [IP_ADDRESS] ) b,cX
Study intervention administration in clinic dX
Study intervention dispensed for at home administration X
Instructio ns for use dispensed X
Dose titration step for cotadutide/placebo X
Study intervention compliance (Section 6.4) X
Participants should withhold alcohol and refrain from intense exercise for 24 hours prior to each study site visit.
aWhenever vital signs and blood draws are scheduled for the same nominal time, the blood draws should 
occur las t.
bAE/SAEs will be collected from the time of signature [CONTACT_43998], throughout the treatment period 
and follow -up period.
cAssessment of injection site reactions to be conducted after injection of study intervention. 
dStudy intervention should be administered after all assessments have been conducted and samples have 
been collected.
AE, adverse event; SAE, serious adverse event
Clinical Study Protocol -3.[ADDRESS_795936] of activit ies for unscheduled safet y visits is presented in Table 6.
Table6 Schedule of Activities for Unscheduled Visit for Safety or Any Other 
Reason
Unscheduled Safety Visit
Review of adherence to diet and lifestyle advice (Section 5.3.1 ) X
Concomitant medication (Section 6.5) X
Clinical safety laboratory assessments based on clinical judgment 
(Section 8.2.5)X
Vital signs (Section 8.2.3 ) aX
Abbreviated (symptom -directed) physical examination including weight 
(Section 8.2.2 ; Section 8.1.4 )X
Assessment of AEs and injection site reactions (Section 8.3;Section [IP_ADDRESS] ) b,cX
Study intervention administration in clinic dX
Participants should withhold alcohol and refrain from intense exercise for [ADDRESS_795937].
bAE/SAEs will be collected from the time of signature [CONTACT_43998], throughout the treatment period 
and follow -up period.
cAssessment of injection site r eactions to be conducted after injection of study intervention. 
dStudy intervention should be administered after all assessments have been conducted and samples have 
been collected.
AE, adverse event; SAE, serious adverse event
2 INTRODUCTION
Cotadutide (ME DI0382) is a synthet ic analog of the human hormone glucagon that has been 
modified, using only natural amino acids, to have a balanced act ivity at both GLP -[ADDRESS_795938] disease -modifying effects alongside improved lipid 
homeostasis, enhanced glycemic control, and body weight loss.
2.1 Study Rationale
Non-alcoholic steatohepatit is has a prevalence of approximately  2% to 3% in the general 
popul ation and can lead to cirrhosis, hepatocellular carcinoma, and end -stage liver disease. It 
has been previously demo nstrated that GLP -1 receptor mono -agoni sts reduce liver fat and 
improve histological features of NASH ( Armstrong et al 2016 , Peti t et al  2017 , Newso me et al 
2021)
.Cotadutide, an oxyntomodulin -like peptide with targeted balance d GLP -[ADDRESS_795939] ivity leading to NASH resolution and on improvement in fibrosis 
in animal models of NASH with fibrosis ( Boland et al  2020 ). In [ADDRESS_795940] on HFF , and treatm ent wi th 
cotaduti de for54weeks in obese T2DM led to significant treatment effects on non -invasive 
measures of NAFLD as well as effects on body weight, glucose lowering, and lipid profile 
param eters ( Ambery  et al  2018 , Nahra et al 2021 )
. 
In a Phase II randomized, double -blind, pl acebo -controlled study (D5671C00002; 
PROXYMO) in overweight/obese participants (n = 74) wi th biopsy -proven non -cirrhoti c 
NASH with fibrosis, treatment with cotadutide at [ADDRESS_795941] and AL T in the 600 μg group. Addit ionally , improvements in bio markers of NASH and 
fibrosis were observed. 
This study  was ori ginally  a 2-part Phase IIb/III study  to eval uate the safet y and efficacy of 
cotaduti de in adult s with biopsy -proven n on-cirrhoti c NASH wi th fibrosi s stage F2 or F3. 
After careful considerat ion, the sponsor decided to discont inue development of cotadutide and 
recrui tment into this study to focus efforts on other, more convenient treatments for patients 
with NASH . 
Rando mized parti cipants and parti cipants in act ive screening (having signed the 
ICF) will  be allowed to continue parti cipati on in the study  as per protocol  unless they  deci de 
to wi thdraw from  the study . The Phase III (Part B) portion of the study  will no l onger be
conducted. As a consequence of these changes, the number of participants in the study will be 
significant ly reduced. Therefore, the primary objective for this study will be safet y, and 
efficacy object ives will be considered exploratory .
2.2 Background
2.2.1 Disease Background
Non-alcoho lic steatohepatit is is part of the spectrum o f liver diseases known as NAFLD, 
ranging from simple steatosis or non -alcoho lic fatty liver to NASH. Non -alcoho lic 
steatohepatit is, the progressive form of the disease with a prevalence of approximately  2% to 
3% in the general populat ion, can lead to cirrhosis and its complications, hepatocellular 
carcino ma, and end -stage liver di sease ( Bellentani et al 2010 ). Non -alcoho lic steatohepatit is is 
expected to become the leading cause for liver transplantation over the next decade ( Wong et 
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 31of 129al 2014 , Pais et al 2016, Cho lankeril et al 2017 ). 
Non-alcoho lic steatohepatit is is closely associated with metabolic risk factors including 
obesit y, T2DM, and dy slipi[INVESTIGATOR_035]. Epi [INVESTIGATOR_601017] T2DM in approximately  80% of  patients wi th NASH and at least 
45% of patients with NASH, respectively ( Younossi et al 2016 ). Path ophysio logically , NASH 
is frequently associated with a hyperinsulin emic or insulin- resistant state, l eading to adi pose 
tissue dysfunction and increased hepatic de novo lipogenesis. Therefore, it is believed that 
both increased adipose tissue lipo lysis and hepat ic de novo lipogenesis contribute to increased 
liver fat and f ormation of lipid metabo lites causing lipotoxicit y. Lipotoxi city, oxidati ve stress, 
and mitochondrial dysfunct ion are believed to contribute to the hallmarks of NASH including 
signs of  cell death or hepatocy te ball ooning, l obular or portal  inflammat ion, an d ultimately in 
some patients, liver fibrosis ( Marra et al 2013 , Neuschwander -Tetri 2017 ).
Non-alcoho lic steatohepatit is is defined histologically as a mult icomponent condition 
composed of hepatic steatosis, inflammat ion, and hepatocy te ball ooning in varying 
proporti ons. Approximately 25% to 35% of patients wi th NASH develop liver fibrosis ( Mishra 
and Y ounossi  2012 ). Fibrosis stage (F1 to F4) has been shown to have significant prognostic 
value in NASH correl ating wit h liver-related outcomes and mortalit y (Angulo et al 2015 , 
Dulaiet al 2017 ). Several  factors have been shown to increase the risk of liver fibrosis 
progression to cirrhosis including presence of co morbi d T2DM, increasing age, hypertensio n, 
and high BMI 
(Angulo 2007 , Angulo et al 2015)
.
There are currently no appro ved pharmacological therapi[INVESTIGATOR_110234], and lifest yle 
modificati ons are the mainstay  of treatment. Many pati ents do not achieve or maintain dietary  
goals and weight loss. Consequent ly, the devel opment of new therapi[INVESTIGATOR_601018] m edical need, parti cularly given the expected increasing burden of this disease 
in parallel wit h the rising global epi[INVESTIGATOR_121995] y and T2DM ( Estes et al  2018 ).
2.2.[ADDRESS_795942] 
treatm entemergent AEs were Grade 1 or 2 in severity  and not seri ous. 
Efficacy
For an overall summary o f efficacy  in humans, see the IB edition 10.0 Secti on 5.2 .2.
In obese patients with T2DM, treatment with cotadutide was associated with improvements in 
glycemic control and hepat ic parameters and reductions in body weight in clinical studies 
(Nahra et al 2021 ).
In overweight/obese participants with biopsy -proven non -cirrhoti c NASH wit h fibrosis 
(PROXYMO study  D5671C00002), s tatistically significant reductions in HFF , ALT, AST , 
Pro-C3, and APRI fro m baseline to W eek 19 (end of treatment) were observed for the [ADDRESS_795943] ions in body  weight fro m baseline to W eek 19 were observed 
for the 300 μg cotadutide gro up and the 600 μg cotadutide co mpared with placebo. Nominal 
reducti ons in HbA1c and total cho lesterol  from baseline to W eek19 in parti cipants wi th 
NASH with or without comorbid T2DM were observed for the 300 and 600 μg cotadutide 
groups com pared wi th plac ebo. In general, greater changes in efficacy parameters were 
observed for 600 v ersus 300 μg cotadutide co mpar ed wi th placebo.
2.3 Benefit/Risk Assessment
More detailed informat ion about the known and expected benefits and potential risks of 
cotaduti de may  be found in the IB.
2.3.1 Risk Assessment
The current IB has further information on the potent ia
l benefit s of cotadutide and an 
assessment of the potential and known risks. Risks associated with cotadutide and with study -
related procedures are presented in Table7along wi th mitigation strategi es. Addit ionally , 
participants will be mo nitored throughout the study for signs, symptoms, and/or laboratory  
analyses suggest ive of hepat ic deco mpensat ion. Parti cipants wi th hepat ic deco mpensat ion will 
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 33of 129be excluded fro m further participation in this study (Section 5.2) and will be treated 
immediately  according t o standard of care. Specified clinical events, including all potential 
cases o f DILI and CV events ,will be adjudicated by  [CONTACT_52880], independent, and blinded 
events adjudication co mmittee (Section 8.3.10 ).
Table7 Risk Assessment
Identified and potential risks of 
clinical significanceSummary of data/rationale for 
riskMitigation strategy
Cotadutide
Identified risks associated with 
cotadutide:
• Nausea
• Vomiting
• Injection site reactions
• Increased heart rate
Potential risks include: 
• Alterations in blood pressure 
• QT interval prolongation
• Anaphy lactic -type reactio ns
• Skin rash
• Hypoglycemia (with 
sulfon ylurea, glitinides, and 
insulin)
• Diabetic ketoacidosis 
(following insulin reduction)
• Acute renal failure secondary 
to dehy dration
• Pancreatitis
• Pancreatic carcinoma
• Thyroid cancer
• Gallbladder -related disordersPotential risks for cotadutide are 
based on available published data 
for GLP -1 receptor agonists and 
glucagon, as well as clinical and 
nonclinical data.
Some potential risks 
(pancreatitis, pancreatic 
carcinoma, thyroid cancer, 
gallbladder -related disorders ) are 
based solely on GLP -1 agonists 
as a class finding • Inclusi on/exclusion criteria 
(Section 5.1and Section 5.2)
• Safety monitoring (Section 
8.2) 
• Uptitration dosing schedule 
(Section 4.3)
• Pen device and instruction on 
proper injection technique 
(Section
 6.2)
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 34of 129Table7 Risk Assessment
Identified and potential risks of 
clinical significanceSummary of data/rationale for 
riskMitigation strategy
Study Proced ures
Liver biopsy • The most common risks 
associated with liver biopsy 
are mild pain and minimal 
bleeding at the procedure 
site. 
• Rare complications of liver 
biopsy include major 
bleeding (0.1%) and death 
(0.01%) (Nalbantoglu and 
Brunt 2014). Risks associated with liver biopsy 
will be minimized by:
• Requiring that each 
investigator or designee that 
obtains a liver biopsy is 
experienced and qualified to 
perform the procedure
• Excluding patients with 
cirrhosis, hepatic 
decompensation, and/or 
coagulopathy (Section 5.2)
• Checking relevant laboratory 
parameters prior to the 
procedure (eg, INR and 
platelet count) (Section 1.3)
Blood draws Routine blood draws have a 
well-established risk profile.The risk is addressed by [CONTACT_601059]. 
Injection administration • Pain at the injection site • Pen device
• Training in proper SC 
injection technique
• Rotatio n of injection sites
GLP-1, glucagon -like peptide; INR, international normalized ratio; SC, subcutaneous
2.3.[ADDRESS_795944] and AL T 
levels, and indices of liver fibrosis such as propeptide of t ype III collagen level (Pro -C3), FIB -
[ADDRESS_795945] , Pro -
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C [ZIP_CODE] 15 May  2023
CONFIDENTIAL AND PROPRIETARY 35of 129C3, and APRI fro m baseline to Week 19 (end of treatment) were observed for the [ADDRESS_795946] yle coaching, and close assessment of their disease and associated 
pathol ogies that may  not otherwise be performed, especially  the ident ification o f progression 
to cirrhosis.
2.3.3 Overall Benefit: Risk Conclusion
The study  design aims to minimize potential risks to participants based on the protoc ol 
inclusio n and exclusio n criteria, safety  monitoring, ti trated dosing scheme, and other measures 
(Table7). T aking into account the measures to minimize risk to participants in this study , the 
potenti al and identified risks associated with cotadutide are just ified by [CONTACT_601060]- cirrhoti c NASH wi th stage F2 or F3 
fibrosis.
3 OBJECTIVES, ENDP OINTS, AND ESTIMANDS
3.1 Objectives and Endpoints: Part A
Table 8 Objectives and Endpoints: Part A
Objectives Endpoints
Primary /Safety
To evaluate the safety and tolerability of 
cotadutide as compared with placebo in 
participants with non -cirrhotic NASH with 
fibrosisSafety and tolerability will be evaluated in terms of AEs, 
vital signs, clinical and laboratory assessments, and ECG.
Assessments related to AEs cover:
• Occurrence/Frequency
• Relationship to IP as assessed by [CONTACT_17062]
• Intensity
• Seriousness
• Death
• AEs leading to discontinuation of IP
• AEs leading to dose reduction of IP
• AEs of special interest 
• Adjudicated CV events including MACE, selected 
liver events, diabetic ketoacidosis, pancreatitis, 
pancreatic carcinoma, and thyroid carcinoma
Vital signs parameters include SBP, DBP, and pulse. 
Assessments cover:
• Observed value
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 36of 129• Absolute change from baseline values over time
• Abnormality at least once on treatment
Laborato ry parameters include Clinical Chemistry 
(including MEL D score) and Hematology parameters as 
well as urinalysis. A complete list of parameters is 
presented in Section 8.2.5 . 
Assessments cover: 
• Observed value 
• Absolute change from baseline values over time
• Abnormality/Clinically significant abnormality in 
laborato ry parameters at least once on treatment  
• Treatment -emergent increase in hematuria, 
proteinuria, and glucose in urinalysis defined as 
change from negative/trace at baseline to ++, +++, or 
++++ at any visit after baseline or an increase of at 
least ++ 
Electrocardiogram measurements include heart rate, RR, 
PR, QRS, and QT intervals. Derived variables cover 
QTcF. 
Assessments cover:
• Obser ved value
• Absolute change from baseline values over time 
• ECG parameters fulfilling potentially clinically 
significant criteria (PCS) at any time during 
treatment, including QRS duration > 118 ms, PR 
interval > 210 ms, RR < 600 ms (resting heart rate 
>100bpm), and RR > 1330 ms (resting heart rate 
<45 bpm)
• QTcF exceeding 450, 480, and 500 ms at any  time 
during treatment 
• Change in QTcF at any time during treatment as 
compared to baseline exceeding 30 ms and 60 ms
• To assess the immunogenicity of 
cotadutide • Incidence of ADAs to cotadutide and titer during 
treatment and follow -up
Explo ratory
• To determine whether cotadutide is 
superior to placebo on resolution of NASH 
without worsening of liver fibrosis in 
participants with non -cirrhotic NASH with 
fibrosis• Proportio n of participants with resolution of NASH 
without worsening of liver fibrosis based on biopsy at 
Week 48
• To assess the effect of cotadutide versus 
placebo on improvement in fibrosis by [CONTACT_601061]• Proportio n of participants with improvement of liver 
fibrosis by [CONTACT_601062] 48
• To assess the effect of cotadutide versus 
placebo on resolution of NASH and 
improv ement in fibrosis• Proportio n of participants with both resolution of 
NASH andimprovement in fibrosis by [CONTACT_601063] 48
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 37of 129• To assess the effect of cotadutide versus 
placebo on improvement in fibrosis by [CONTACT_12697] o ne stage• Propo rtion of participants with improvement in 
fibrosis by [CONTACT_601064] 48
• To assess the effect of cotadutide versus 
placebo on i mprovement in NAS• Proportio n of participants with improvement in NAS 
based on biopsy at Week 48
• Change f rom baseline in NAS based on biopsy at 
Week 48
• To assess the effect of cotadutide versus 
placebo on change in fibrosis• Change f rom baseline in fibrosis stage based on 
biopsy at Week 48
• Proportio n of participants with progression, no 
change, o r regression in fibrosis stage based on 
biopsy at Week 48
• To assess the effect of cotadutide versus 
placebo on i mprovement in each key 
histological feature of NASH• Proportio n of participants with improvement in key 
histological features of NASH based on bio psy at 
Week 48, including:
 Inflammation
 Steatosis
 Ballooning
•
• To characterize using AI -based histology 
assessment the effect of cotadutide versus 
placebo on NASH histology, including:
 Resolution of NASH without 
worsening of liver fibrosis
 Improvement of liver fibrosis by [CONTACT_12697] o ne stage without worsening of 
NASH
 Resolution of NASH and 
improvement in fibrosis
 Improvement in fibrosis by [CONTACT_601055]
 Improvement in NAS
 Change in fibrosis 
 Improvement in each key histological 
feature of NASH• AI-base d histology  assessment of: 
 Proportio n of participants with resolution of 
NASH without worsening of liver fibrosis based 
on biopsy at Week 48
 Proportio n of participants with improvement of 
liver fibrosis by [CONTACT_601065] 48
 Proportio n of participants with both resolution 
of NASH and improvement in fibrosis by [CONTACT_12697] o ne stage based on biopsy at Week 48
 Proportio n of participants with improvement in 
fibrosis by [CONTACT_601054] 48
 Proportio n of participants with improvement in 
NAS based on biopsy at Week 48
 Change f rom baseline in NAS based on biopsy 
at Week 48
 Change f rom baseline in fibrosis stage based on 
biopsy at Week 48
 Proportio n of participants with progression, no
change, o r regression in fibrosis stage based on 
biopsy at Week 48
 Proportio n of participants with improvement in 
histological features of NASH based on biopsy 
at Week 48, including:
Inflammation
Steatosis
Ballooning
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 38of 129Resolution of NASH is defined as the absence of fatty liver disease or isolated simple steatosis without 
steatohepatitis an d a NAS ballooning score of 0, inflammation score of 0 to 1, and steatosis score of any degree 
(from 0 to 3), as assessed by [CONTACT_468327]/NAS score.
Improvement in fibrosis is defined as a one or more category improvement in the fibrosis category (NASH 
Clinical Research Network fibrosis stage) without worsening of NASH.
Worsening of NASH is defined as any increase in the ballooning, inflammation, or steatosis scores even if total 
NAS does not increase.
ADA, anti -drug antibody; AE, adverse event; AI, artificial intelligence; ALT, alanine aminotransferase; APRI, 
AST -to-platelet ratio index; AST, aspartate aminotransferase; BARD, body mass index, AST/ALT ratio, 
diabetes; BP, blood pressure; CAP, controlled attenuation parameter; CV, cardiovasc ular; DBP, diastolic blood 
pressure; ECG, electrocardiogram; ELF, enhanced liver fibrosis; FAST, FibroScan -AST; FIB -4, fibrosis -4; 
HbA1c, hemoglobin A1c; HDL, high -density lipoprotein; IP, investigational product; LDL, low -density  
lipoprotein; LSM, liver s tiffness measurement; MACE, major adverse cardiovascular event(s); MELD, model for 
end-stage liver disease; NAS, non -alcoholic fatty liver disease activity score; NASH, non -alcoholic 
steatohepatitis; NFS, non -alcoholic fatty liver disease fibrosis score; P K, pharmacokinetic(s); QTcF, Fridericia -
corrected QT interval; SBP, systolic blood pressure
3.2 Objectives and Endpoints: Part B
Due to the decisio n to end recruit ment into the study , Part B of the study  will not be • To assess the effect of cotadutide v ersus 
placebo on circulating markers of hepatic 
inflammation• Change f rom baseline in liver enzymes including 
ALT and AST through Week 48
• To assess the effect of cotadutide versus 
placebo on lipid profile and glycemic 
control• Change f rom baseline in triglycerides, LDL
cholesterol, HDL cholesterol, non -HDL cholesterol, 
total cholesterol , and HbA1c through Week 48
• To summarize the PK profile of cotadutide • Cotadutide PK exposure will be summarized and 
compared with prior data for consistency
• To asses s the effect of cotadutide versus 
placebo on liver stiffness • Change f rom baseline at Week 48 in:
 LSM as assessed by [CONTACT_21699]
 Percentage CAP as assessed by [CONTACT_21699]
• To assess the effect of cotadutide versus 
placebo on disease -specific biomarkers• Changes from baseline at Week 48 in non -invasive 
disease -specific biomarkers, including but not limited 
to:
 Collagen turnover (Pro -C3)
 ELF score
 FIB-4
 APRI
 NFS
 BARD score
 FAST score 
 Agile 3+ 
• To determine whether cotadutide is 
superior to placebo for weight reduction• Percent change from baseline in body weight at 
Week 48
• To assess the effect of cotadutide versus 
placebo on glucose, adiponectin, and C -
peptide• Change f rom baseline in fasting plasma glucose, 
adipo nectin, and C -peptide at Week 48
• To determine w hether treatment with 
cotadutide compared with placebo will 
result in a reduction of BP• Change f rom baseline in SBP through Week [ADDRESS_795947] are:
Part A
In pati ents wi th non-cirrhoti c NASH wi th liver fibrosis with a treatment strategy  to titrate to a 
maximum dose of 300 or 600 µg cotadutide versus placebo, what is the difference in 
proporti on achieving resolution of NASH w ithout worsening of liver  fibrosis at W eek 48 in 
patients regardl ess of treatm ent discont inuat ion, deviat ions from the protocol  titration 
schedule, changes in background medication, liver events, or use of prohibited medicat ion or 
other protocol deviat ions.  
The primary  estimands are described by  [CONTACT_941] f ollowing attributes:
Population : Patients wi th non-cirrhoti c NASH wi th liver fibrosis (F2 or F3), with or without 
T2DM.
Endpoints :Resolut ion of NASH wit hout worsening of liver fibrosis at W eek 48
Treatment condition : Treatm ent strategy  to titrate to a m aximum dose of [ADDRESS_795948] ion 6.5.2 . 
Treatment Policy  Strategy : If a bi opsy  is obtained wi thin the analysis window, the 
endpo int will be defined based on the observed bio psy resul t regardl ess of the occurrence 
of intercurrent e vents of treatment discont inuat ion, deviat ions from the protocol t itration 
schedule, changes in background medication, liver event, or use of prohibited medicat ions 
or other protocol deviations.
Population -level summary : Difference in proportio n of respon ders
Rationale for  estimand : The endpo ints and intercurrent event strategies for the primary 
estimands are aligned to current regulatory
 guidance for invest igation of non -cirrhotic NASH 
therapi [INVESTIGATOR_014].
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 40of 1294 STUDY DESIGN
4.1 Overall Design
This study  was ori ginally  designed as a 2-part, Phase IIb/III, global, rando mized, parallel -
group, doubl e-blind, pl acebo -controlled, mult icenter , proof of concept study  to assess the 
safet y and efficacy  of [ADDRESS_795949] ive screening will be allo wed to continue 
participat ion. Given the reduced sample size, the primary  goal  of this study  is to evaluate the 
safet y and tolerabilit y of cotaduti de in parti cipants wi th non-cirrhoti c NASH wi th fibrosis.
The Phase III portion of the study  (Part B) will not be conducted. 
Part A (Phase II )will assess the safet y and efficacy of 300 µgand 600 µg cotadutide 
treatm ent. 
Parti cipants will be ≥ 18 to ≤ 75 years of age (inclusive) with biopsy -proven NASH (historical 
biopsy performed ≤ 180 days from randomizat ionor on -study  biopsy) dem onstrating a 
NAS ≥4 (wi th a score of at least 1 for eac h component: steatosis, lobular inflammat ion, and 
ballooning) and liver fibrosis stage F2 or F3. Approximately 600participants will be
screened/enrolled in the study (in approximately  20 countri es)to achieve approximately 55
rando mly assigned to study  intervent ion.
At randomizat ion, parti cipants will be stratified by [CONTACT_207028]/absence of T2DM and by 
[CONTACT_365615] (Section 6.3.1 ). Part icipants will undergo dose titration steps every 4 weeks to 
reach the target dose of 300 μgor 600 μg qd. Dose titration will start from 50 μg cotaduti de 
(or m atching pl acebo) qd and increase to 100 μg qd after 4 weeks, and then increase by 
100-μ g incremen ts every  4 weeks, until reaching the final intended dose at W eek 12 for the 
300 μ g treatment groups and W eek 24 for the 600 μg treatment groups. T o mit igate the risk of 
gastrointestinal AEs, it is important to follow the 4 -week dose escalat ion intervals ( refer to
Secti on 6.6for dose modificat ions). Each cotadutide treatment group will be placebo -matched 
with respect to ti tration schedule and dose l evels
.
An independent DMC will be established to monitor data on an ongoing basis to ensure safet y 
of parti cipants enrolled in this study  (Secti on 9.6).
Figure 1(Section
 1.1) is an overview of the study  design. Details on treatments given during 
the study  are presented in Section [ADDRESS_795950] acebo in the proportion of participa nts with resol ution of NASH without 
worsening of liver fibrosis at W eek 48. In Part A, 300 adult participants who are eligible
according to the inclusio n/exclusio n criteria were pl anned to be rando mized in a 2:1:2:[ADDRESS_795951] acebo m atching cotaduti de 300 µg, cotadutide 600 µg, or 
placebo m atching cotaduti de 600 µg. The representation by [CONTACT_601066] (F2 or F3) was 
to be capped at approximately 70%. Due to termination of recruit ment,approximately 55
participants are planned to berando mized. Parti cipants will be in the study  for up to 1.2 years 
(60 weeks), including a screening period of up to 8 weeks, a 48- week treatment period, and a 
4-week safet y follow-up peri od. Participants will return unused study intervent ion at the end 
of treatment (or early discont inuat ion)visit, and assessments will be conducted as described in 
the SoA  (Secti on 1.3). The fo llow-up visi t shoul d be scheduled to occur 4 weeks (± 5 days) 
later.
4.1.[ADDRESS_795952] on health 
(currently identified as the target populat ion within NASH wi th fibrosi s who warrant 
pharmaco logic intervent ion), thi s study  will be conducted in patients wit h non-cirrhoti c 
NASH with liver fibrosis. Participants with biopsy -proven non -cirrhoti c NASH wi th NAS ≥ 4 
with a com ponent score of ≥1 for steatosis, lobular inflammation, and ballooning, as well as 
liver fibrosis stage F2 or F3 on histology  with or wit hout T2DM will be recruited. Participants 
will be stratified based on fibrosis stage and the presence or absence of T2DM at 
rando mizat ion. Participants with stage F4 fibrosis (cirrhosis, compensated and 
decom pensated) will not be included. 
4.2.2 Rationale for Tre
atment Duration
Histological evidence of NASH resolut ion may be observed as early as 36 weeks after 
initiation of treatment ( Harrison et al 2019). Therefore, a [ADDRESS_795953] a potenti al signal on NASH reso lution, while 
also provi ding sufficient treatment exposure for safet y monitoring . 
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 42of 1294.2.3 Rationale for Endpoints
[IP_ADDRESS] Rationale for Primary /SafetyEndpoints
Standard safet y endpo ints will be assessed, including vital signs, ECG, safet y laboratory  
analysis, AEs, and SAEs. Increases in heart rate have been observed in clinical studies 
conducted to date with cotadutide (studies D5670C00001, D5670C0 0002, and 
D5670C00004), accompanied by a trend toward a reduction in BP with repeat dosing. A 
particular focus on CV safet y will invo lve mo nitoring of CV events, which will be adjudicated 
by [CONTACT_52880], independent, and blinded events adjudicat ion committ ee (Secti on 8.3.10 ).
The ADA  and ti ter (if participants are ADA  posi tive) will be used to assess potential 
immunogenicit y in NASH.
[IP_ADDRESS] Rationale for Expl oratory Endpoints
The goal for therapi[INVESTIGATOR_601019]. 
However, rate of disease progression in NASH with fibrosis and event rates for liver outcom es 
requi re prol onged tri al durati ons to eval uate and dem onstrate im provements in liver outcom e 
events. Hi stological features of NASH, including fibrosis, appear to have predict ive value for 
liver outcom es and have been designated as surrogate endpoints of efficacy  for novel NASH 
therapeuti cs. Therefore, improveme nts in histol ogy-based endpo ints in response to cotadutide 
treatm ent will be explored in this tri al.
Current ly applied manual methods of disease staging for NASH with fibrosis, particularly for 
staging o f fibrosis, have limit ed sensit ivity and reproducibil ity. AI-based methods are expected 
to provi de improved sensit ivity and reproducibilit y of histopathology  reporting. AI-based 
histopathology  assessments will be collected for all histology  endpoints.
The endpo int on body  weight will provide assessment of the beneficial effect of cotadutide on 
body  weight in non -cirrhoti c NASH wi th fibrosis and allo w for correlation wit h improvement 
in NASH liver histology  and other param eters rel ated to m etabolic contr ol. Glycemic control 
as measured by [CONTACT_13505]1c will be assessed in participants with T2DM as a high proportion of 
patients wi th NASH have co morbid T2DM. Evaluation of triglycerides will provide 
assessment of the beneficial effects of cotadutide on lipid profile in participants with NASH 
and attendant comorbidit ies.
Cotadutide is expected to lead to improvements in glucose and lipid ho meostasis. Therefore, 
measures of metabo lic ho meostasis in circulat ion will be measured including but not limited 
to HbA1c, lipid profile, adi ponectin, and C -pepti de. 
Although histology  remains the preferred tool for diagnosis and assessment of treatment 
effects for NASH with fibrosis, given the invasive nature of a liver biopsy , there i s a m ajor 
unmet need to ident ify non-invasive tools that can reduce or replace the number of biopsies in 
Clinical Study Protocol -3.[ADDRESS_795954] and 
monitor responsiveness to cotadutide therapy . 
Hepatocellular injury  will be assessed by [CONTACT_508631] (ie, ALT and AST). In addit ion, liver 
fibrosis will be assessed non -invasively by [CONTACT_601067] ™ test, whi ch is a com posite measure of 
hyaluronic acid, TIMP -1, and the amino -terminal propepti de of ty pe III procollagen (PI[INVESTIGATOR_120861]). 
Non-invasive imaging- based tool s are em erging as potential candidates to inform on disease 
progression and treatment effects in NASH. FibroScan -based transi ent el astography  and 
FibroScan -based markers (FAST score, Agile 3+ score) will be used to assess liver st iffness 
and related bio logy, indicators of reduced tissue elasticit y associ ated wi th inflammat ion and 
fibrosis (LSM [kPa]) , and independent ly of steatosis (CAP [dB/m]) as well. 
A marker of collagen extracellular matrix turnover (specifically , released N -terminal 
propeptide of ty pe III collagen [Pro-C3]) will be measured. 
Various non -invasive indices such as FIB -4, APRI, BARD, NFS, FLI have been reported to 
have value for monitoring of disease and treatment response. These indices leverage routinely 
measured parameters and will be assessed in the current trial. 
4.2.4 Participant Input into Design
During protocol development, the study  team  met wi th patients living with NASH to provide 
their feedback on the study . Five parti cipants were interviewed from 3 countries (Italy , Uni ted 
States, United Kingdo m). The visit schedule, visit procedures, and study  burden were 
discussed to gain a better understanding of whether parti cipants will be able to manage the 
visit schedule for the duration of the trial and whether the procedures would cause them to 
withdraw from  the study . These interviews provided an opportunity for the patients to provide 
their input as a pe rson living with NASH. 
The fo llowing support will be added to the study  based on pati ent input: 
The sites being considered for the study  shoul d have the capabilit ies to com plete all  the 
assessments at one location where possible as recommended by [CONTACT_493228]. 
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 44of 129A digital platform  will be incl uded as part of study support to house study  
communicat ion, informat ion, and resources. Some sites will have their own plat form and 
may prefer that method of co mmu nicati on to support thei r pati ents. 
The study  team  will work with local countries supporting the study  at [COMPANY_008] to 
encourage an option for transportation support for patients and caregivers participat ing in 
the study  (where acceptable for local ethics boards). 
The study  team  will work wi th sites to en courage reminders and stress the need for 
diabetic pat ients to have morning appo intments while fast ing. In addit ion, where allowed 
by [CONTACT_601068], meals or snacks after fast ing visits may be provided. 
4.[ADDRESS_795955] effects at the 300 µg 
dose (Section 2.2.2 ). Cotadutide [ADDRESS_795956] an acceptable safet y (including hepatic safety ) profile in non -cirrhoti c NASH wi th 
fibrosis a nd in previous trials in obesit y and T2DM. T aken together it is reasonable to carry 
forward the 300µgand 600 µg dose levels for further assessment in non -cirrhoti c NASH wi th 
fibrosis. 
To mitigate the risk o f gastrointestinal AEs it is important to fo llow the 4 -week dose escalat ion 
intervals. Dose titration will start from 50 μ g, increase to 100 μg daily after 4 weeks, and then 
increase by 100 μg increments every  4 weeks, unt il reaching the final intended dose at W eek 
12 for the 300 μg treatment groups an d Week 24 for the 600 μg treatment groups. 
4.4 End of Study Definition
For the purpose of Clinical Trial Transparency , the definit ion of the end of the study  differs 
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 45of 129under FDA  and EU regul atory  requi rements:
European Unio nrequi rements define study  com pletionas the l ast vi sit of the l ast parti cipant 
for any  protocol  related activit y.
Food and Drug Administration requirements defines 2 completion dates:
Primary Co mpletion Date –the date that the final participant is examined or receives an 
intervent ion for the purposes of final co llection of data for the primary  outcom e measure, 
whether the clinical study  concluded according to the pre -specified protocol or was 
terminated. In the case of clinical studies with more than one primary outcome measure with 
differ ent com pletion dates, this term refers to the date on which data collect ion is completed 
for all of the primary  outcom es.
Study  Com pletion Date –the date the final part icipant is examined or receives an intervent ion 
for purposes of final co llection o f data for the primary  and secondary  outcom e measures and 
AEs (for example, last participant ’s last visit), whether the clinical study  concl udes according 
to the pre -specified protocol or is terminated.
A participant i s consi dered to have com pleted the study  ifhe/she has co mpleted all phases of 
the study  including the 4-week follow- up visi t.
The end o f the study  is defined as the date of the last visit of the last participant in the study . 
5 STUDY POPULATION
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known 
as protocol waivers or exemptions, is not permitted.
5.1 Inclusion Criteria
Parti cipants are eligible to be included in the study only if all o f the following criteria apply:
Age
1Parti cipant m ust be ≥18 to ≤75 years o f age (inclusive) at the time of signing the 
inform ed consent. 
Type of Participant and Disease Characteristics
2Histologically confirmed NASH per NASH Clinical Research Network criteria as 
diagnosed by [CONTACT_601069] a liver bi opsy performed ≤ 180 days fro m randomizat ion and 
fulfilling all of the fo llowing histol ogical criteria, read by  a central  pathol ogy review 
committee:
(a)NAS ≥4 with a score of ≥1 for each component: steatosis, lobular inflammat ion, and 
ballooning
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 46of 129(b)Presence of fibrosis stage F2 or F3 
OR
(c)Willingness to undergo a liver biopsy at screening, result of which should fulfill the 
above histological criteria
Invest igators should determine eligibilit y for liver biopsy on participants who are found to 
be eligible wit h respect to all other criteria, based on local procedures and clinical 
judgment, including the use of non- invasive techniques (such as FibroScan, FIB -4,and 
other clinical and laboratory -based measures).
3HbA1c ≤10.5% in pat ients with T2DM m anaged on a stabl e dose of ant idiabet ic 
medica tion and/or di et for at l east 90 days prior to screening. HbA1c testing may be 
repeated once.
Sex
4Male or female (non -pregnant and non -breast feeding)
Reproduction and Contraception
There i s no requi rement for m ale participants to alter their usual contraceptive practices. 
Contraceptive use by [CONTACT_601070] d be consistent with local regulat ions regarding the 
methods of contraception for those participat ing in clinical studies.
5Female participants of childbearing potential must use at least one highly e ffective form 
of birth control . A highly effect ive method of contraception is defined as one that can 
achieve a failure rate of less than 1% per y ear when used consistently and correctly. 
Women of childbearing potential who are sexually active with a non -sterilized male 
partner must agree to use at l east one highly effect ive method of birth control, as defined 
below, from enro llment throughout the study  and unt il at least [ADDRESS_795957] resul t at 
Visit 1. 
(a)Women not of childbearing potential are defined as women who are either 
perm anent ly sterilized (hysterectomy, bilateral oophorect omy, or bilateral  
salpi[INVESTIGATOR_1656] ), or who are postm enopausal . Women will be considered 
postm enopausal if they  have been amenorrhoei c for [ADDRESS_795958] anned 
date of rando mizat ion without an al ternat ive medical cause. The fo llowing age -
specific re quirements apply:
 Women <[ADDRESS_795959] fo llicle -stimulat ing hormone levels in the 
postm enopaus al range.
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 47of 129 Women ≥[ADDRESS_795960] been 
amenorrhoei c for 12 m onths or more fo llowing cessation o f all exogenous 
horm onal treatm ent.
(b)Highly effect ive birth control methods include sexual abst inence (when this is t he 
preferred and usual lifest yle o f the participant), a vasectomized partner, Implanon®, 
bilateral  tubal  occl usion, intrauterine device/levonorgestrel intrauterine system, 
Depo -Provera™ inject ions, oral contraceptive, and Evra Patch™, Xulane™, or 
NuvaRing® . Peri odic abst inence (calendar, symptothermal, post -ovulation methods), 
withdrawal  (coitus interruptus), spermicides only, and lactational amenorrhea method 
are not acceptable methods of contraception. Female condo m and male condo m 
shoul d not be used toge ther, and neither is considered to be a highly effect ive birth 
control  method.
6Female participants must refrain fro m egg cell donation and breastfeeding while on study  
and for 4 weeks after the final dose of study  intervent ion.
Informed Consent
7Capable of giving signed informed consent as described in Appendix A, which includes 
compliance wi th the requi rements and restri ctions listed in the ICF and in t his protocol
8Provisio n of signed and dated written Optional Genet ic Research Informat ion informed 
consent prior to collection o f samples for optional genet ic research that supports Genomic 
Initiative
5.2 Exclusion Criteria 
Parti cipants are excl uded from  the study  if any of the fo llowing cri teria apply:
Medical Conditions
1History  of, or any  exist ing condit ion that, in the opi[INVESTIGATOR_3078] n of the investigator, would 
interfere wi th eval uation of  the study  intervent ion, put the participant at risk, influence the 
participant’s abilit y to parti cipate, or affect the interpretation of the results of the study
2Liver di sease of other etio logies (eg, al coho lic steatohepatit is; drug- induced, viral, or 
autoimmune hepat itis; primary biliary cirrhosis; primary sclerosing cho langit is;
hemochro matosis; alpha 1 ant itrypsin deficiency; Wilson's disease). Participants cured of 
HCV infect ion less than 2 y ears pri or to the Screening visit are not eligible
3History  of cirrhosis and/or hepat ic deco mpensat ion, including evidence of portal 
hypert ensio n (eg, low platelet count, spleno megaly, asci tes, history  of hepatic 
encephalopathy , esophageal  varices, or vari ceal bleeding)
4Prior or pl anned liver transplantation
5Prior or pl anned bari atric surgery  
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 48of 1296Alcoho l consumpt ion >21 units (units calculated per local regulat ions) per week ([ADDRESS_795961] drinks per week) for men and >14 units per week ([ADDRESS_795962] drinks per week) 
for wom en on average wit hin 2 years prior to baseline liver biopsy (historical or at 
screening). Evidence of alcoho l dependence as a ssessed by  [CONTACT_601071]
7Type 1 di abetes m ellitus, a history  of di abetic ketoaci dosis, or symptoms of acutely  
decompensated bl ood gl ucose control  (eg, thi rst, polyuria, wei ght loss)
8History  of acute pancreat itis (unless previously re solved gallstone pancreat itis and post 
cholecystectomy), or current chronic pancreatit is
9Clinically significant inflammatory  bowel  disease, gastroparesi s, or other severe disease 
or surgery  affect ing the upper gastrointestinal tract (including bariatric su rgery ) that m ay 
affect gastric empt ying or could affect the interpretation of the safet y and tol erabilit y data
10History  of any of the f ollowing that in the opi[INVESTIGATOR_3078] n of the invest igator is not stable within 
90 day s prior to the screening visit: 
(a)>5% weight l oss (self -reported or documented)
(b)Treatment with glucose -lowering agent(s) 
(c)Treatment with lipid -lowering agent(s)
(d)Parti cipation in weight l oss program s
11Clinically significant CV or cerebrovascular disease within [ADDRESS_795963] 
90days or who are due to undergo these procedures at the time of screening
12Cardi ac arrhy thmia
(a)Second or third degree atrial ventricular block or sinus node dy sfunct ion with 
clinically significant pause, not treated with pacemaker
(b)Ventri cular arrhy thmia requi ring treatment
(c)Parti cipants wi th atrial fibrillat ion/flutter with ventricular rate (> [ADDRESS_795964]) 
13Severe congest ive heart failure ([LOCATION_001] Heart Associat ion Class IV)
14History  of malignant neoplasms within [ADDRESS_795965] igator
Prior/Concomitant Therapy
16Recent (within 90 days of screening biopsy or historical biopsy through screening) use of 
therapi [INVESTIGATOR_601020] (eg, methotrexate, tamoxifen, 
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 49of 129amiodarone, or long- term useof tetracy clines or systemic corticosteroids [inhaled, nasal, 
topi[INVESTIGATOR_330930]])
17Recent (within 180 days of screening biopsy or historical biopsy through screening) use 
of obeti cholic acid or other therapy  under invest igation for NASH
18Pi[INVESTIGATOR_601021] h igh dose vitamin E (> 400 IU) unless on a stable dose for at least 
180days prior to the baseline biopsy  (either screening or historical) and not init iated after 
the biopsy was taken 
19Recent (within 90 days of screening biopsy or historical biopsy through screening) use of 
GLP -[ADDRESS_795966] containing therapi[INVESTIGATOR_601022](s) (approved and/or off -label use)
Prior/Concurrent Clinical Study Experience
20Parti cipation in another clinical study  with an IP administered within the l ast 30 days or 
5half-lives of the therapy  (whichever is l onger) at the time of screening or the time of the 
histori cal bi opsy , not covered under exclusion criteria 16 or 17
21Concurrent participat ion in another intervent ional study  of any kind or pri or 
rando mizat ion in this study
22Severe allergy/hypersensit ivity to any  of the proposed study  treatm ents or exci pi[INVESTIGATOR_601023]
23Contraindicat ion to liver biopsy (eg, bleeding diathesis, such as hemophilia, suspected 
hemangio ma, or suspected echinococcal infection) or inabilit y to safely  obtain a liver 
biopsy as determined by [CONTACT_3170] (Section 8.1.1 ) 
24Parti cipants wi th serum  triglyceride concentrati ons above 1000 mg/dL (11.3 mmo l/L) at 
screening
25Abnorm al laboratory  values at screening, including any  of the f ollowing: 
(a)AST or ALT ≥ 5 × ULN
(b)Alkaline phosphatase > 2
×ULN 
(c)Impaired renal  function defined as eGFR ≤ 30 mL/minute/1.73 m2at screening 
(estimated according to the CKD Epi[INVESTIGATOR_361973]) ( Inker et al 2021)
(d)Albumin <3.5g/dL (35 g/L)
(e) INR ≥1.3
(f)TBL ≥1.3mg/dL in the absence of known Gilbert’s syndro me or in individuals with 
Gilbert’s syndrome, TBL ≥3 mg/dL
(g)Platelet coun t < 150
× 103/μL
(h)Any other clinically  significant abnorm alities in serum  chemistry , hematol ogy, or 
urinalysis results as judged by  [CONTACT_601072] -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 50of 12926Severely  uncontrolled hypertension defined as SBP ≥ 180 mmHg or DBP ≥ [ADDRESS_795967] 10 minutes at 
screening or randomizat ion 
27Basal calcitonin level ≥ 50 ng/L (i e,≥ 50 pg/mL) at screening, or history /family history  of 
medullary  thyroi d carcino ma or mult iple endocrine neoplasia t ype [ADDRESS_795968]
Other Exclusions
29Involvement in the planning and/or conduct of the study (applies to both [COMPANY_008] 
staff and/or staff at the study  site)
30Judgment by  [CONTACT_271089], restrict ions, and requirements
31Fibrosis stage F2 if the cap has been reached on F2 participants or fibrosis stage F3 if the 
cap has been reached on F3 participants
5.[ADDRESS_795969] yle reco mmendat ions from 
screening unt il the end of the safet y follow-up period and will be reminded at each study  visit. 
The gui dance will  be in accordance wit h the sites ’ local process es. 
In addit ion to the scheduled clinic visits, invest igators may contact [CONTACT_601073]. During the telephone contacts, participants should be asked about 
their general wellbeing and reminded to adhere to diet and li festyle advice. Participants should 
also be counseled about mit igation of gastrointestinal side -effects. 
5.3.[ADDRESS_795970] 8 hours, ie, no food or beverage except water , 
prior to study  site visi ts according to the SoA (Secti on 1.3). 
5.3.3 Alcohol
Parti cipants shoul d withhol d alcohol  for 24 hours pri or to each study  site visi t.
5.3.4 Activity
Parti cipants shoul d refrain fro m intense exercise for 24 hours prior to each study  site visi t.
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 51of 1295.4 Screen Failures
Screen failures are defined as part icipants who consent to participate in the clinical study  but 
are not subsequent ly randomly assigned to study  intervent ion. A minimal set of screen failure 
inform ation is required to ensure transparent reporting of screen failure participants to meet 
the Consolidated Standards of Reporting Trials publishing requirements and to respond to 
queri es fro m regul atory  authorities. Minimal informat ion includes demography , screen failure 
details, eligibilit y criteria, and any  SAE.
Individuals who do not meet the criteria for participation in this study during the 56 -day 
screening period (screen failure) may be rescreened if the reason for screen failure was 
transi ent (including but not limited to laboratory  tests or unforeseen personal events that 
mandate missed screening visit s as determined by  [CONTACT_601074] a rationale for rescree ning). Rescreening m ay be considered at any  time pri or to 
rando mizat ion and in part icular, although not limit ed to, for reasons related to the COVID -19 
pandemic (ie, lack of available kits, local lockdowns and imposed quarantines). Up to 2 
rescreenings are allowed in the study . Rescreened parti cipants shoul d re-sign informed 
consent on the rescreening visit. If a participant is rescreened , he/she must continue to meet all 
inclusio n/excl usion criteria. Procedures performed within [ADDRESS_795971](s) retested once as part of the screening procedure if the reason for 
failing the laboratory  criteria was transient (as determined by [CONTACT_601075] a rationale for retest). If they fail twice to meet the appli cable 
laboratory  criteria during the screening period, they  may still be rescreened.
Parti cipants who do not m eet the central HbA1c inclusion criteria for participation in the study  
may have their HbA1c retested once as part of the screening procedure. If they fail twice to 
meet the HbA1c inclusion criterion during the screening period, they  may still be rescreened 
but no sooner than [ADDRESS_795972] visit.
In the event the historical biopsy is deemed not eval uable and the site has determined that no 
additional histori cal samples are available for an addit ional central patho logy review and a 
participant screen fails, participant may  be rescreened and an on -study  liver bi opsy  may be 
scheduled only if the on -study  liver bi opsy is schedul ed for a date that is ≥180 day s after the 
date of the historical biopsy and after all other screening procedures are completed and once it 
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 52of 129has been confirmed that the participant meets all other inclusio n/exclusio n criteria.
Rescreened participants should be assigned the same participant number as for the init ial 
screening. However, rescreening should be documented so that its effect on study results, if 
any, can be assessed.
[ADDRESS_795973] igational intervent ion(s), m arketed product(s) or 
placebo intended to be administered to or medical device(s) utilized by a study  parti cipant 
according to the study  protocol . Study  intervent ion in this study  refers to cotaduti de or 
placebo.
6.1 Study Interventions Administered
6.1.1 Investigational Products
Intervention name [CONTACT_601103](s) Multidose prefilled pen device 
containing 2.7 mL at a 
concentration of 1 mg/mL for 
doses 50 -100 μg.
Multidose prefilled pen device 
containing 2.7 mL at a 
concentration of 5 mg/mL for 
doses 200 -600 μg.Multidose prefilled pen device 
containing 2.7 mL at a 
concentration of 1 mg/mL for 
doses 50 -100 μg.
Multidose prefilled pen device 
containing 2.7 mL at a 
concentration of 5 mg/mL for 
doses 200 -600 μg.
Dosage level(s) 50 to 600 μg once daily Matched to 50 to 600 μg 
cotadutide once daily
Route of 
administrati onSingle SC injection Single SC injection
Administration 
instructions One single injection per calendar 
day, preferably at the same time of 
the day following guidance in the 
IFUOne single injection per calendar 
day, preferably at the same time of 
the day following guidance in the 
IFU
Use Experimental Placebo
IMP and NIMP IMP IMP
Sourcing Provided centrally by [CONTACT_601076] a carton a. Each carton Study intervention will be 
provided in a carton a. Each carton 
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 53of 129Intervention name [CONTACT_601104].and prefilled pen will be labeled as 
required per country requirement.
Current/former 
name(s) or alias(es)MEDI0382 NA
aBoth the liquid drug product and prefilled pen constitute the investigational product. AEs and SAEs that 
occur with the investigational product should be reported per the processes outlined in Section 8.3.
AE, adverse events; IFU, instructions for use; IMP, investigational medicinal product; NA, not applicable; 
NIMP, non -investigational medicinal product; SAE, serious adverse event; SC, subcutaneous
6.1.2 Medical Devices
Medical devices (stand -alone medical  device products) not m anufactured by  [CONTACT_601077]:
1Professio nal, m ultichannel electrocardiograph devices for cardiac safet y monitoring 
(MAC2000). Electrocardio graphs will be delivered only to sites participating in Part A of 
the study . 
2Laboratory  kits that include tubes, butterflies, urine containers, glass slides, and other 
items requi red to collect bl ood and urine samples that will be evaluated by  [CONTACT_601078] . 
3Single-use disposable pen needles to be used with pen inject ion devices (applicable only 
for countri es where i t is not possible to locally reimburse the cost of needle purchase).
Medical devices will be used per manufacturer’ s instructions, whic h will  be provi ded to the 
sites pri or to si te init iation visit. All device deficiencies (including malfunct ion, use error, and 
inadequate labeling) shall be documented and reported by  [CONTACT_601079] (Section 8.3.13 ) and appropriately managed by  [CONTACT_456] .
6.2 Preparation/Handling/Storage/Accountability
1The invest igator or designee must confirm appropriate temperatu re condit ions have been 
maintained during transit for all study  intervent ion received and any discrepancies are 
reported and resolved before use of the study  intervent ion.
2Only participants rando mized in the study may receive study intervent ion and only 
authorized si te staff may  supply  or administer study  intervent ion. All study  intervent ion 
must be stored in a secure, environmentally controlled, and mo nitored (m anual  or 
autom ated) area in accordance wit h the l abeled storage conditions with access limited t o 
the invest igator and authorized site staff.
3The invest igator, institution, or the head of the medical inst itution (where applicable) is 
responsible for study  interventi on accountabilit y, reconciliat ion, and record maintenance 
(ie, recei pt, reconciliat ion, and final disposit ion records).
Clinical Study Protocol -3.[ADDRESS_795974] ion. Participants will be trained on proper SC injection technique at Visit 1 (screening) or 
at Visit 2 prior to randomizat ion(Secti on 1.3). For handling of study  intervent ion and 
instructi ons on administration, see the Instructions for Use. Study interventi on shoul d be 
stored at the recommended storage condit ions according to the label. Storage condit ions are 
also to be found in the Instructions for Use.  
6.3 Measures to Minimize Bias: Randomization and Blinding
6.3.1 Method for Assigning Treatment Group s
All participants will be centrally assigned to randomized study  intervent ion using an 
IRT/RTSM. Before the study  is init iated, the l og-in informat ion and directions for the 
IRT/RTSM will be provided to each site. 
A participant i s consi dered randomized i nto the study  when the invest igator notifies the 
IRT/RTSM that the participant meets eligibilit y criteri a and the IR T/RTSM provi des the 
assignment of blinded IP kit numbers to the participant.
In Part A, participants will be rando mized 2:1:2:1 to receive c otaduti de 300 µg, placebo 
matching cotadutide 300 µg, cotadutide 600 µg, or placebo matching cotadutide 600 µg. The 
rando mizat ion will be stratified by [CONTACT_207028]/absence of T2DM and by [CONTACT_365615].
T2DM at the time of rando mizat ion is based on:
Estab lished diagnosis of T2DM
OR
HbA1c ≥6.5% (48 mm ol/mol) by [CONTACT_601080] [ADDRESS_795975] ion 1.3. 
Returned study  intervent ion shoul d not be re -dispensed to the participants.
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 55of 1296.3.2 Methods to Ensure Blinding
The IR T/RTSM will provide to the invest igator(s) or pharmacists the kit ident ificat ion number 
to be allocated to the participant at the dispensing visit. Routines for this will be described in 
the IRT/RTSM user manual that will be provided to each site. 
The rando mizat ion code should not be broken except in medical emergencies when the 
appro priate management of the participant requires knowledge of the treatment 
rando mizat ion. The investigator documents and reports the action to [COMPANY_008], without 
revealing the treatment given to participant to the [COMPANY_008] staff.
[COMPANY_008] retains the right to break the code for SAEs that are unexpected and are 
suspected to be causally  related to an IP and that potentially require expedited reporting to 
regul atory  authori ties. Rando mization codes will not be broken for the planned analyses of 
data unti l all decisi ons on the evaluabilit y of the data from  each individual participant have 
been made and documented. 
6.3.3 Methods for Unblinding
The IR T/RTSM will be programmed with blind -breaking instructions. In case of an 
emergency , in which the knowl edge of the specific blinded study  interventi on will  affect the 
immediate management of the participant ’s condi tion, the invest igator has the sole 
responsibilit y for determining if unblinding of a participants ’ intervent ion assignment is 
warranted. Participant safet ymust al ways be the first considerat ion in making such a 
determinat ion. If a participant ’s intervent ion assignment is unblinded, the sponsor must be 
notified wit hin 24 hours after breaking the blind. The investigator documents and reports the 
action to [COMPANY_008], without revealing the treatment given to participant to the [COMPANY_008] 
staff.
[IP_ADDRESS] Unblinding for Analysis
After all participants of the study  have co mpleted the study , a database l ock will be perform ed 
and the data will be unblinded and analyzed. 
6.4 Study Intervention Compliance
When participants are dosed at the site, they  will self -administer the study  intervent ion under 
medical supervisio n from the investigator or designee. The date and time of dose administered 
in the clinic will be recorded in the source documents and in the eCRF . 
When participants self -administer study  intervention(s) at home, compliance wit h study  
intervent ion will be assessed at each visit. Compliance will be assessed by [CONTACT_601081] . Deviat ion(s) fro m the prescribed dosage regimen based on 
patient recall  shoul d be recorded in the eCRF .
Clinical Study Protocol -3.[ADDRESS_795976] by  [CONTACT_601082]/returned pens, so it is particularly important 
to discuss with the patient at each visit whether he/she has used the medicine on a daily basis, 
in the prescribed dose, and whether the medicine has been stored under appropriate 
condi tions. If there is a suspi[INVESTIGATOR_24510] n that a patient is not using the correct dose or is not 
administering the drug regularly , retraining and discussio n with the patient should take place. 
If, despi[INVESTIGATOR_601024], the patient still does not comply wit h the invest igator's 
instructi ons, discont inuat ionof study  intervent ion should be considered (Section 7.1).
A record of the number of pens dispensed to each participant must be maintained and 
recon ciled wit h study  interventi on and com pliance records. Intervent ion start and stop dates, 
including dates for intervent ion delays and/or dose reductions will also be recorded in the 
eCRF . 
6.5 Concomitant Therapy
Any medicat ion or vaccine (including over -the-counter or prescript ion medicines, vitamins, 
and/or herbal supplements) that the participant is receiving at the time of enrollment or 
receives during the study  must be recorded along with:
Reason for use
Dates of administration including start and end dates
Dosage information including dose and frequency
The study  physician should be contact[CONTACT_601083] .
6.5.[ADDRESS_795977] igators may prescribe concomitant medicat ions or treatments deem ed necessary to 
provi de adequate supportive care except for those medicat ions identified as “excluded” as 
listed in Section 6.5.[ADDRESS_795978] itutional 
guidelines. Parti cipants shoul d receive care for hy pertensi on and CV risk factors according to 
local guidelines. 
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 57of 129Parti cipants on a stabl e dose (for at l east 180 day s) of pi [INVESTIGATOR_601025]-dose vi tamin E 
(>400IU) at the time of th e baseline biopsy  will be permi tted to rem ain on this medicat ion 
during the course of the study , provi ded no changes are made to the dose.
6.5.[ADDRESS_795979] consult ing wit h the investigator
Use of the following medicat ions will be restricted ( Table9) or prohibited ( Table10 ) as 
specified:
Table9 Restricted Medications
Medication/class of drug: Usage (including limits for duration permitted and 
special situations in which it is allowed ):
Systemic corticosteroids by [CONTACT_68058], intravenous, or 
intramuscular routeNot to be used within 90 days prior to baseline biopsy 
(historical or screening) and during the study unless 
prescribed for a very brief period of less than 14 days
Prokinetic agents such as domperidone and 
metoclopramideOnly to be used during the study for the treatment of 
nausea and vomiting if a centrally acting antiemetic is 
deemed ineffective or not tolerated by [CONTACT_601084] (acetaminophen )is allowed, 
not to exceed 3 g/d
Table10 Prohibited Medications
Prohibited medication/class of drug: Usage
Therapi[INVESTIGATOR_601026], tamoxifen, 
amiodarone, or long- term use of tetracyclines or 
systemic corticosteroidsWithin 90 days prior to baseline biopsy (historical or 
screening) until the end of the study. Systemic 
corticosteroid and tetracycline use are restricted during 
the study  unless prescribed for a very brief period of 
≤ 14 days.
Therapi[INVESTIGATOR_601027] (except for SGLT -2 
inhibito rs), such as obeticholic acid, pi[INVESTIGATOR_051], 
and Vitamin EWithin [ADDRESS_795980] 180 days 
prior to baseline biopsy (historical or on -study). Potential 
drugs with new regulatory approvals for the treatment of 
NASH with fibrosis stage F2/F3 could be considered 
after discussion with study physician, if the investigator 
deems it not to be safe for the participant to postpone the 
start of such treatment until study end.
GLP-[ADDRESS_795981] containing therapi[INVESTIGATOR_601028] 90 days of baseline biopsy (historical or on-
study) until the end of the study
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 58of 129Table10 Prohibited Medications
Prohibited medication/class of drug: Usage
Drugs approved for weight loss (eg, o rlistat, 
bupropi[INVESTIGATOR_2394]/naltrexone, phentermine -topi[INVESTIGATOR_052], 
phentermine, lo rcaserin), as well as those drugs 
used off -labelConcurrent or previous use within 90 days of baseline 
biopsy (historical or on-study) until the end of the study
Herbal preparations or dietary supplements 
marketed for control of body weight or appetite or 
with any  suspected hepatotoxicityConcurrent or prior use in the period starting within 
14days prior to the start of screening and for the duration 
of the study. Furthermore, starting new herbal 
preparations or dietary supplements of any kind is not 
allowed once screening activities are initiated.
GLP-1, glucagon -like peptide -1; NAFLD, non -alcoholic fatty liver disease; NASH, non -alcoholic steatohepatitis; 
SGLT -2, sodium -glucose co tr ansporter [ADDRESS_795982] 
instance, conservat ive measures should be advised, including reducing meal size and 
maintaining adequate hy dration. If there is persistent vomit ing, a participa nt may be given an 
antiemetic to control his/her symptoms; a [ADDRESS_795983] (eg, 
ondansetron) or anti -histamine (eg, cy clizine) is preferable rather than ant iemetics, which may 
affect gastri c em ptying, and dopamine receptor antag onists (eg, metoclopramide or 
domperidone). Investigators should mo nitor parti cipants with vo miting for si gns of 
hypovo lemia. Parti cipants wi th impaired renal function could be especially sensit ive to 
hypovo lemia; such participants should be informed about the importance of adequate 
hydrat ion in case o f nausea and vo miting. These participants should also undergo addit ional 
laboratory  testing for poten tial creat inine increases as appropriate. Addit ional laboratory  
testing will be recorded in the eCRF . 
6.5.4 Manag emen t of Type 2 Diabetes Mellitus
[IP_ADDRESS] Use of Medications Known to Cause Hypoglycemia in Type [ADDRESS_795984] a higher risk of e xperiencing hypoglycemic events 
compared wi th those treated wi th other anti diabet ic agents. Investigators should consider 
insulin and sulfo nylurea dose reduction for any  parti cipant whom  they  consider m ay be at ri sk 
of hypoglycemia upon init iation of study intervent ion. 
[IP_ADDRESS] Therapi[INVESTIGATOR_601029] 2 Diabetes Mellitus
Parti cipants with T2DM should be managed on a stable dose of ant idiabet ic (glucose -
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 59of 129lowering) m edicat ion and/or di et for at least 90 days prior to screening ( Section 5.1). Minimal 
change ( ≤ 20%) to the total daily insulin dose within the 90 -day period pri or to screening will 
not be considered exclusio nary. For parti cipants with T2DM, additional management of 
glycemic control should be according to local guidelines as required. Details concernin g 
permitted and prohibited therapi[INVESTIGATOR_474899] T2DM are provided in Table11.
Table11 Permitted and Prohibited Thera pi[INVESTIGATOR_601030] 
2 
Diabetes Mellitus
Permitted therapi[INVESTIGATOR_601031]
• Any type of insulin 
• Biguanides
• Sulfon ylurea
• Glitinide
• Acarbose/alpha -glucosidase inhibitors
• SGLT2 inhibitor
• DPP-4 inhibitor• GLP-1 analog
• GLP-1 analog/insulin combination (eg, 
IDegLira)
• Pramlintide
DPP-4, dipeptidyl peptidase -4; GLP -1, glucago n-like peptide; SGLT2, sodium -glucose cotransporter 2
[IP_ADDRESS] Management of Hypoglycemia
A hypoglycemic event is considered severe if associated with severe cognit ive impairment 
requi ring external assistance for recovery , as defined by  [CONTACT_236050]; 
clinically significant hy poglycemia is defined as a capi[INVESTIGATOR_601032] <3.0 mmo l/L (54mg/dL). Few events of clinically significant hypoglycemia (< 3 mmo l/L) 
have been reported in participants treated with cotadutide up to [ADDRESS_795985] symptom s of 
hypoglycemia (hunger, dizziness, shaking, sweat ing, or irritabilit y) or feel unwell . Local  
protocol s for treatm ent and follow -up of  any hypoglycemic epi[INVESTIGATOR_601033]. Any 
clinically significant hy poglyce mia (gl ucose < 3.0 mmo l/l) should be reported by  [CONTACT_601085]. 
Pharmaco logical treatm ents administered for hy poglycemia (eg, dextrose/glucose tablets, 
glucagon, etc) should be recorded i n the eCRF as concomitant medicat ions. When possible, 
participants wi th T2DM should be priorit ized for early/m orning visi ts on days when the 
participant is fast ing (Section 1.3).
[IP_ADDRESS] Management of Hyperglycemia
When hyperglycemia is suspected, if deemed appropriate by [CONTACT_601086] T2DM guidelines, addit ional venous fast ing plasma glucose 
measurements may  be perfor med. In addit ion, ho me glucose and urine ketone monitoring to 
be perform ed by [CONTACT_601087] l ocal clinical pract ice. 
In parti cipants who have sustained hyperglycemia, the fo llowing opti ons are preferred:
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 60of 129An increase in insulin (if used)
Open -label changes to antidiabetic therapy  such as uptitration of sulfo nylurea/glit inide 
dose (if these agents were dose adjusted at the beginning of the study)
Addit ional drug slisted under the permitted therapi[INVESTIGATOR_351891]11may also be used at the 
discreti on of  the invest igator or the participant ’s general pract itioner. Any changes should be 
docum ented in the rel evant secti on of  the eCRF .
6.[ADDRESS_795986] igator 
shoul d consul t with the sponsor for guidance on restarting treatment.
Any int errupti on of theIP for 7 consecut ive days during the uptitration phase or for 14 days 
during the treatment period (after reaching the target dose of 300 or 600 μg) will const itute an 
important protocol deviat ion. 
6.[ADDRESS_795987] igator should:
Evaluate the participant to determine, in consultat ion with the sponsor, if possible, 
whether study  intervent ion shoul d be interrupted or whether the dose should be reduced.
Closely  monitor the parti cipant for any  AE/SAE and laboratory  abnorm alities as 
medically appropriate. Refer to Section [IP_ADDRESS] for details o f AE/SAE reporting related 
to overdose.
6.9 Intervention After the End of the Study
There i s no intervent ion following the end of the study . 
7 DISCONTINUATION OF STUDY INTERVENTION AND 
PARTICIPA NT DISCONTINUATION/WITHDRAWAL
7.1 Discontinuation of Study Intervention
It may be necessary  for a parti cipant to perm anent ly discont inue (definit ive discontinuation) 
study  interventi on. Parti cipants who discont inue study  intervent ion early will have an early  
discontinuat ion visit as described in the SoA  (Section 1.3). After the early discont inuat ion 
visit, participants will be encouraged to remain in the study  for all remaining visit s and study  
procedures as outlined in the SoA, with the exception of the urine pregnancy test, dispensation 
of study  intervent ion and In structi ons f or Use, and PK sampling. Participants will be 
encouraged to have the biopsy at W eek [ADDRESS_795988] 36 weeks. Samples 
for clinical safet y laboratory  assessments, amylase and lipase, coagulat ion parameters, and 
calcitonin do not need to be collected at visits occurring more than 30 days after 
discontinuat ion of study  interventi on except as needed for lab abnormalit ies/AEs that require 
follow-up to resolut ion. 
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 62of 129Note that discontinuation fro m study  intervent ion is NOT the same thing as a withdrawal fro m 
the study .
An individual participant will not rec eive any  further IP  if any of the f ollowing occur:
Withdrawal o f consent/assent from further treatment with IP.
Lost to follow -up.
Noncom pliance that, in the opi[INVESTIGATOR_3078] n of the invest igator or sponsor, warrants withdrawal 
(eg, refusal to adhere to scheduled v isits).
Pregnancy in a female part icipant .
An AE that, in the opi[INVESTIGATOR_1649] o f the invest igator or the sponsor, contraindicates further 
dosing; specific examples include:
Clinically significant tachyarrhyt hmias, including but not limited to life -threatening 
arrhythmia, eg, sustained ventricular tachycardia or ventricular fibrillat ion.
Acute pancreat itis 
oParti cipants will be instructed to contact [CONTACT_601088], with or without 
vomiting, because this is the hallmark symptom of acute pancreatit is warranting 
prom pt eval uation of serum amylase and lipase and prompt abdominal 
ultrasound. If pancreat itis is suspected, study  medicati on shoul d be di scontinued. 
If pancreat itis is confirmed , appropriate treatment should be init iated, and the 
participant shoul d be carefully mo nitored until recovery . 
Suspected or confirmed diagnosis of DILI
oIn case a participant shows an AST or ALT ≥ 3 × ULN together with TBL 
≥ 2 × ULN ,refer to Appendix E. Figure 2and Figure 3provide addit ional 
guidance in evaluat ing for DILI in this study  populati on.
Refer to the SoA  (Secti on 1.3)
 for data to be collected at the time of intervent ion 
discontinuat ion and 4- week fo llow-up.
7.2 Participant Withdrawal from the Study
A participant may withdraw fro m the study  at any  time at hi s/her own request or may be 
withdrawn at any  time at the di screti on of  the investi gator for safet y, behavioral, 
compliance, or administrative reasons (after discussion wit h the sponsor). This is 
expected to be uncommo n.
A participant who considers wit hdrawing fro m the study  must be inform ed by  [CONTACT_122610]
-up opti ons (eg, telephone contact, a contact [CONTACT_4490] a 
relative or treating physician, or information fro m medical records).
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 63of 129Refer to SoA for data to be collected at the time of study withdrawal and 4 -week fo llow-
up and for any  further eval uations that need to be completed.
If the participant withdraws consent for disclosure of future informat ion, the sponsor may  
retain and cont inue to use any data collected before such a withdrawal o f consent.
If a part icipant wi thdraws fro m the study , it shoul d be confirmed if he/she st ill agrees for 
exist ing samples to be used in line with the original consent. If he/she requests withdrawal 
of consent for use of samples, destruction of any samples taken and not tested should be 
carried out in line with what was stated in the informed consent and local regulat ion. The 
investigator must document the decisio n on use of exist ing samples in the site study  
records and inform the Global Study  Team .
7.[ADDRESS_795989] to fo llow-up if he /she repeatedly  fails to return for 
scheduled visits and is unable to be contact[CONTACT_17066].
The fo llowing acti ons m ust be taken if a participant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact [CONTACT_394096] o f maintaining the assigned visit 
schedule and ascertain whether the participant wishes to and/or should continue in the 
study .
Before a participant is deemed lost to fo llow up, the invest igator or designee must make 
every effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls and, 
if necessary , a certified l etter to the parti cipant’ s last known mailing address or local 
equivalent m ethods). These contact [CONTACT_13140]’s 
medical record.
Shoul d the participant continue to be unreachable, he/she will be considered to be lost to 
follow up . 
Discontinuat ion of specific sites or of the study  as a who le are handled as part of Appendix A.
8 STUDY ASSESSMENTS AND PROCEDURES
Study  procedures and their timing are summarized in the SoA  (Secti on 1.3). Protocol waivers 
or exempt ions are not allowed.
Immediate safet y concerns shoul d be discussed wit h the sponsor immediately upon occurrence 
or awareness to determine if the participant should continue or discont inue study  intervent ion.
Clinical Study Protocol -3.[ADDRESS_795990] reasons for 
screening failure, as applicable.
8.1 Efficacy Assessments
8.1.1 Liver Biopsy- based Histopathology
Liver biopsy samples taken at baseline (either historical [co llected within 180days of 
rando mizat ion] or taken during the screening period), at W eek 48, or at Early Discont inuat ion 
will be assessed centrally  by a Central  Pathol ogy Review Committee to determine the NAS 
and fibrosis staging. Details of liver biopsy procedure are des cribed in the Histopathol ogy 
Manual . 
8.1.2 Artificial Intelligence- based Histopathology
Artificial intelligence -based histopathology  assessments will be conducted for all histology  
endpo ints related to NAS and fibrosis staging ( Bosch et al 2021 , Taylor-Weiner et al 2021 ) at 
the time po ints specified in Sect ion 1.3.
 
8.1.3 FibroScan and FibroScan -derived Biomarkers
FibroScan®will be used to assess liver st iffness and CAP at sites where it is feasible to do so, 
at the time points spec ified in Sect ion 1.3. If a site has access to appropriate FibroScan 
equipment, as well as compat ible so ftware and probes, they  must com plete the assessments 
per the schedule. If not and the assessment cannot be conducted, this will not constitute a 
deviat ion from the protocol. The LSM must be performed in a fast ing state and according to 
site standard procedures. At sites with FibroScan equipment w ith CAP option available, 
measurements of liver steatosis must be performed at the specified visits . FibroScan -derived 
biomarkers will be assessed. F AST score (a combinat ion of FibroScan -derived CAP , LSM, 
and AST level) and Agile 3+ score (a combinat ion ofFibroScan -derived LSM, AST , ALT, 
platelet, age, sex, and diabetes status ) will be calculated for participants at sites that have the 
requi red software or access to the website.
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 65of 1298.1.4 Height and Weight
Standing height andbody  weight will be m easured at the time points specified in the SoA  
(Secti on 1.3). 
Height will be measured once at screening only  and recorded in centimeters. 
The parti cipant's weight sho uld be m easured after the participant has removed bulky clothing 
including shoes. The participant's body weight will be recorded in kilograms to [ADDRESS_795991] (Section 8.2.5)
Disease -specific 
biomarkersCollagen turnover: Pro -C3
ELF™ (components): PI[INVESTIGATOR_120861], hyaluronic acid, and TIMP -1
FIB-4 index (components): platelet count, ALT, AST
APRI (components): AST, platelet count
NFS (components): ALT, AST, platelet count, albumin
BARD score (components): ALT, AST
FAST score a(components): CAP, LSM, AST ( Section 8.1.3 )
Agile 3+ a(components): LSM, AST, ALT, platelet count, age, sex, diabetes status
(Section 8.1.3)
Glucose control HbA1c, fasting plasma glucose, adiponectin, C -peptide
Blood pressure SBP (Section 8.2.3 )
Lipi[INVESTIGATOR_462734], LDL cholesterol, HDL cholesterol, triglycerides, non -HDL 
cholesterol
Optional biomarkers 
(serum based)Biomarker research, including markers disease status and response to cotadutide 
(Section 8.5.2)
aFAST score and Agile 3+ will be calculated only at sites that have the required software.
ALT, alanine aminotransferase; APRI, AST -to-platelet ratio index; AST, aspartate aminotransferase; BARD, body mass
index, AST/ALT ratio, diabetes; CAP, controlled attenuation parameter; ELF, enhanced liver fibrosis score; FAST, 
FibroScan -AST; FIB -4, fibrosis -4; HbA1c, hemoglobin A1c; HDL, high -density  lipoprotein; LDL, low -density  lipoprotein; 
LSM, liver stiffness measurement; NFS, non -alcoholic fatty liver disease fibrosis score; PI[INVESTIGATOR_120861], amino -terminal propeptide of 
type III -procollagen, Pro-C3, released N -terminal propeptide of type III collagen; SBP, systolic blood pressure; TIMP -1, 
tissue in hibitor of metalloproteinase type -1 
8.2 Safety Assessments
Planned time po ints for all safet y assessments are provided in the SoA  (Secti on 1.3).
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 66of 1298.2.1 Medical History
Com plete m edical history  will include history  and current m edical condit ions; past or present 
CV disorders; respi[INVESTIGATOR_696] , gastrointestinal, renal, hepatic, neurological, endoc rine, lymphat ic, 
hematol ogic, immunol ogic, dermatological, psychiatric, genitourinary , or any  other di seases 
or disorders; drug and surgical history; and history of alcoho l and tobacco use. If the 
participant reports a history  of gallbladder ul trasound per formed < 12 m onths pri or to 
screening, the ultrasound report should be obtained and should be noted on the eCRF . 
Presence or absence of gallbladder disease/cho lelithiasis should be noted f or all partici pants 
and recorded on the eCRF.
The AUDIT questionnair e (Appendix F) to assess al coho l use habits will be co mpleted at 
screening only (Sect ion 1.3). The results will be used for determining participant eligibilit y 
(Secti on
 5.2). 
8.2.2 Physical Examinations
Physical examinat ion will be performed at timepoints as specified in Section 1.3. 
A full physical examinat ion will be performed an d incl ude assessments of the following: 
general appearance including skin inspect ion, lymph nodes, thy roid, 
musculoskeletal/extremit ies, CV system, lungs, abdomen, and reflexes . 
An abbreviated physical examination will include, at a minimum, assessments o f the skin, 
extremit ies, CV system, lungs, and abdo men.
Clinically significant abnormalit ies in physical examinat ion findings at study  termination must 
be followed up by [CONTACT_601089] h addit ional tests/procedures if necessary , 
until the underlying cause is diagnosed or resolution occurs. As appropriate, the diagnosis and 
resol ution date of the physical examinat ion abnormalit ies must be reported as AEs.
Invest igators should pay special attention to clinical signs related to previous se rious illnesses. 
New or worsening abnormalit ies m ay qualify  as AEs; addit ional details are provided in 
Secti on 1.3. 
8.2.3 Vital Signs
Vital sign m easureme nts (SBP , DBP , pulse, body  temperature, and respi [INVESTIGATOR_2842]) will be 
obtained in accordance with appropriate guidelines after the participant has rested in the 
seated posit ion for at least 10 minutes in a quiet setting without distractions at the visits 
specified in Secti on
 1.3. 
Vital sign m easurements shoul d be taken pri or to IP administration (where applicable) and 
before blood drawing. BP and puls e measurem ents will be assessed with a completely  
autom ated device. Manual techniques will be used only  if an autom ated device is not 
Clinical Study Protocol -3.[ADDRESS_795992] 10 minutes, according to the SoA  (Secti on 1.3). The 
investigator may  add extra [ADDRESS_795993] blinded to the study  
treatm ent. Where digital transmissio n is not possible, a process for receipt and analysis of 
scanned or paper ECGs is also established.
Confirmed ECGs will be available on a study  portal within the contracted turnaround time.
On-screen measurements of the RR, PR, QRS, and QT interval durat ions will be performed, 
and variables for QT cF, QTcB,and heart rate will be calculated. Each fiducial po int (onset of 
P wave, onset of Q wave, off set of  S wave, and offset of T wave) will be electronically 
marked. The original ECG waveform and such annotations will be saved separately in XML  
format for independent revi ew.
The invest igator or authorized delegate will make an init ial assessment of whe ther the ECG 
Clinical Study Protocol -3.[ADDRESS_795994] igator ’s init ial assessment and the central ECG reading, the 
central  reading will take precedence.  
If a site requi res expedited reporting for ECGs due to suspected ECG abnormalit ies or for 
urgent decisio n making, the site should contact [CONTACT_601090].
In case of an ECG device malfunction, the site should fo llow the steps recommended within 
the Cardi ac Safet y Study  Manual in order to have the ECG analyzed in a timely manner . 
8.2.[ADDRESS_795995] 
inform ation, specific to this clinical research study . Blood and urine samples for determinat ion 
of clinical chemistry , hematol ogy, coagul ation, and urinalysis will be collected at the visits 
indicated in the SoA  (Secti on 1.3).
The invest igator should make an assessment of the available results with regard to clinically 
relevant abnorm alities. The l aboratory  resul ts should be si gned and dated and retained at 
center as source data for laboratory  variables. The investigator should follow all clinically  
significant laboratory  abnorm alities occurring during the study  that were not present at 
baseline. These abnormalit ies shoul d be evaluated with addit ional tests, if necessary , until  the 
underlying cause is diagnosed, or resol ution occ urs. The diagnosis and reso lution date must be 
reported to the sponsor.
Inform ation about how AEs based on laboratory tests should be recorded and reported are 
provi de in Sect ion 8.3.5 .
Addit ional safet y samples may  be collected if clinically indicated at the discret ion of the 
investigator . The date of co llection will be recorded on the appropriate eCRF .
Laboratory  variables to be measured are listed i n Table13.
Table13 Laboratory Safety V ariables
Hematology/hemostasis (whole blood) Clinical chemistry (plasma or serum)
  B-Hemoglobin   S/P -Creatinine
  B-Leukocyte count   S/P -Bilirubin, total
  B-Leukocyte differential count (absolute count)   S/P -Alkaline phosphatase
  B-Platelet count   S/P -AST
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 69of 129Table13 Laboratory Safety V ariables
  B-Red blood cell count   S/P -ALT
  B-Hematocrit   S/P -Albumin
  B-Mean corpuscular hemoglobin concentration   S/P -Potassium
  B-Mean corpuscular volume   S/P -Calcium, total
  B-Red cell distribution width   S/P -Sodium
  B-Red blood cell morphology   S/P -Blood urea nitrogen
  S/P -Phosphorous
Urinalysis (dipstick)   S/P -Bicarbonate
  U-Hem oglobin/erythrocytes/blood   S/P -Glucose
  U-Protein   S/P -Chloride
  U-Microscopic analysis (if positive for blood, nitrites, or protein)   S/P -GGT
  U-Glucose
  U-Ketones
  U-pH
  U-Specific gravity
  U-Bilirubin
  U-Color
  U-Appearance
  U-Nitrites
  U-Leukocytes
  U-Ur obilinogen
  U-Drugs of abuse, standard panel (Screening only)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; B, blood; GGT, gamma glutamyl transferase;
P, plasma; S, serum; U, urine
NB. In case a participant shows an AST orALT ≥ 3 × ULN together with TBL  ≥ 2 × ULN 
please refer to Appendix E. Actions required in cases of increases in liver bio chemistry  and 
evaluat ion of HL, for further instructi ons. Figure 2and Figure 3provide addit ional guidance 
inevaluat ing for DILI in this study  popul ation.Reproduction (Female Participants of 
Childbearing Potential Only)
Serum  beta -hCG at screening onl y 
Urine hCG, by  [CONTACT_5230], thereafter 
Follicle -stimulating horm one at screening only  (if not m easured in the previous 
12months) 
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 70of 129Additional Laboratory Assessments
Safety
Serum  calcitonin
Serum  amylase and lipase
HBsAg, ant i-HCV, HCV RNA (screening only )
HIV-1 and HIV -2 antibodies (screening only)
Coagulation parameters (prothrombin t ime, activated partial thromboplast in time, and 
INR)
MELD score (composite of INR, sodium, bilirubin, and creatinine) 
Direct bilirubin (in the presence of Gilbert's syndrom e)
eGFR (CKD -EPI [INVESTIGATOR_361987] [ Inker et al  2021 ])
8.2.6 Other Safety Assessments
[IP_ADDRESS] Assessment of Injection Sites
Site staff will assess the inject ion si te for injecti on si te reacti ons at the times specified in the 
SoA (Section 1.3). Inject ion site reactions will be recorded as AEs. The site of injection should 
be rotated to avoid previously injected sites. In the case of an inject ion site react ion, these 
shoul d be ini tially managed with a cold compress. Symptomatic treatment with ant ihistamines 
may be required in the presence of itching, and/or topi[INVESTIGATOR_601034], particularly if the reaction progresses over several days. Oral nonsteroidal 
anti-inflammatory  therapy  may also be consi dered.
8.[ADDRESS_795996] ion.
The definit ions of an AE or SAE can be found in
 Appendix B.
Adverse event s will be reported by  [CONTACT_17071] (or, when appropriate, by  a caregiver, 
surrogate, or the participant's legally authorized representative). 
The invest igator and any designees are responsible for detecting, documen ting, and recording 
events that meet the definit ion of an AE. Informat ion about how to fo llow up AEs is provided 
in Section 8.3.[ADDRESS_795997] igator becomes aware of an SAE with a suspected cau sal relati onship to the IMP
that occurs after the end of the clinical study  in a parti cipant treated by  [CONTACT_198671], the 
investigator shall, wit hout undue delay , report the SAE to the sponsor .
8.3.2 Follow- up of AEs and SAEs
Any AEs/SAEs that are unresolved at the participant ’s final visit of the study  are f ollowed up 
by [CONTACT_24549], but without further recording in the 
eCRF . [COMPANY_008] retains the right to request additional information for any  parti cipant wi th 
ongoing A E(s)/SAE(s) at the end of the study , if judged necessary .
Adverse Event Variables
'The following variables will be collected for each AE: 
AE (verbat im)
The date when the AE started and stopped
Maximum intensit y
Whether the AE is serious or not
Invest igato r causalit y rating against the IP(s) (y es or no)
Invest igator causalit y rating against the study  procedure(s) (yes or no) 
Action taken with regard to IP(s)
AE caused participant’s withdrawal fro m study  (yes or no) 
Outcom e
In addit ion, the fo llowing vari ables will be collected for SAEs:
Date AE m et cri teria for SAE
Date invest igator became aware of SAE
AE is seri ous due to
Date of hospi[INVESTIGATOR_059]
Date of discharge
Probable cause of death
Date of death
Autopsy  performed
Causalit y assessment to other medica tion
Clinical Study Protocol -3.[ADDRESS_795998], study  
procedure, medical device and each AE, and answer ‘yes’ or ‘no’ to the questi on ‘Do y ou 
consider that there is a reasonable possibilit y that the event may  have been caused by [CONTACT_33155]? ’
For SAEs, causal relat ionship should also be assessed for other medicat ion, study  procedures, 
or medical devices. Note that for SAEs that could be associated with any study  procedure the 
causal relat ionship is implied as ‘yes’.
A guide to the interpretation of the causalit y question is found in Appendix Bto the Clinical 
Study  Protocol . 
8.3.4 Adverse Events Based on Signs and Symptoms
All AEs spontaneously reported by [CONTACT_122613]: “Have y ou had any  heal th probl ems since the previous visit ?”or 
revealed by  [CONTACT_531428] . When collecting AEs, the 
recording of diagnoses is preferred (when possible) to recording a list of signs and symptom s. 
However, if a diagnosis is known and there are other signs or symptoms that are not generally 
part of the diagnosis, the diagnosis and each sign or symptom will be recorded separately .
8.3.[ADDRESS_795999] igator (which may include but not limited to consideration as to whether 
treatm ent or non -planned visits were required or other actio n was taken with the study  
intervent ion, eg, dose adjust ment or drug interruption).
If deteri oration in a laboratory  value/vi tal sign i s associ ated wi th clinical signs and symptoms, 
the sign or symptom  will be reported as an AE and the associated laborato ry resul t/vital sign 
will be considered as addit ional informat ion. Wherever possible the reporting invest igator 
uses the clinical, rather than the laboratory  term  (eg, anemia versus low hemoglobin value). In 
the absence of clinical signs or symptoms, clini cally  relevant deteri orations in non -mandated 
param eters shoul d be reported as AE(s).
Any new or aggravated clinically relevant abnormal medical finding at a physical examinat ion 
as com pared wi th the baseline assessment will be reported as an AE unless une quivocally 
Clinical Study Protocol -3.[ADDRESS_796000] for this study  include: 
Nausea
Vomit ing
Increased heart rate
Inject ion site reaction
Blood pressure al terati on (hypotension/hypertensio n)
Hypoglycemia
Diabetic ketoacidosis
Anti-drug ant ibody
Pancreat itis
Pancreat ic carc inoma
Thyroid carcino ma
Acute renal failure secondary to dehy dration
Drug -induced liver injury
Cardi ovascular events
Gallbladder -related disease
These AESIs are to be reported as described in Section 8.3.[ADDRESS_796001] ive of liver biopsy co mplicat ion (eg, pain, bleeding [intraperitoneal 
hemorrhage, hematoma, hemo bilia], etc) should be reported as AEs or SAEs, as applicable. 
8.3.8 Hy’s Law
Case s where a participant shows elevations in liver biochemistry  may requi re further 
evaluat ion and occurrences of AST or ALT ≥ 3 × ULN together with TBL  ≥ 2 × ULN may 
need to be reported as SAEs. Please refer to Figure 2, Figure 3, 
and Appendix Efor further 
instructi on on cases of increases in liver biochemistry  and evaluat ion for HL.
8.3.[ADDRESS_796002] to be reported, whether considered causally  related to the IP , or to the study  
procedure(s). All SAEs will be recorded in the eCRF .
If any SAE occurs in the course of the study , investi gators or other site personnel will inform 
the appropriate [COMPANY_008] representatives within 1day ie, immediately but no later  than [ADDRESS_796003] igator or other study  site 
staff reports the SAE via secure method to the appropriate [COMPANY_008] representative.
When the electronic data capture sy stem is tem porarily  not accessible, the [COMPANY_008] Study  
Representative should confirm that the investigator/site staff enters the SAE in the 
[COMPANY_008] electroni c data capture system when access resumes.
For further guidance on the definit ion of an SAE, refer to Appendix B. The reference 
docum ent for defini tion of expectedness/listedness is the IB. 
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 75of 1298.3.10 Clinical Events for Adjudication
A CEA  committee, blinded to the treatment of the participant, will independent lyadjudicate 
certain clinical AEs. The CEA  committee will operate in accordance with the CEA  Charter 
and Event Handling Manual for sites and site monitors. 
The CEA  commi ttee will adjudicate events possibly  related to the following:
1Events of hepat ic deco mpensati on include:
(a)Clinically apparent ascites requiring treatment
(b)Com plicat ion of ascites (eg, spontaneous bacterial peritonit is, di uretic-resistant 
ascites [refractory  ascites], hepato -pleural effusio n)
(c)Hepati c encephal opathy  of Grade 2 or above (accordin g to the West Haven criteria as 
defined in Appendix G) requi ring treatm ent
(d)Portal hypertensio n-related upper gastrointestinal bleeding identified by  [CONTACT_601091][INVESTIGATOR_3094], including events of bleeding fro m esophageal varices, 
gastri c varices, and portal  hypertensive gastropathy
(e)Liver transplantation or qualificat ion for liver transplantation, defined as a MELD 
score ≥ [ADDRESS_796004] 4 weeks apart
2Clinical cirrhosis
3Events of suspected DILI
4Hepatocellular carcino ma
5All deaths (and CV deaths)
6Cardi ac ischemic events:
(a)Myocardial  infarct ion
(b)Hospi[INVESTIGATOR_10929]
7Cerebrovascular events:
(a)Stroke
8Hospi[INVESTIGATOR_19934] 
9Diabetic ketoacidosis
10Events of thy roid carcino ma, pancreat itis, and pancreatic carcino ma 
For all Clinical Events ident ified for adjudicat ion, the invest igator will complete the 
appropriate modules of the eCRF and provi de source docum entati on. In order to provide the 
independent adjudicat ion committee with appropriate and adequate informat ion for 
adjudicat ion of the listed events, consult the CEA  Charter and Event Handling Manual for 
Sites and Monitors.
Possible cases of DILI will be mo nitored and managed using the algorithm described in 
Clinical Stu dy Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 76of 129Figure 2and Figure 3, whi ch is based on the IQ DILI Init iative consensus guideline ( Regev et 
al 2019 )as well as
 Appendix E, which will be use d for the reporting of PHL cases.
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 77of 129Figure 2 Stoppi[INVESTIGATOR_601035]/Near 
Normal ALT at Baseline
aLiver -related symptoms include: severe fatigue, nausea, vomiting, right upper quadrant pain .
Baseline pretreatment ALT is derived from theaverage ofthe last ALT measurement prior to randomization and the randomization visit (V2) based on central 
laborato ry assessments . Elevated baseline is de fined as ALT > 1.5 × ULN. 
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DILI, drug -induced liver injury; INR, international normalized 
ratio; TBL, total bilirubin; ULN, upper limit of normal

Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 78of 129Figure 3 Stoppi[INVESTIGATOR_601036] -related symptoms include: severe fatigue, nausea, vomiting, right upper quadrant pain .
Baseline pretreatment ALT is derived from the average of the last ALT measurement prior to randomization and the randomization visit (V2) based on cent ral 
laborato ry assessments. Elevated baseline is defined as ALT > 1.5 × ULN. If on treatment a participant has 2 or more consecutiv e ALT values at scheduled visits
based on central laboratory assessments, each less than 50% of the baseline ALT and they are within 40% of each other (with percentage calculated based on the 
larger value as the denominator), then a new baseline should be set to be the minimum of the latest consecutive pair of values that are “stable” (ie, within 40% of 
each other).
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DILI, drug -induced liver injury; INR, international normalized 
ratio; TBL, total bilirubin; ULN, upper limit of normal

Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 79of 1298.3.11 Pregnancy
All pregnancies and outcomes of pregnancy should be reported to [COMPANY_008] except for:
If the pregnancy  is discovered before the study  parti cipant has receiv ed any  study  
intervent ion
Pregnancies in the partner of male participants
[IP_ADDRESS] Maternal Exposure
If a participant beco mes pregnant during the course of the study , IP should be discontinued 
immediately .
Pregnancy itself is not regarded as an AE unless there is a suspi[INVESTIGATOR_24510] n that the IP under study 
may have interfered with the effect iveness of a contraceptive medicat ion. Congenital 
anomalies/bi rth defects and spontaneous miscarriages should be reported and handled as 
SAEs. Elective abortions wit hout complicat ions should not be handled as AEs. The outcome 
of all pregnancies (spontaneous miscarriage, elect ive terminat ion, ectopic pregnancy , normal  
birth or congenital ano maly/birth defect) should be fo llowed up and docum ented even if the 
participant was discont inued fr om the study .
If any pregnancy  occurs in the course of the study , then the investigator or other site personnel 
informs the appropriate [COMPANY_008] representatives within [ADDRESS_796005] igator to ensure that all 
relevant informat ion is provided to the [COMPANY_008] Pati ent Safet y data entry  site within 1 or  
5calendar  days for SAEs (Section 8.3.9 ) and within 30 days for all other pregnancies.
The same timelines apply when outcome informat ion is available.
The PREGREP module in the eCRF is used to report the pregnancy and the paper -based 
PREGOUT module is used to report the outcome of the pregnancy .
8.3.12 Medication Error, Drug Abuse, and Drug Misuse
[IP_ADDRESS] Timelines
If an event of medication error, drug abuse, or drug misuse occurs during the study , then the 
investigator or other s ite personnel informs the appropriate [COMPANY_008] representatives within 
1calendar  day, ie, immediately  but no later  than [ADDRESS_796006] igator to ensure that all 
relevant informat ion is completed wi thin 1(Initial Fatal /Life -Threatening or follow up 
Clinical Study P rotocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 80of 129Fatal /Life -Threatening) or 5(other serious init ial and fo llow up) calendar  days if there is an 
SAE associated with the medicat ion error , drug abuse, or misuse (Section 8.3.9 ) and within 
30days for all other medicat ion errors.
[IP_ADDRESS] Medication Error
For the purposes of this clinical study , a m edicat ion error is an unintended failure or mistake 
in the treatment process for an IMP or [COMPANY_008] NIMP that either causes harm to the 
participant or has the potential to cause harm to the participant.
The full definit ion of medicat ion error can be found in Appendix B 4. 
[IP_ADDRESS] Drug Abuse
Drug abuse is the persistent or sporadic intentional , non -therapeutic excessive use of IMP or 
[COMPANY_008] NIMP for a perceived reward or desi red non -therapeuti c effect.
The full d efinition of drug abuse can be found in Appendix
 B 4. 
[IP_ADDRESS] Drug Misuse
Drug misuse is the intentional and i nappropriate use (by a study  partici pant) of  IMP or 
[COMPANY_008] NIMP for medicinal purposes outside of the authorized product informat ion, or 
for unauthorized IMPs or [COMPANY_008] NIMPs, outside the intended use as specified in the 
protocol  and includes del
iberate administration of the product by  [CONTACT_244972].
The full definit ion of drug misuse can be found in Appendix B 4
. 
[IP_ADDRESS] Reporting of Overdose
Refer to Section
 6.8for definit ion and treatment of overdose. 
An overdose with associated AEs is recorded as the AE diagnoses/symptoms on the 
relevant AE m odules in the eCRF and on the Overdose eCRF module.
An overdose without associated symptoms is only  reported on the Overdose eCRF 
module.
If an overdose on an IMP or [COMPANY_008] NIMP occurs in the course of the study , the 
investigator or other si te personnel inform appropriate [COMPANY_008] representatives 
immediately , but no later  than [ADDRESS_796007] igator to ensure that all 
relevant informat ion is provided to the [COMPANY_008] Pati ent Safet y data entry  site within 1 or
 
5calendar  days for overdoses associated with an SAE (Section 8.3.9 ) and within [ADDRESS_796008] confident iality. For further details on Handling of Human Bio logical 
Samples refer to Appendix C.
Samples will  be stored for a m aximum  of 15 y ears fro m the date of the i ssue of the CSR in 
line with consent and local requirements, after which they will be destroyed/repatriated. 
PK samples will be disposed of after the Bioanaly tical Report finalizat ion or 6 m onths 
after issuance of the draft Bioanaly tical Report (whichever is earlier), unless consented 
for future analyses. 
PK samples may be disposed of or anonymized by [CONTACT_76435]. A dditional analyses may 
be conducted on the anonymized, pooled PK samples to further evaluate and validate 
the analy tical method. Any results from such analyses may  be reported separately  
from the CSR.
Remaining ADA sample aliquots will be retained at Astra Zeneca or its designee for a 
maximum o f 15 years fo llowing issue of the CSR. Addit ional use includes but is not 
limited to further characterizat ion of any ADAs, confirmat ion and/or requalificat ion of 
the assay as well as addit ional assay  devel opment work. The results from future analysis 
will not be reported in the CSR.
8.4.1 Pharmacokinetics
Plasma sam ples will be collected for measurement of concentrations of cotadutide as 
specified in Secti on 1.3.
Samples may  be collected at addi tional time points during the study  if warranted and 
agreed upon between the invest igator and the sponsor, eg, for safety reasons. The timing 
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 82of 129of sampling may be altered during the course of the study based on newly available data 
(eg, to obtain data closer to the time of peak or trough matrix concentrations) to ensure 
appropriate monitoring. 
Plasma samples will be used to analyze the PK of cotadutide. Samples collected for 
analyses o f cotaduti de plasma concentrati on m ay also be used to evaluate safety  or 
efficacy  aspects rel ated to concerns arising during or after the study .
Samples will  be collected, l abeled, stored, and shipped as detailed in the Laboratory  
Manual .
Determination of Drug Concentration
Samples for determination of drug concentration in plasma will be assayed by  [CONTACT_415536] o f Ast raZeneca, using an appropriately validated 
bioanalyt ical method. Full details o f the analy tical method used will be described in a separate 
Bioanaly tical Report.
Drug concentration informat ion that mayunblind the study  will not be reported to 
investigat ive sites or blinded personnel .
Incurred sample reproducibilit y analysis, if any ,will be perform ed al ongside the bioanalysis 
of the test samples. The results from the evaluat ion, if performed, will be reported in a 
separate Bioanaly tical Report.
8.4.[ADDRESS_796009] raZeneca, 
using appropriately validated bioanalyt ical methods. Tiered analyses will be performed to 
include screening, confirmatory , and ti ter assay  components . Assessment of cross- reactivit y to 
GLP -1 and gl ucagon may be performed on samples that are confirmed posit ive for ADA.
ADA  samples may also be further tested for characterizat ion of the ADA  response. Addit ional 
analyses may be conducted on anonymized, individual or pooled immunogenicit y samples to 
further evaluate and validate the analyt ical method. Any results fro m such analyses may  be 
reported separately  from the CSR.
Samples will  be collected, l abeled, stored, and shipped as detailed in the Laboratory  Manual.
8.4.3 Pharmacodynamics 
8.5 Human  Biological Sample Biomarkers
8.5.1 Collection of Mandatory Samples for Biomarker Analysis
Requi red samples for bi omarker research (Section 8.1.5 ) will be collected from all part icipants 
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 83of 129in this study  as specified in the SoA  (Section 1.3).
Analysis of biosamples may be performed for safety analytes or for biomarkers or analytes 
that may  play a rol e in NASH and related condit ions including but not limited to their 
associ ation with disease progressi on and observed clinical responses to cot adutide. The results 
of this biomarker research may  be reported ei ther in the CSR or as an addendum, or separately 
in a scient ific report or publicat ion. The results of this bio marker research may be pooled with 
biomarker data from other studies to generat e hypotheses to be tested in future research.
8.5.[ADDRESS_796010] ion of opti onal samples for bi omarker research is also part of this study  as specified in 
the SoA  (Secti on 1.3) and i s subject to agreement to optional consent. Optional blood samples 
will be co llected, and analysis may be performed for safet y analytes or for bio markers thought 
to play a rol e in NASH a nd rel ated condi tions including, but not limited to, their associat ion 
with disease progressi on and observed clinical responses to cotadutide. Optional bio marker 
samples will be co llected according to local regulatory approval. 
8.[ADDRESS_796011] for cotadutide 
versus placebo inthe FAS. 
9.2 Sample Size Determination
Approximately  7440 parti cipants were ori ginally planned to be screened/enrolled to achieve 
1860 randomly assigned to study  intervent ion, including 300 in Part A. However, t his study 
has prem aturely  stopped randomizat ion as the cotaduti de program  has been d iscont inued. The 
sample size fo r this study  includes approximately 55randomized participants . The original 
Clinical Study Proto col-3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 84of 129sample size calculat ions for Part Aare detailed below .
In Part A, 300 participants were originally  to be rando mized in a 2:1:2:[ADDRESS_796012] to the comparison of 
each cotadutide group to the pooled placebo group for the proportion o f participants wi th 
resol ution of NASH without worsening of liver fibrosis at W eek 48. The sample size woul d 
provi de > 90% power for the test of each dose versus placebo to detect a difference o f 20% in 
NASH reso lution assuming a placebo response rate of 1 5%. The calculat ions assume da 
2-sided alpha level o f 0.05.
The effects were assumed after any  impacts from  treatm ent discont inuat ion, early  withdrawal , 
missing data imputation, etc. The assumed effect sizes for the histology -based endpo ints took 
into account the PROXYMO interim analysis results as well as the published effects for a 
GLP -[ADDRESS_796013] ( Newsome et al 2021).
Note : “Enro lled” means a parti cipant ’s, or thei r legally  acceptable representative ’s, agreement 
to parti cipate in a clinical study  following com pletion of the informed consent process. 
Potenti al parti cipants who are screened for the purpose of determining eligibilit y for the study 
butare not randomly assigned/assigned in the study , are considered “screen failures. ” 
9.3 Populations for Analyses
The fo llowing popul ations are defined:
Table 14 Populations for  Analysis
Population/Analysis 
setDescription
Enrolled All participants who sign the ICF .
Randomized All participants randomized into the study .
FAS All participants who have been randomized to and received at least one dose of IP .
PP Subset of FAS population with evaluable post -baseline biops y after at least [ADDRESS_796014] one dose 
of IP. Erroneously treated participants (eg, those randomized to treatment A but 
actually  given treatment B) are accounted for in the treatment group with the majority
of estimated usage. In all cases, the dose level for analysis will correspond to the 
randomized dose. 
PK The PK population includes all participants w ho receive at least [ADDRESS_796015] 1 complete intended PK sample contai ning detectable 
cotadutide concentrations.
FAS, full analysis set; ICF, informed consent form; IP ,investigational product; PK ,pharmacokinetic(s) ; PP,per 
protocol
Clinical Study Protocol -3.[ADDRESS_796016] ics.
Exploratory  efficacy a nalys es will use nominal 2-sided 5% si gnificance levels (equivalent to 
nominal 1-sided 2.5% si gnificance levels) unless otherwise stated.  
The primary estimand o f interest for the histological endpo ints will usethe treatm ent policy  
strategy .The treatm ent policy  approach applies to intercurrent events of treatment 
discontinuat ion, deviat ions from  the protocol  titration schedule, changes in background 
medicat ion,liver events, or use of prohibited med ication or other protocol  deviat ions. The 
treatm ent policy strategy  will also be used to handle the intercurrent events for continuous 
endpo ints.
Parti cipants will be analyzed according to their randomized IP assignment and dose, 
irrespect ive of the treatm ent they  actually received. Analyses will be performed using the F AS 
and/or per protocol analysis sets, as appropriate (Table 14).The F AS will include all 
rando mized and treated participants who received at least one dose of IP irrespect ive of their 
protocol  adherence, addi tion or m odificat ion of background medication s, discont inuat ion of 
study  interventi on or swi tches to al ternat ive medications, and continued participation in the 
study .
9.4.2 Efficacy 
The fo llowing exploratory  endpo ints will be analyzed descript ively versus placebo with 
95% CIs at the nominal 2- sided alpha 5% level:  
Reso lution of NASH at Week 48 without worsening of fibrosis
Improvem ent in fibrosis at Week 48 without worsening of NASH
Reso lution of NASH and improvement in fibrosis at Week 48
Improvem ent in fibrosis by [INVESTIGATOR_136] l east one stage at Week 48
Change from baseline in triglycerides, LDL cho lesterol , HDL cho lesterol , non -HDL 
cholesterol , total  chol esterol , and HbA1c through Week 48
Addit ional exploratory  endpo ints and their analyses will be detailed in the SAP .  
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 86of 129The binary endpoint(s) will be analyzed using a Cochran -Mantel -Haenszel test wi th 
stratificat ion by T2DM presence and F2/F3 fibrosis stages. The treatment effects will be 
summarized by  [CONTACT_601092], 95% CI, and p- value. For the exploratory  
analysis of binary  histol ogical endpoin tsusing F AS, parti cipants wi th no liver outcom e and 
missing histology  data due to any  reason may be imputed as non -responders. 
Continuous endpo ints (abso lute change in body  weight, change in HbA1c, percent change in 
triglyceri des) will  be analyzed using Analysis of Covariance models, adjusting for baseline 
value, presence of T2DM, and fibrosis stage (F2/F3). For the primary analyses of these 
endpo ints, missing data will be imputed via mult iple imputations.
9.4.[ADDRESS_796017] ics unless otherwi se specified and will not be formally  tested. 
Safety events and findings will be summarized by [CONTACT_1570]. Erroneously treated 
participants (eg, th ose ran domized to treatment A but actually  given treatment B) are 
accounted for in the treatment group with the majo rity estimated usage. The majorit y 
estimated usage will be determined based on which treatment had more kits dispensed (not 
including kits returned unused). In the case of a tie, the randomized treatment will be used for 
safet y analyses. In all cases, the dose group will be the same as randomized dose level.
Adverse Events
Adverse events will be coded using the most recent versio n of the MedDRA  that will have 
been released for execution at [COMPANY_008]. AEs will be presented for each treatment group by  
[CONTACT_93455]/or Preferred T erm covering number and percentage of participants reporting at least 
one event and number of events where appropriate. Exposure -adjusted incidence rates may  be 
provi ded as appropri ate. Only  treatm ent-emergent AEs will be summarized.
An overview of AEs will present the number and percentage of participants with any AE, AEs 
with outcome of death, serious AEs, AEs leading to discont inuation of IP , and AEs leading to 
dose reduction of IP for each treatment group.
Separate AE tables will be provided taking into consideration the relat ionship as assessed by  
[CONTACT_3170] , maximum intensit y, seriousness, death and events leading to disco ntinuat ion 
of IP as well as AESIs. 
In accordance with the requirements of the FDA, a separate table will present non -serious AEs 
occurring in more than 5% of participants in any treatment group. 
Vital Signs
Vital sign param eters will  be presented for eac h treatment group. Summary  statist ics for 
Clinical Study Protocol -3.[ADDRESS_796018] been ident ified during the course of the study . 
Electrocardiogram
ECG pa rameters will be presented for each treatment group. Summary statistics for 
continuous variables will cover n, mean, SD, min, median and max. Frequency tables will 
cover number and percentage of participants in the respective category . The (uncorrected) QT
interval  will be corrected according to the Fridericia ’s formula. Param eters to be tabul ated are 
listed in Section 3.1.
For each scheduled post- basel ine assessment, descriptive statist ics for all ECG parameters will 
be presented for observed values and change fro m baseline. Addit ionally , summaries will be 
made of all ECG parameters fulfilling potentially  clinically  significant cri teria during the 
treatment period.
9.4.[ADDRESS_796019] the PK data (such as, but not 
limited to participants not receiving complete/full intended cotadutide dose) may result in the 
Clinical Study Protocol - 3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 88of 129exclusio n of concentration data fro m the PK analysis or exclusio n from the PK summaries or
descript ive statistics, the reason(s) for exclusio n will be documented. The available 
concentration data for any  partici pants excluded from  the PK data summaries or descriptive 
statist ics will be listed. If data are used in the populat ion PK and the expos ure-response 
analyses, the results will be reported in a separate report. 
9.5 Interim Analyses
Not applicable. 
9.6 Data Monitoring Committee
An independent DMC will be established to monitor data on an ongoing basis to ensure the 
safet y of parti cipants enrolled in this study and the integrit y of the study . The DMC will meet 
periodically  during the study  to revi ew the safet y data and operate according to the procedures 
and processes described in full detail in the DMC charter . 
For details on the DMC , refer to Appendix A 5.
10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 89of 129Appendix ARegulatory, Ethical, and Study Oversight Considerations
A 1 Regulatory and Ethical C onsiderations
This study  will be conducted in accordance wit h the protocol and with the fo llowing:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizat ions of Medic al 
Sciences (CIOMS) International Ethical Guidelines .
Applicable ICH GCP Guidelines .
Applicable laws and regulations .
The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant 
docum ents (eg, adverti sements) m ust be submitted to an IRB/IEC by  [CONTACT_122641]/IEC before the study  is init iated.
Any amendments to the protocol will require IRB/IEC and applicable Regulatory  
Authori ty approval  before implementati on of  changes m ade to the study  design, except 
for changes necessary  to eliminate an immediate hazard to study  parti cipants.
[COMPANY_008] will be responsible for obtaining the required authorizat ions to conduct the 
study  from the concerned Regulatory  Authori ty. This responsibilit y may be delegate d to a 
CRO but the accountabilit y remains wi th [COMPANY_008].
The invest igator will be responsible for providing oversight of the conduct of the study at 
the site and adherence to requirements of 21 CFR, ICH guidelines, the IRB/IEC, 
European Regulation 536/2 014 f or clinical studi es (if applicable), European Medical 
Device Regulation 2017/745 for clinical device research (if applicable), and all other 
applicable local regulat ions.
Regulatory Reporting Requirements for Serious Adverse Events
Prom pt notificat ion by [CONTACT_32847] a SAE is essent ial so that l egal 
obligat ions and ethical responsibilit ies toward the safet y of parti cipants and the safet y of a 
study  interventi on under clinical invest igation are met.
The sponsor has a legal responsibilit y to notify both the l ocal regulatory  authori ty and 
other regulatory  agencies about the safet y of a study  intervent ion under clinical 
investigat ion. The sponsor will co mply with country -specific regulatory  requi rements 
relating to safet y reporting to the regulatory  authorit y, IRB/IEC , and invest igators.
For all studies except those utilizing medical devices, invest igator safet y reports must be 
prepared for suspected unexpected serious adverse reactions ( S[LOCATION_003]R )according to local 
regul atory  requi rements and sponsor policy and forwarded to invest igators as necessary.
European Medical Device Regulat ion 2017/745 for clinical device research (if 
applicable), and all other applicable local regulat ions
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 90of 129An invest igator who receives an invest igator s afety  report describing a SAE or other 
specific safet y informat ion (eg, summary or list ing of SAEs) fro m the sponsor will review 
and then file it along with the [Invest igator’s Brochure or state other documents] and will 
notify the IRB/IEC, if appropriate accordi ng to l ocal requi rements.
Regulatory Reporting Requirements for Serious Breaches
Prom pt notificat ion by [CONTACT_244983] (potential) serious breach of 
the protocol or regulations is essential so that legal and ethical obligat ions are m et.
A ‘serious breach’ means a breach likely to affect to a significant degree the safet y 
and ri ghts of  a parti cipant or the reliabilit y and robustness o f the data generated in the 
clinical study .
If any (potential) serious breach occurs in the co urse of the study , investi gators or other 
site personnel will inform the appropriate [COMPANY_008] representatives immediately after 
he or she beco mes aware of it.
In certain regions/countries, [COMPANY_008] has a legal responsibilit y to notify both the local 
regul atory  authori ty and other regul atory  agencies about such breaches.
[COMPANY_008] will comply wit h country -specific regulatory  requi rements rel ating to 
serious breach reporting to the regulatory  authori ty, IRB/IEC, and invest igators. If 
EU Clinical Trial s Regulati on 536/2014 applies, [COMPANY_008] is required to enter 
details o f serious breaches into the European Medicines Agency  CTIS. It i s important 
to note that redacted versions of serious breach reports will be available to the public 
via CTIS.
The inve stigator should have a process in place to ensure that:
The site staff or service providers delegated by [CONTACT_093]/inst itution are able to 
ident ify the occurrence of a (potential) serious breach .
A (potential) serious breach is pro mptly reported to [COMPANY_008] or delegated party, 
through the contacts (email address or telephone number) provided by [CONTACT_38227].
A [ADDRESS_796020] igators will provide the sponsor with sufficient, accurate financial 
inform ation as requeste d to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authori ties. Investi gators 
are responsible for providing information on financial interests during the course of the study
and for 1 y ear after com pletion of  the study .
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 91of 129A 3 Informed Consent Process
The invest igator or his/her representative will explain the nature of the study to the 
participant or his/her legally  authori zed representative and answer all quest ions regarding 
the study.
Parti cipants m ust be inform ed that thei r parti cipat ion is vo luntary and they  are f ree to 
refuse to participate and may wit hdraw their consent at any  time and for any  reason 
during the study . Partici pants or thei r legally  authori zed representative wil l be required to 
sign a statem ent of  inform ed consent that meets the requirements of [ADDRESS_796021] 
(HIPAA) requirements, where applicable, and the IRB/IEC or study  center.
The m edical  record m ust include a statem ent that wri tten inform ed consent was obtained 
before the participant was enrolled in the study  and the date the written consent was 
obtained. The authorized person obtaining the info rmed consent must also sign the I CF.
Parti cipants m ust be re -consented to the most current version of the ICF(s) during their 
participat ion in the study. 
A copy  of the ICF(s) m ust be provi ded to the participant or the participant’s legally  
authori zed representative.
Parti cipants who are rescreened are required to sign a new ICF .
The ICF will contain a separate section that addresses and documents the collect ion and use of 
any mandatory  and/or opti onal human bio logical  sam ples. The invest igator or authorized 
designee will explain to each participant the objectives of the analysis to be done on the 
samples and any potential future use. Participants will be told that they  are free to refuse to 
participate in any optional samples or the future use and may wit hdraw their consent at any  
time an d for any  reason during the retention period. 
A 4 Data Protection
Parti cipants will be assigned a unique ident ifier by [CONTACT_456]. Any part icipant records or 
datasets that are transferred to the sponsor will contain the ident ifier only; part icipant 
names or any inform ation which would make the participant ident ifiable will not be 
transferred.
The parti cipant must be inform ed that hi s/her personal  study -related data will  be used by  
[CONTACT_456] i n accordance with local data protection law. The level of disclo sure and use 
of their data m ust al so be explained to the participant in the informed consent .
The parti cipant must be inform ed that hi s/her m edical  records m ay be examined by 
[CONTACT_17080] y Assurance auditors or other authorized personnel appo inted by  [CONTACT_130376], by  [CONTACT_6667]/IEC members, and by [CONTACT_32857].
Clinical Study Protocol -3.[ADDRESS_796022] igators, and also by  [CONTACT_601093], or in the CEA 
process as specified in the CEA  charter . The CEA  member(s) will not have access to 
individual treatment codes for any  parti cipant. The precise responsibilit ies and procedures 
applicable for CEA  will be detailed in the CEA  charter .
A 6 Dissemination of Clinical Study Data
For scientific reasons (as otherwise st atisti cal analysis is not relevant), any  resul ts for this 
study  (both technical and lay  summaries) will  be submi tted to EU CTIS wi thin a year from the 
global End of  Study  date in all  parti cipat ing countries.
A descri ption of this clinical study  will be ava ilable on 
http://astrazenecagrouptrials.pharmacm.com and http://www .clinicaltrials.gov as will the 
summary of the main study  resul ts when they  are available. The clinical study  and/or 
summary of main study  resul ts may also be available on other websites ac cording to the 
regul ations of the countries in which the study  is conducted.
A 7 Data Quality Assurance
All participant data relat ing to the study  will be recorded on eCRF unless transmitted to 
the sponsor or designee electronically (eg, laboratory  data). The invest igator is 
responsible for verifying that data entries are accurate and correct by  [CONTACT_122642].
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 93of 129The invest igator must maintain accurate documentation (source data) that supports the 
inform ation entered in the eCRF.
The invest igator must permit study -related m onitoring, audi ts, IRB/IEC review, and 
regul atory  agency inspecti ons and provi de di rect access to source data documents.
Moni toring details describing strategy  (eg, risk -based init iatives in operations and qualit y 
such as Risk M anagement ,Mitigation Strategies and Analyt ical Risk-Based Monitoring), 
methods, responsibilit ies,and requirements, including handling of nonco mpliance issues 
and mo nitoring techniques (central, remote, or on -site monitoring) are provi ded in the 
Moni toring Pl an and Protocol  Deviat ions Pl an.
The sponsor or designee is responsible for the data managemen t of this study  including 
qualit y checking of the data.
The sponsor assumes accountabilit y for acti ons delegated to other individuals (eg, CROs).
Study  monitors will perform  ongoing source data verification to confirm that data entered 
into the eCRF by [CONTACT_601094], com plete, and verifiable fro m 
source documents; that the safet y and ri ghts of  participants are being protected; and that 
the study  is being conducted in accordance with the currently approved protocol and any 
other stud y agreem ents, ICH GCP, and all applicable regulatory  requi rements.
Records and documents, including signed ICFs, pertaining to the conduct of this study  
must be retained by [CONTACT_601095] 
(https://www.astrazenecapersonaldataretention.com/pat ients.html) unless l ocal 
regul ations or inst itutional policies requi re a l onger retenti on peri od. No records m ay be 
destroy ed during the retention period wi thout the wri tten approval  of the sponsor. No 
records m ay be transferred to another location or party  without wri tten notificat ion to the 
sponsor.
A 8 Source Documents
Source documents provide evidence for the existence of the participant and substantiate 
theintegrity of the data collected. Source documents are filed at the invest igator’s site.
Data entered in the eCRF that are transcribed from source documents must be consistent 
with the source documents or the discrepancies must be explained. The investigat or may 
need to request previous medical records or transfer records, depending on the study. 
Also, current medical records must be available.
Definit ion of what constitutes source data can be found in GCP, ie, all informat ion in 
original  records and certif ied copi[INVESTIGATOR_34504], observations, 
or other activit ies in a clinical trial necessary  for the reconstructi on and evaluat ion of the 
trial. Source data are contained in source documents (original records or certified copi[INVESTIGATOR_014]). 
Clinical Study Protocol -3.[ADDRESS_796023] igator may init iate study  site closure at any  time, provi ded there i s reasonable cause 
and sufficient notice is given in advance of the intended terminat ion.
Reasons for the early closure of a study  site by [CONTACT_17095]:
Failure of the invest igator to comply wit h the protocol, the requirements of the IRB/IEC 
or local health authori ties, the sponsor's procedures, or GCP guidelines .
Inadequate recruit ment of parti cipants by  [CONTACT_17062] .
Discontinuati on of  further study  intervent ion developm ent.
If the study  is prem aturely  terminated or suspended, the sponsor shall prompt ly inform  the 
investigators, the I ECs/IRBs, the regulatory  authorit ies, and any contract research 
organizat ion(s) used in the study  of the reason for terminat ion or suspensio n, as specified by 
[CONTACT_122644]. The invest igator shall pro mptly inform the participant 
and shoul d assure appropriate participant therapy  and/or foll ow-up.
Parti cipants from  terminated si tes will  have the opportuni ty to be transferred to another site to 
continue the study . 
A 10 Publication Policy
The results of this study  may be published or presen ted at sci entific meet ings. If this is 
foreseen, the invest igator agrees to submit all manuscripts or abstracts to the sponsor 
before submissio n. This allows the sponsor to protect proprietary  information and to 
provi de comments.
The sponsor will co mply wi th the requi rements for publication of study  resul ts. In 
accordance with standard editorial and ethical practice, the sponsor will generally support 
Clinical Study Protocol -3.[ADDRESS_796024] igator will be designated by [CONTACT_11402].
Authorship will be determined by  [CONTACT_73008] h Internat ional 
Committee of Medical Journal Editors authorship requirements.
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadu tide-D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 96of 129Appendix BAdverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
B [ADDRESS_796025] a caus al 
relationship with this treatment. An AE can therefore be any unfavorable and unintended sign 
(eg, an abnormal laboratory  finding), symptom (for example nausea, chest pain), or disease 
temporally  associ ated wi th the use of a m edicinal product, whether or not considered related 
to the m edicinal product. 
The term  AE is used to include both serious and non -serious AEs and can include a 
deteri oration of  a pre -exist ing medical occurrence. An AE may occur at any  time, including 
run-in or washout periods, even if no study  intervent ion has been administered.
B 2 Definition of Serious Adverse Events
An SAE is an AE occurring during any  study  phase (i e, run -in, treatment, washout, follow -
up), that fulfills one or more of the fo llowing cri teria:
Results in death
Is immediately life -threatening
Requi res in -partici pant hospi [INVESTIGATOR_325352] 
Results in persistent or significant disabilit y or incapaci ty
Is a congenital ano maly or bi rth defect
Is an important medical event that may j eopardize the participant or may require medical 
treatm ent to prevent one of the outcomes listed above
Adverse events for malignant tumors reported during a study  shoul d generally be assessed as 
Serious AEs. If no other seri ousness criteria apply , the ‘Important Medi cal Event ’ criterion 
shoul d be used. In certain situat ions, however, medical judgment on an individual event basis 
shoul d be applied to clarify  that the malignant tumor event should be assessed and reported as 
a non-serious AE. For exam ple, if the tum or is included as medical history  and progressi on 
occurs duri ng the study , but the progression does not change treatment and/or prognosis of the 
malignant tumor, the AE m ay not fulfill  the attributes for being assessed as serious, although 
reporting of the progressi on of  the m alignant tum or as an AE is valid and should occur .Also, 
some ty pes of  malignant tum ors, which do not spread remotely after a routine treatment that 
does not require hospi[INVESTIGATOR_3094], may be assessed as non -serious; examples in a dults include 
Stage 1 basal cell carcino ma and S tage 1A1 cervical cancer removed via cone biopsy .
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 97of 129Life-threatening
‘Life-threatening ’ means that the participant was at immediate risk of death fro m the AE as i t 
occurred or it is suspected that use or contin ued use of the product would result in the 
participant ’s death. ‘Life-threatening ’ does not m ean that had an AE occurred in a more severe 
form it might have caused death (eg, hepatit is that resolved wit hout hepatic failure).
Hospi[INVESTIGATOR_601037] a serious AE, although the reasons 
for it may be (eg, bronchospasm, laryngeal edema). Hospi[INVESTIGATOR_33094]/or surgical 
operati ons planned before or during a study  are not consi dered AEs if the illness or disea se 
existed before the participant was enrolled in the study , provi ded that i t did not deteriorate in 
an unexpected way  during the study .
Important Medical Event or Medical Treatment
Medical and scientific judgment should be exercised in deciding whether a case is serious in 
situations where important m edical events may  not be immediately life threatening or result in 
death, hospi [INVESTIGATOR_3094], disabilit y,or incapacit y but may jeopardize the participant or may 
requi re medical treatm ent to prevent one or more outcomes listed in the definit ion of seri ous. 
These should usually be considered as serious.
Simply stoppi[INVESTIGATOR_33095]; medical 
judgment must be used.
Angioedema not severe enough to require intubation but requiring iv hydrocortisone 
treatm ent
Hepatotoxicit y caused by [CONTACT_33153] l (acetaminophen) overdose requiring treatment with 
N-acetylcysteine
Intensive treatment in an emergency room or at home for allergic bronchospasm
Blood dy scrasias (eg, neutropenia or anemia requiring blood transfusio n, etc.) or 
convulsio ns that do not result in hospi[INVESTIGATOR_3094]
Development of drug dependency or drug abuse
Intensity Rating Scale:
Mild (awareness of sign or symptom, but easily tolerated)
Moderate (di scomfort sufficient to cause interference with normal act ivities)
Severe (incapacitat ing, with inabilit y to perform  norm al activities)
It is important to dist inguish between serious and severe AEs. Severit y is a measure of 
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 98of 129intensity whereas seri ousness is defined by [CONTACT_73010] B 2. An AE of severe 
intensity need not necessarily be considered serious. For example, nausea that persists for 
several hours may  be consi dered severe nausea, but not a SAE unless it meets the criteria 
shown in Appendix
 B 2.
 On the other hand, a stroke that results in only a limited degree of 
disabili ty may be considered a mild stroke but would be a SAE when it satisfies the criteria 
shown in Appendix B 2.
B 3 A Guide to Interpreting the Causality Question
When making an assessment of causalit y consi der the foll owing f actors when deciding if there 
is a ‘reasonable possibilit y’that an AE m ay have been caused by [CONTACT_33641].
Time Course. Exposure to suspect drug. Has the participant actually received the suspect 
drug? Did the AE occur in a reasonable temporal relat ionship to the administration of the 
suspect drug?
Consistency wit h known drug profile. Was the AE consistent with the previous 
knowl edge of the suspect drug (pharmaco logy and toxi cology) or drugs of the same 
pharmaco logical class? Or could the AE be ant icipated from its pharmaco logical 
properties?
De-challenge experience. Did the AE resolve or improve on stoppi[INVESTIGATOR_122570]?
No al ternative cause. The AE cannot be reasonably explained by [CONTACT_33154], other drugs, other h ost or environmental factors.
Re-challenge experi ence. Di d the AE reoccur if the suspected drug was reintroduced after 
having been stopped? [COMPANY_008] would not normally reco mmend or support a re-
challenge .
Laboratory  tests. A specific laboratory  invest igation (if performed) has confirmed the 
relationship .
In difficult cases, other factors could be considered such as:
Is this a recogni zedfeature of overdose of the drug?
Is there a known mechanism?
Causalit y of 
‘related ’ is made if fo llowing a re view of the relevant data, there is evidence for a 
‘reasonable possibilit y’of a causal relationship for the individual case. The expression 
‘reasonable possibilit y’ of acausal  relati onship is meant to convey , in general, that there are 
facts (evidence) o r arguments to suggest a causal relat ionship.
The causalit y assessment i s perform ed based on the available data including enough 
Clinical Study Protocol -3.[ADDRESS_796026] a 
causal relat ionship, the event(s) w ill be assessed as ‘not rel ated’.
Causal relat ionship in cases where the disease under study  has deteri orated due to l ack of 
effect shoul d be classified as no reasonable possibilit y.
B 4 Medication Error, Drug Abuse, and Drug Misuse
Medication Error
For the pu rposes of this clinical study ,a medicat ion error is an unintended failure or mistake 
in the treatment process for an [COMPANY_008] study  intervent ion that either causes harm to the 
participant or has the potential to cause harm to the participant. 
A medica tion error i s not l ack of  efficacy of the drug, but rather a human or process related 
failure while the drug is in control of the study  site staf f or parti cipant.
Medicat ion error includes situat ions where an error . 
Occurred
Was i dentified and intercepted before the participant received the drug
Did not occur, but circumstances were recognized that could have led to an error
Examples of events to be reported in clinical studies as medication errors:
Drug name [CONTACT_33165] n
Dispensing error eg, medication prepared incorrectly , even if i t was not actually  given to 
the participant
Drug not administered as indicated, for example, wrong route or wrong site of 
administration
Drug not taken as indicated eg, tablet disso lved in water when it should be taken as a 
solid tablet 
Drug not stored as instructed eg, kept in the fridge when it should be at room temperature 
Wrong participant received the medicat ion (excluding IRT/RTSM errors)
Wrong drug administered to participant (excluding IRT/RTSM errors)
Examples of events that do not require reporting as medicat ion errors in clinical studies:
Errors related to or resulting fro m IRT/RTSM -including those which lead to one of the 
above listed events that would otherwise have been a medication error 
Parti cipant acci dentally  missed drug dose(s) eg, forgot to take medication
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 100of 129Accidental  overdose (will be captured as an overdose)
Parti cipant f ailed to return unused medicat ion or empt y packaging
Errors related to background and rescue medicat ion, or standard of care m edicat ion in 
open l abel studi es, even if an [COMPANY_008] product 
Medicat ion errors are not regarded as AEs but AEs may occur as a consequence of the 
medicat ion error .
Drug Abuse
For the purpose of this study , drug abuse is defined as the persistent or sporadi c intent ional, 
non-therapeut ic excessive use of IMP or [COMPANY_008] NIMP for a perceived reward or desired 
non-therapeut ic effect.
Any events of drug abuse, with or without associated AEs, are to be captured and forwarded to 
the DES using the Drug Abuse Report Form . This form should be used both if the drug abuse 
happened in a study  parti cipant or if the drug abuse involves a person not enrolled in the study  
(such as a relative o f the study  parti cipant).
Examples of drug abuse include but are not l imited to:
The drug is used with the intent of getting a perceived reward (by [CONTACT_355663] a person not enrolled in the study )
The drug in the form o f a tabl et is crushed and injected or snorted with the intent of 
getting high
Drug Misuse
Drug misuse is the intent ional and inappropriate use (by  a study parti cipant) of IMP or 
[COMPANY_008] NIMP for medicinal purposes outside of the authori zed product inform ation, or 
for unauthori zed IMPs or [COMPANY_008] NIMPs, outside the intended use as specif ied in the 
protocol  and includes deliberate administration of the product by  [CONTACT_244972].
Events of drug misuse, with or without associated AEs, are to be captured and forwarded to 
the DES using the Drug Misuse Report Form. This form should be used both if the drug 
misuse happened in a study  parti cipant or if the drug misuse regards a person not enrolled in 
the study  (such as a rel ative of the study part icipant).
Examples of drug misuse include but are not limited to:
The drug is used with the intent ion to cause an effect in another person
The drug is so ld to other people for recreational purposes 
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 101of 129The drug is used to facilitate assault in another person
The drug is deliberately administered by [CONTACT_244972]
The drug is split in half because it is easier to swallow, when it is stated in the protocol 
that it must be swallowed whole
Only half the dose is taken because the study  partici pant feels that he/she is feeling 
better when not taking the whole dose
Someone who i s not enrolled in the study  intentionally  takes the drug
Clinical Study Protocol -3.[ADDRESS_796027] igator at each center keeps full traceability of co llected bio logical sam ples f rom the
participants while in storage at the center until shipment or disposal (where appropriate) and 
records relevant processing information related to the samples whil eat site.
The sample receiver keeps full traceabilit y of the sam ples while in storage and during use unt il 
used or disposed of or until further shipment and keeps record of receipt of arrival and onward 
shipment or disposal.
[COMPANY_008] or delegated representatives will keep oversight of the ent ire life cycle through 
internal  procedures, m onitoring of study  sites, auditing or process checks, and contractual 
requi rements of external laboratory  provi ders.
Samples retained for further use will be stored in the [COMPANY_008] -assigned bi obanks or other 
sample archive facilit ies and will be tracked by  [CONTACT_601096] T eam during for 
the rem ainder of the sam ple life cycle.
If required, [COMPANY_008] will ensure that remaining bio logical samples are returned to the site 
according to local regulations or at the end of the retention period, whichev er is sooner .
C 2 Withdrawal of Informed Consent for Donated Biological Samples 
Where required, [COMPANY_008] ensures that bio logical samples are returned to the source or 
destroy ed at the end of a specified period as described in the informed consent. 
If a pa rticipant wi thdraws consent to the use of donated bio logical  samples, the sam ples will 
be disposed of/destroy ed/repatriated, and the action documented. If samples are already  
analyzed ,[COMPANY_008] is not obliged to destroy  the resul ts of this research.
Following wi thdrawal  of consent for bio logical samples, further study  partici pation shoul d be 
considered in relat ion to the wi thdrawal  processes outlined in the informed consent.
The invest igator:
Ensures participant’s withdrawal of informed consent to the us e of donated samples is 
highlighted immediately to [COMPANY_008] or delegate.
Ensures that relevant human bio logical samples from  that parti cipant, if stored at the 
study  site, are immediately  identified, disposed of as appropriate, and the action 
docum ented .
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 103of 129Ensures that the participant and [COMPANY_008] are informed about the sample disposal.
[COMPANY_008] ensures the organizat ion(s) ho lding the samples is/are informed about the 
withdrawn consent immediately and that samples are disposed of or repatriated as a ppropri ate, 
and the action is documented and study  site is notified.
C [ADDRESS_796028] SAMPLES
International Airline Transportation Associat ion (IA TA) 
(https://www .iata.org/whatwedo/cargo/dgr/Pages/download.aspx ) classifies infect ious 
substances into 3 categories: Category  A, Category B or Exempt
Category A Infectious Substances are infect ious substances in a form that, when exposure to 
it occurs, i s capable of causing permanent disabilit y, life-threatening, or fatal  disease in 
otherwi se healt hy humans or animals. 
Category A Pathogens are eg, Ebol a, Lassa fever virus. Infectious substances meet ing these 
criteria which cause disease in humans or both i n hum ans and animals must be assigned to 
UN2814. Infect ious substances which cause disease only in animals must be assigned to 
UN2900.
Category B Infectious Substances are infect ious Substances that do not meet the criteria for 
inclusio n in Category  A. C ategory  B pathogens are eg, Hepatit is A, C, D, and E viruses. They 
are assigned the fo llowing UN number and proper shippi[INVESTIGATOR_72919]:
UN 3373 –Biological Substance, Category  B
Are to be packed in accordance with UN [ADDRESS_796029] to these Regulations unless they  
meet the criteria for inclusio n in another class.
Clinical study samples will fall into Category  Bor exempt under IATA regulat ions
Clinical study  samples will routinely  be packed and transported at ambient temperature in 
IATA 650 compliant packaging 
(https://www.iata.org/whatwedo/cargo/dgr/Documents/DGR -60-EN-PI650.pdf)
Biological samples transported in dry ice require addit ional dangerous goods specificat ion 
for the dry  ice content
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 104of 129Appendix DOptional Genomics Initiative Sample
D 1 Use/Analysis of DNA
[COMPANY_008] intends to collect and store DNA for genet ic research to explore how genetic 
variat ions may affect clini cal parameters, ri sk and prognosi s of diseases, and the response 
to medicat ions. This genetic research may lead to better understanding of diseases, better 
diagnosis of diseases or other improvements in healt hcare and to the discovery  of new 
diagnosti cs, treatm ents,or medicati ons. Therefore, where local regulations and IRB/IEC 
allow, a blood sample will be collected for DNA analysis fro m consent ing participants.
This optional genet ic research may consist of the analysis o f the structure of the 
participant´s DNA ie, the ent ire geno me. 
The results of genet ic analyses may be reported in a separate study summary.
The sponsor will store the DNA samples in a secure sto rage space with adequate 
measures to protect confident iality.
D 2 Genetic Research Plan and Procedures
Selection of Genetic Resear ch Population
All participants will be asked to participate in this genet ic research. Participat ion is 
voluntary and if a partici pant declines to participate there will be no penalt y or loss of 
benefit. The participant will not be excluded fro m any aspect of the main study .
Inclusion Criteria
For inclusio n in this genet ic research, participants must fulfill all of the inclusio n criteria 
described in the main body  of the Clinical Study  Protocol  andprovi de inform ed consent for 
the Geno mics Init iative sampling and analyses.
Exclusion Criteria
Exclusio n from this genet ic research may be for any o f the excl usion criteria specified in 
the main study  or any  of the f ollowing:
Previous allogeneic bone marrow transplant
Non-leukocyte depleted whole blood transfusio n wit hin [ADDRESS_796030] ion
Withdrawal of Consent for Genetic Research
Parti cipants may  withdraw from  this genet ic research at any t ime, independent of any 
decisio n concerning participation in other aspects of the main study . Vol untary  
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 105of 129withdrawal  will not prej udice further treatment. Procedures for withdrawal are outlined in 
Secti on 7.2of the m ain Clinical Study  Protocol .
Collection of Samples for Genetic Research
The blood sample for this genetic research will be obtained fro m the parti cipants at 
Visit 2. Al though DNA is stable, early sample co llection is preferred to avoid introducing 
bias through excluding participants who may withdraw due to an AE. If for any reason 
the sam ple is not drawn at Visit 2, it may be taken at any  visit unt il the last study v isit. 
Only one sample should be co llected per participant for genetics during the study. 
Coding and Storage of DNA Samples
The processes adopted for the coding and storage of samples for genet ic analysis are 
important to maintain participant confident iality. Sam ples will  be stored for a m aximum  
of 15years fro m the date of l ast parti cipant l ast visit, after which they  will be destroy ed. 
DNA is a finite resource that is used up during analyses. Samples will be stored and used 
until no further analyses are possible or the maximum storage time has been reached.
An addit ional second code will be assigned to the sample eit her before or at the time of 
DNA extraction replacing the informat ion on the sample tube. Thereafter, the sample will 
be ident ifiable only by [CONTACT_33160], unique number. This number is used to identify  the 
sample and corresponding data at the [COMPANY_008] genet ics laboratori es, or at the 
designated organizat ion. No personal details identifying the individual will be available to 
any person (Astra Zeneca emplo yee or desi gnated organi zations working wit h the DNA).
The link between the participant enrollment/randomizat ion code and the second number 
will be maintained and stored in a secure environment, with restricted access at 
[COMPANY_008] or designat ed organizations. The link will be used to identify the relevant 
DNA samples for analysis, facilitate correlat ion of genoty pic resul ts wi th clinical data, 
allow regulatory  audi t, and permi t tracing of samples for destruction in the case of 
withdrawal  of consent.
Ethical and Regulatory Requirements
The principles for ethical and regulatory  requi rements for the study , incl uding this 
genet ics research component, are outlined in
 Appendix A.
Informed Consent
The genetic component of this study  is opti onal and the parti cipant m ay part icipate in 
other components of the main study  without parti cipating in this genet ic component. To 
participate in the genet ic component of the study ,the participant must sign and date both 
the consent form for the main study  and the addendum  for the Genomics Init iative 
Clinical Study Protocol -3.[ADDRESS_796031] igator(s) is 
responsible for ensuring that consent is given freely and that the participant understands 
that they  may freely wi thdrawal  from the genetic aspect of the study  at any  time.
Participant D ata Protection
[COMPANY_008] will not provide individual genoty pe resul ts to parti cipants, any  insurance 
company, any emplo yer, thei r family members, or general physician unless required to do 
so by  [CONTACT_2371].
Extra precautions are taken to preserve confident iality and prevent genetic data being 
linked to the ident ity of the parti cipant. In except ional circumstances, however, certain 
individuals might see both the genet ic data and the personal ident ifiers of a participant. 
For example, in the case of a medical emer gency , an [COMPANY_008] Physician or an 
investigator might know a participant’s ident ity and al so have access to his or her genetic 
data. Regul atory  authori ties may requi re access to the rel evant files, though the 
participant’s m edical  information and the ge netic files would remain physically separate.
Data Management
Any genet ic data generated in this study will be stored at a secure system at [COMPANY_008] 
and/or designated organizations to analyze the samples.
[COMPANY_008] and its designated organizat ions may share summary results (such as genet ic 
differences fro m groups of individuals with a disease) fro m this genetic research with 
other researchers, such as hospi[INVESTIGATOR_600], academic organizat ions,or heal th insurance 
companies. This can be done by [CONTACT_601097], where they  can 
be co mbined with the results of similar studies to learn even more about health and 
disease. The researchers can only  use thi s inform ation for heal th-related research 
purposes. Researchers may  see summary  resul ts but they  will not be able to see individual 
participant data or any  personal ident ifiers. 
Some or all  of the clinical datasets from the main study  may be merged wi th the genet ic 
data in a suitable secure environment separate from the clinical database.
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 107of 129Appendix EActions Required in Cases of Increases in Liver Biochemistry 
and Evaluation of Hy’s Law
E [ADDRESS_796032] ions 7.1and 8.3.10 of the 
Clinical Study  Protocol . 
During the course of the study ,the investigator will remain vigilant for increases in liver 
biochemistry . The investigator is responsible for determining whether a participant meets 
potenti al PHL  criteria at any  point during the study .
All sources of l aboratory  data are appropri ate for the determinat ion of PHL  and HL  events; 
this includes samples taken at scheduled study  visits and other vi sits including central  and all 
local laboratory  evaluat ions even if co llected outside of the study  visit s; for exam ple, PHL  
criteria coul d be m et by  [CONTACT_96724] a central  laboratory  and/or elevated TBL  from 
a local laboratory . 
The invest igator will also review AEdata (for example, for AEs that may indicate elevat ions 
in liver bio chemistry ) for possible PHL  events.
The invest igator participates, together with [COMPANY_008] clinical project representatives, in 
review and assessment of cases meet ing PHL  criteria to agree whether HL  criteria are m et. HL  
criteria are met if th ere is no al ternat ive explanation for the elevat ions in liver biochemistry  
other than DILI caused by  [CONTACT_2203] . 
The invest igator is responsible for recording data pertaining to PHL/HL  cases and for 
reporting SAEs and AEs according to the outcome of the revi ew and assessment in line with 
standard safet y reporting processes.
E 2 Definitions
Potential Hy’s Law
Aspartate Aminotransferase or ALT ≥ 3 × ULN together  with TBL 
≥ 2× ULN at any po int 
during the study  following the start of study  intervent ionirrespective of an increase in ALP .
Hy’s Law
AST or ALT ≥ 3× ULN together  with TBL ≥ 2× ULN, where no other reason, other than the 
IMP, can be found to explain the co mbinat ion of increases eg, elevated ALP indicat ing 
Clinical Study Protocol -3.[ADDRESS_796033] precede or be coincident with (ie, on the 
same day ) the el evati on in TBL, but there is no specified timeframe within which the 
elevations in transaminases and TBL  must occur .
E 3 Identification of Potential Hy’s Law Cases
In order to i dentify  cases of PHL ,it is important to perform a comprehensive review of 
laboratory  data for any  parti cipant who m eets any of the fo llowing identificat ion criteria in 
isolation or in combinat ion:
ALT ≥ 3 × ULN 
AST ≥ 3 × ULN
TBL ≥ 2 × ULN
When a participant meets any of the PHL  identification criteria, in iso lation or in co mbinat ion, 
the central  laboratory  will immediately send an alert to the investigator (also sent to 
[COMPANY_008] representative). 
The invest igator will also remain vigilant for any local laboratory reports where the PHL  
ident ificat ion criteria are met ;where this is the case the invest igator will:
Notify  the [COMPANY_008] representative 
Request a repeat of the test (new blood draw) by  [CONTACT_244994]
Com plete the appropri ate unscheduled laboratory  eCRF m odule(s) wi th the ori ginal  local 
laboratory  test resul t
When the identificat ion criteria are m et from central  or local laboratory  resul ts,the 
investigator will wit hout delay:
Determine whether the participant meets PHL criteria ( refer to Section E 2for definit ion) 
by [CONTACT_96791] (including both central and local 
laboratory  resul ts)
E 4 Follow -up
E4.1 Potential Hy’s Law Criteria not met
If the participant does not meet PHL  criteria the investigator will:
Inform  the A straZeneca representative that the participant has not met PHL criteria. 
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 109of 129Perform  follow-up on subsequent laboratory  resul ts according to the guidance provided in 
the Clinical Study  Protocol .
E4.2 Potential Hy’s Law Criteria met
If the participant does meet PH L criteria the investigator will:
Notify  the [COMPANY_008] representative who will then inform the central Study  Team  
Within [ADDRESS_796034] igator will report the case as an SAE of 
PHL ; serious criteria ‘Important medical event’ and causalit y assessment ‘y es/rel ated’ 
according to CSP process for SAE reporting.
For parti cipants that met PHL criteria prior to starting IMP, the invest igator is not 
requi red to submit a PHL SAE unless there is a significant change#in the participant’s
condi tion.
The Study  Physician contacts the investigator, to provide guidance, discuss and agree an 
approach for the study  parti cipants’ fo llow-up (including any further laboratory  testing) 
and the continuous review of data.
Subsequent to this contact [CONTACT_33157]:
Moni tor the parti cipant until liver bio chemistry  param eters and appropri ate clinical 
symptoms and signs return to normal or baseline levels, or as long as medically 
indicated. Completes fo llow-up SAE Form as required.
Invest igate the et iology of the event and perform diagnostic investigat ions as 
discussed wi th the Study  Physician. This includes deciding which of the tests 
available in the HLlab kit shoul d be used. 
Com plete the 3 Liver eCRF Modules as informat ion beco mes available .
#A ‘significant ’ change in the participant ’s condi tion refers to a clinically  relevant change 
in any of the individual liver biochemistry  parameters (AL T, AST , or TBL) in iso lation or in 
combinat ion, or a clinically  relevant change in associated symptoms. Th e determinati on of  
whether there has been a significant change will be at the discret ion of the investigator, this 
may be in consultat ion with the Study  Physician if there is any uncertaint y.
E 5 Review and Assessment of Potential Hy’s Law Cases
The instructions in this Section should be fo llowed for all cases where PHL  criteria are m et.
As soon as possible after the biochemistry  abnormalit y was ini tially detected, the Study  
Physician contacts the invest igator in order to review available data and agree on whether 
there is an alternat ive explanat ion for meeting PHL  criteria other than DILI caused by  [CONTACT_86184], to ensure timely analysis and reporting to healt h authorit ies wit hin [ADDRESS_796035] and TBL elevat ions, a 
determinat ion of whether the alternat ive explanat ion is an AE will be made and subsequent ly 
whether the AE meets the criteria for a SAE:
If the alternat ive explanat ion is notan AE, record the alternative explanation on the 
appropriate eCRF.
If the alterna tive explanat ion is an AE/SAE ,update the previously submitted PHL SAE 
and AE eCRFs accordingly wit h the new informat ion (reassessing event term; causalit y 
and seriousness criteria) fo llowing the [COMPANY_008] standard processes.
If it is agreed that there is no explanat ion that would explain the AL T or AST and TBL 
elevations other than the IMP:
Send updated SAE (report term ‘Hy’s Law’) according to [COMPANY_008] standard 
processes. 
 The ‘Medically  Important’ seri ous cri terion shoul d be used if no other seriou s 
criteria apply .
 As there is no alternat ive explanation for the HL case, a causalit y assessment of 
‘related’ should be assigned.
If, there i s an unavo idable delay of over 15 calendar day s in obtaining the informat ion 
necessary  to assess whether or not th e case meets the criteria for HL, then it is assumed that 
there is no alternat ive explanation unt il such time as an informed decisio n can be made:
Provi des any  further update to the previously submitted SAE of PHL , (report term  now 
‘Hy’s Law case’) ensurin g causalit y assessment i s related to IMP and seriousness criteria 
is medically important, according to CSP process for SAE reporting.
Continue fo llow-up and review according to agreed plan. Once the necessary  
supplementary  informat ion is obtained, repeat t he review and assessment to determine 
whether HL criteria are still met. Update the previously submitted PHL SAE report 
following CSP process for SAE reporting, according to the outcome of the review and 
amending the reported term if an alternat ive explana tion for the liver biochemistry  
elevations is determined.
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 111of 129E 6 Actions Required When Potential Hy’s Law Criteria are Met 
Before and After Starting Study Intervention 
This sect ion is applicable to participants who meet PHL  criteria on study  intervent ion, havin g 
previously met PHL  criteria at a study  visit pri or to starti ng study  interventi on.
At the first on -study  intervent ion occurrence of PHL criteria being met ,the invest igator will 
determine if there has been a significant change in the participants ’ condi tion#compared wi th 
the last visit where PHL  criteria were met#
If there is no significant change ,no action is required
If there is a significant change, notify the [COMPANY_008] representative, who will inform the 
central  Study  Team , then foll ow the subsequent process described in Sect ion E4.2  
E 7 Actions Required for Repeat Epi[INVESTIGATOR_33099]’s Law
This sect ion is applicable when a participant meets PHL  criteria on study  intervent ion and has 
already met PHL  criteria at a previous on -study  intervent ion visit
The requi rement to conduct fo llow-up, revi ew,and assessment of a repeat occurrence(s) of 
PHL is based on the nature of the alternative cause identified for the previous occurrence. 
The invest igator should determine the cause for the previous occurrence of PH L criteria being 
met and answer the fo llowing quest ion:
Was the al ternat ive cause for the previous occurrence of PHL  criteria being met found 
to be the di sease under study  eg, chronic or progressing malignant disease, severe 
infect ion,or liver disease ?
If No: follow the process described in Sect ion
 E4.2for reporting PHL  as an SAE .
If Yes: Determine if there has been a significant change in the participant ’s condi tion#
compared wi th when PHL  criteria were previously met .
If there is no significant change ,no action is required .
If there is a significant change ,#follow the process described in Sect ion E4.2for 
reporting PHL as an SAE .
# A ‘significant ’ change in the participant ’s condi tion refers to a clinically  relevant change in 
any of the individual liver biochemistry  param eters (AL T, AST,or TBL ) in iso lation or in 
combinat ion, or a clinically  relevant change in associated symptoms. The determination of 
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 112of 129whether there has been a significant change will be at the discret ion of the investigator ;this 
may be in consultat ion with the Study  Physician if there is any uncertaint y.
E 8 Laboratory Tests
Hy’s Law Lab Kit for Central Laboratories 
Additional standard chemistry and coagulation 
testsGGT
LDH
Prothrombin time
INR
Viral hepatitis IgM anti -HAV 
HBsAg
IgM and IgG anti -HBc
HBV DNAa
IgG anti -HCV
HCV RNA b
IgM anti -HEV
HEV RNA
Other viral infections IgM and IgG anti -CMV
IgM and IgG anti -HSV
IgM and IgG anti -EBV
Alcoholic hepatitis Carbohydrate deficient transferrin ( CD-
transferrin) c
Autoimmune hepatitis Antinuclear antibody (ANA)
Anti-Liver/Kidney Microsomal Ab (Anti -LKM)
Anti-Smooth Muscle Ab (ASMA)
Metabolic diseases Alpha-1-antitrypsin
Ceruloplasmin
Iron
Ferritin
Transferrin
Transferrin saturation
aHBV DNA is only recommended when IgG anti -HBc is positive
bHCV RNA is only recommended when IgG anti -HCV is positive or inconclusive 
cCD-transferrin is not available in China. Study teams should amend this list accordingly
Clinical Study Protocol -3.[ADDRESS_796036] (AUDIT)
Subject Number: Visit Number: Assessment Date:
TheAlcohol UseDisorders Identification Test: Interview Version
Read questions as written. Record answers carefully. Begin the AUDIT by [CONTACT_3041] “Now I am 
going to ask you some questions about your use of alcoholic bev erages during this past year.” 
Explain what is meant by “alcoholic beverages” by [CONTACT_601098], wine, v odka, etc. 
Code answers in terms of “standard drinks.” Place the correct answer number in the box at the 
right.
1.How often doyouhave adrink containing alcohol?
(0)Never [Skip toQs9-10]
(1)Monthly orless
(2)2to4times amonth
(3)2to3times aweek
(4)4ormore times aweek6.How often during the last year have you needed a first drink 
in the morning to get yourself going after aheavy drinking
session?
(0)Never
(1)Lessthan monthly
(2)Monthly
(3)Weekly
(4)Daily or almost daily
2.How many drinks containing alcohol doyouhave ona
typi[INVESTIGATOR_601038]?
(0)1or2
(1)3or4
(2)5or6
(3)7,8,or 9
(4)10or more7.How oftenduring thelastyear have youhada feeling of
guilt or remorse after drinking?
(0)Never
(1)Lessthan monthly
(2)Monthly
(3)Weekly
(4)Daily or almost daily
3.How oftendoyouhave sixormore drinks onone
occasion?
(0)Never
(1)Lessthan monthly
(2)Monthly
(3)Weekly
(4)Daily or almost daily
Skip toQuestions 9and 10 ifTotal Score for 
Questions 2and3 = 08.How oftenduring thelastyear have youbeen unable to
remember what happened thenight beforebecause you
hadbeen drinking?
(0)Never
(1)Lessthan monthly
(2)Monthly
(3)Weekly
(4)Daily or almost daily
4.How often during the last year have you found thatyou
were notabletostop drinking once you had started?
(0)Never
(1)Lessthan monthly
(2)Monthly
(3)Weekly
(4)Daily or almost daily9.Have youor someone elsebeen injured asa result ofyour
drinking?
(0)No
(2)Yes,but not inthelastyear
(4)Yes, during thelastyear
5.How oftenduring the lastyear have youfailed to do 
what was normally expected from you because of
drinking?
(0)Never
(1)Lessthan monthly
(2)Monthly
(3)Weekly
(4)Daily or almost daily10.Hasarelative orfriend oradoctoror an other health worker
been concerned about your drinking orsuggested youcut
down?
(0)No
(2)Yes,butnotinthelastyear
(4)Yes, during thelastyear
Record total ofspecific items here  
Iftotal isgreater than recommended cut-off,consult User’s Manual.
AUDIT -Test_cv1_Orig_WS_Paper_English -US_02Dec2021_D5671C00006
Clinical Study Protocol -3.[ADDRESS_796037] response for each question (eg, 
never) scoring 0, the second (eg, less than monthly) scoring 1, the third scoring 2, the fourth 
scoring 3, and the last response (eg, 4 or more times a week) scoring 4. For question s [ADDRESS_796038] Haven Criteria for Hepatic Encephalopathy
Grade Description
I Trivial lack of awareness
Euphoria or anxiety
Shortened attention span
Impairment of addition or subtraction
II Lethargy  or apathy
Disorientation for time
Obvious personality change
Inappropriate behavior
III Somnolence to semi -stupor
Responsive to stimuli
Confused
Gross disorientation
Bizarre behavior
IV Coma
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 116of 129Appendix HAbbreviations
Abbreviation or special 
termExplanation
ADA anti-drug antibody
AE adverse event
AI artificial intelligence
ALT alanine aminotransferase/transaminase
ANA antinuclear antibody
APRI AST -to-platelet ratio index
AST aspartate aminotransferase/transaminase
AUDIT Alcohol Use Disorder Identification Test
BARD BMI, AST/ALT ratio, diabetes
BMI body mass index
BP blood pressure
CAP controlled attenuation parameter
CEA clinical event(s) adjudication
CKD chronic kidney disease
CRO contract research organization
CSP Clinical Study Protocol
CSR Clinical Study Report
CTIS Clinical Trial Information System
CV cardiovascular
DBP diastolic blood pressure
DES data entry  site
DILI drug-induced liver injury
DMC Data Monitoring Committee
ECG electrocardiogram
eCRF electronic Case Report Form
eGFR estimated glomerular filtration rate
ELF enhanced liver fibrosis
FAS full analy sis set
FAST FibroScan -AST
FDA [LOCATION_002] Food and Drug Administration
FIB-4 fibrosis -4
GCP good clinical practice
GGT gamma glutamyl transferase
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 117of 129Abbreviation or special 
termExplanation
GLP-1 glucagon -like peptide 1
HbA1c hemoglobin A1c
HbsAg hepatitis B surface antigen
HCV hepatitis C virus
HDL high-density lipoprotein
HFF hepatic fat fraction
HIV human immunodeficiency virus
HL Hy’s Law
IB Investigator’s Brochure
IATA International Airline Transportation Association
ICF informed consent form
ICH International Council for Harmonisation
IEC independent ethics committee
IMP investigational medicinal product
INR internatio nal no rmalized ratio
IP investigational product
IRB institutional review board
IRT interactive response technology
LDL low-density  lipoprotein
LSM liver stiffness measurement
MACE major adverse cardiovascular event
max maximum
MedDRA Medical Dictionary for Regulatory Activities
MELD model for end -stage liver disease
min minimum
NAFLD non-alcoholic fatty liver disease
NAS non-alcoholic fatty liver disease activity score
NASH non-alcoholic steatohepatitis
NFS non-alcoholic fatty liver disease fibrosis score
PHL potential Hy’s Law
PK pharmacokinetic(s)
QTcF Fridericia -corrected QT interval
RTSM randomization and trial supply management
SAE serious adverse event 
SAP statistical analysis plan
Clinical Study Protocol -3.[ADDRESS_796039] upper limit of normal
WOCBP wom en of childbearing potential
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 119of 129Appendix IProtocol Version History
The Summary  of Changes T able for the current revisio n is located di rectly before the T able of 
Contents.
Clinical Study Protocol Version 2
Overall Rationale for the Amendment:
Text revisio ns result ing from this amendment are incorporated in the body  of Protocol  
Amendment 2. The principal reason for this amendment is to address feedback from the FDA  
on the study  protocol  in its ent irety including revisio n of the study  design of  Part A to rem ove 
the 36-week ex tension period. The primary  intent for the [ADDRESS_796040] addit ional co mparat ive safet y data, especially  cardi ovascular events; however, 
with only 300 parti cipants, i t is unlikely that a significant number of cardiovascul ar events 
woul d be observed during the extensio n peri od. The 36 -week extensio n was also removed to 
enable full read out and closure of Part A prior to read out of Part B. This will further help 
delineate the Phase IIb portion from the Phase III portion of the trial. The amendment also 
includes other changes aimed at clearer articulat ion of inclusio n/exclusion criteria and 
potenti al operati onal simplifications, both based on feedback from study  invest igators.
Substant ial changes to the protocol are summarize d below .
Section # and Name [CONTACT_601102] 1.1 (Synopsis), Section 1.2 
(Schema), Table 5 (Part A Schedule 
of Activities), Section 4.1.1 (Part A 
Overall Design), Section 4.1.3 
(Adaptation Considerations and 
Dose Selection in Part B), Section 
[IP_ADDRESS] (Unblinding for Part A 
Analy sis), Section [IP_ADDRESS] 
(Unblinding for Part B Analysis), 
Section 9.4.1 (General 
Considerations), Section [IP_ADDRESS] 
(Possible Adaptations for Part B), 
Section 9.5 (Interim Analysis)• Rem oved the 36 -week extension in Part A because it is unlikely 
that a significant number of cardiovascular events would be 
observed during the extension period. 
• Rem oved the interim analysis from the study because the Week 
48 analysis of Part A will now b e a complete analysis of the Part 
A data after database lock. Text on adaptive actions resulting 
from analysis of Part A has been moved from Section 9.5 (Interim 
Analy sis) to Section [IP_ADDRESS] (Possible Adaptations for Part B).
• Adjusted wording on blinding o f Part A because of the 
elimination of the 36 -week extension. After database lock, sites, 
participants, and sponsor will be unblinded.
Section 1.1 (Synopsis), Section 5.1 
(Inclusion Criteria), Section 8.1.1 
(Liver Biopsy -based 
Histopathology)Updated the timeframe for historical biopsy in the inclusion criteria so 
that it is o nly defined from the time of randomization to provide 
clarity . 
Section 1.1 (Synopsis), Section 4.1 
(Overall Design), Section 9.2 
(Sample Size Determination)The estimate d number of participants to be screened was increased 
from [ADDRESS_796041] updated estimate of the screen failure rate. 
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 120of 129Section # and Name [CONTACT_601102] 1.1 (Synopsis), Section 
9.4.1 (General Considerations)• The strategy for the primary estimand of histology endpoints was 
clarified to be a hybrid of the treatment policy and composite 
strategies.
• The strategy for intercurrent events for liver outcomes was 
clarified. 
Section 1.3.1 (Schedule of 
Activities: Screening), Table 6 (Part 
B Schedule of Activities), Section 
3.2 (Objectives and Endpoints Part 
B), Section [IP_ADDRESS] Rationale for 
Explo ratory  Endpoints, Section 5.1 
(Inclusion Criteria), Section 7.1 
(Discontinuation of Study 
Intervention), Section 8.1.3 
(MRE/MRI)The substudy in Part B to assess endpoints using MRI, MRE , and 
abdominal ultrasound was removed to enhance operational feasibility 
of the study and focus on the primary objectives. The abdominal 
ultrasound is replaced by [CONTACT_601099], which will provide a more 
thorough knowledge base than performing ultrasounds in a sub 
populatio n.
Section 1.3.1 (Schedule of 
Activities: Screening), Section 8.2.5 
(Clinical Safety Laboratory 
Assessments)Rem oved assessment of blood alcohol at screening. Alcohol 
dependence will be based on urine ethanol drug screen and AUDIT 
questionnaire, which determines participant eligibility over the past [ADDRESS_796042], which only reflects recent alcohol 
consumption.
Section 1.3.1 (Schedule of 
Activities: Screening)• Descriptio n of the timing of the biopsy and collection of tissue 
from a historical biopsy were edited to clarify that tissue must be 
sent for central evaluation at least 21 days from planned 
randomization to allow enough time for histopathology 
assessment.
• Clarified that on -study biopsy tissue must be submitted to the 
central histopathology review laboratory at least 21 days prior to 
planned randomization. 
Section 1.3.1 (Schedule of 
Activities: Screening), Table 5 (Part 
A Schedule of A ctivities), Table 6 
(Part B Schedule of Activities), 
Section 6.2 
(Preparation/Handling/Storage/Acc
ountability)Edited to allow training activities related to subcutaneous 
administration to be completed on Visit 2 (randomization day) to allow 
more flexibili ty to sites and participants. 
Section 1.3.1 (Schedule of 
Activities: Screening), Table 5 (Part 
A Schedule of Activities), Table 6 
(Part B Schedule of Activities), 
Section 3.1 (Objectives and 
Endpoints: Part A), Section 3.2 
(Objectives and Endpoints: Part B), 
Section [IP_ADDRESS] (Rationale for 
Explo ratory  Endpoints); Section 
8.1.8 (Exploratory Biomarker 
Assessments)Reduced the list of exploratory biomarkers to be assessed to reduce the 
blood volume required for study participants. The study will still retain 
optional serum samples for exploratory purposes, and therefore 
additional biomarker analysis can be conducted post hoc. 
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 121of 129Section # and Name [CONTACT_601102] 1.3.1 (Schedule of 
Activities: Screening), Table 5 (Part 
A Schedule of Activities), Table 6 
(Part B Schedule of Activities), 
Section 8.1.3 (Fibroscan)• Clarified that FibroScan and FAST score assessment are only 
required at sites with so ftware and probes and for participants 
who do not have a historical FibroScan within 90 days. 
• Added that FibroScan assessment must be conducted in a fasted 
state. 
• Clarified FibroScan visit windows. 
Section 1.3.1 (Schedule of 
Activities: Screening)Chan ged the requirement for discussion of alternative pre -biopsy 
screening strategy with sponsor to a recommendation to allow more 
flexibility. 
Table 5 (Part A Schedule of 
Activities) Clarified that participants who discontinue study intervention and have 
an early  discontinuatio n visit in Part A should also have a follow -up 
visit 4 weeks later.
Table 5 (Part A Schedule of 
Activities), Table 6 (Part B 
Schedule of Activities)Added a review of adherence to diet and lifestyle advice to Visit 9 and 
Visit 11 for both Part A and Part B to ensure consistency with Section 
5.3.1 (Diet and Lifestyle Education).
Table 5 (Part A Schedule of 
Activities), Table 6 (Part B 
Schedule of Activities), Section 
8.5.2 (Collection of Optional 
Biomarker Samples)Rem oved optional biomarker plasma collection to reduce blood 
volume and burden on participants. 
Table 5 (Part A Schedule of 
Activities), Table 6 (Part B 
Schedule of Activities)Added text describing scheduling of Visit 2 (randomization) to clarify 
that t he visit can occur after confirmation that the participant meets all 
eligibility criteria. 
Table 5 (Part A Schedule of 
Activities), Table 6 (Part B 
Schedule of Activities), Section 7.1 
(Discontinuation of Study 
Intervention) Rem oved the requirement for conducting a biopsy at the early 
discontinuation visit for participants who discontinue study 
interventio n; instead, participants will be encouraged to have the 
biopsy at Week 48 (Part A) or Week 84 (Part B) but can have the 
biopsy at early discontinuation if they are unwilling or unable to wait 
until Week 48 (Part A) or Week 84 (Part B). 
Table 5 (Part A Schedule of 
Activities), Table 6 (Part B 
Schedule of Activities)• Edited the footnote on ADA follow -up to note that monitoring is 
required only for partic ipants with titer ≥30 at the Follow -Up 
visit for consistency with FDA recommendations. 
• Provided additional guidance for handling of ADA monitoring for 
participants who still meet the criteria [ADDRESS_796043] IP 
dose. 
Table 6 (Part B Schedule o f 
Activities)Added confirmation of fasting at EOT in Part B to ensure collection of 
the optional biomarker sample in fasted state.
Table 6 (Part B Schedule of 
Activities)Added 2 additional ECG timepoints to Part B (Visit 9 and Visit 11) for 
alignment wi th Part A. 
Table 6 (Part B Schedule of 
Activities)Rem oved the urine pregnancy test in Part B at Visit 12 and added 
assessment at V14. 
Table 6 (Part B Schedule of 
Activities)• Added assessment of calcitonin at EOT in Part B for consistency 
with Part A.
• Rem oved assessment of calcitonin at visits between Week [ADDRESS_796044] an administrative error. 
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 122of 129Section # and Name [CONTACT_601105] 6 (Part B Schedule of 
Activities)Edited the schedule of activities to note that a follow -up visit should be 
conducted for all participants in Pa rt B, regardless of whether their 
previous visit for EOT or E/D or whether they discontinued study 
interventio n but remained in the study. 
Section 3.1 (Objectives and 
Endpoints: Part A)Added an exploratory objective and endpoint to Part A and Part B to 
assess improvements in other histological features of NASH including 
portal inflammation.
Section 4.4 (End of Study 
Definitio n)Added FDA and EU definitions of the end of study to align with 
sponsor template. 
Section 5.2 (Exclusion Criteria) Added evidence of portal hypertension to the exclusion criterion on 
hepatic decompensation to provide further clarification on the 
definition. 
Section 5.2 (Exclusion Criteria); 
Appendix GDefinitio n of alcohol unit was updated to use local regulations be cause 
the definition of a standard drink varies across countries/regions. 
Section 5.2 (Exclusion Criteria) To align with Table 13 (Prohibited Medications), edited the criterion 
on weight loss medications so that they are not allowed even with 
stable use.
Section 5.2 (Exclusion Criteria) Added a total bilirubin cut -off for participants with Gilbert’s syndrome 
to the exclusion criteria.
Section 5.4 (Screen Failures) • Added more laboratory tests that can be retested without 
rescreening to reduce burden on investigators and participants.
• Clarified that an on -study biopsy for participants being rescreened 
must occur at least 180 days from the date of the previous biopsy 
and o nly once the participant has met all other eligibility criteria 
and completed other s creening requirements.
Section 6.5.2 (Prohibited 
Concomitant Medications)• Added herbal preparations with any suspected hepatotoxicity to 
the list of prohibited concomitant medications. 
• Added that starting new herbal preparations or dietary 
supplements is not allowed once screening activities are initiated. 
Section [IP_ADDRESS] (Therapi[INVESTIGATOR_601039] 2 Diabetes 
Mellitus)Provided additional guidance on insulin dose to clarify that minimal 
change (≤ 20%) to the total daily insulin dose within the 90 -day period 
prior to screening will not be considered exclusionary
Section 6.6 (Dose Modification) • Clarified that participants should discontinue treatment either 
because they are unable to successfully uptitrate to 200 µg or 
because their dose needs to be reduced below 200 µg. 
• Added a sentence stating that the lowest dose of IP allowed for a 
participant to continue in the study is 200 µg to provide further 
clarificatio n. 
Section 6.7 (Missed Dose) Clarified IP compliance and criteria for defining IP -related important 
protocol deviation. 
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 123of 129Section # and Name [CONTACT_601102] 6.8 (Treatment of 
Overdose) (previously Section 8.4), 
Section 8.3.9 (Reporting of Serious 
Adverse Events), Section 8.3.12 
(Medication Error, D rug Abuse, and 
Drug Misuse), Appendix B4Updated sections on overdose, drug abuse, and drug misuse and on 
reporting of serious adverse events to align with sponsor template 
language. Text on actions to take in the event of an overdose was 
added.
Section 6 .8 (Treatment of 
Overdose)The time frame for the definition of an overdose was changed from 
24hours to one calendar day to avoid reporting an overdose if the 
second dose is given slightly less than [ADDRESS_796045]. 
Section 7.1 (Discontinuation of 
Study Intervention)Corrected the guidance on early discontinuation visits due to the 
removal of the extension period from Part A and clarified that the early 
discontinuation visit is to be conducted for participants who 
discontinue study intervention early.
Section 8.2.1 (Medical History) Added collection of gallbladder disease history to Medical History 
because gallbladder -related disease was added as an adverse event of 
special interest.
Section 8.2.5 (Clinical Safety 
Laborato ry Assessments)• Added red cell distribution width and red blood cell morphology 
to reflect that these are part of the standard complete blood count 
panel. 
• Follicle -stimulating hormone was added to Section 8.2.5 (Clinical 
Safety Laboratory Assessments) to support assessment of 
menopausal status for inclusion criterion 5. 
• Added direct bilirubin to the list of additional laboratory 
assessments in participants with Gilbert’s syndrome.
Section 8.3.6 (Adverse Events of 
Special Interest)Added gallbladder -related disease to the list of AESIs because 
gallbladder disease has been associated with the use of GLP -1 receptor 
agonists.
Section 8.3.10 (Clinical Events for 
Adjudication)• Added CV deaths parenthetically after all deaths for consistency 
with MACE endpoint.
• Edited the wording on the clinical event for adjudication related 
to heart failure. This adjudication endpoint was streamlined to 
hospi[INVESTIGATOR_601040]. 
• Edited a footnote in Figure 2 and Figure 3 to clarify the definition 
of baseline pretreatment ALT for management of possible drug -
induced liver injury. 
• Added a cross reference to Appendix E (Actions Required in 
Cases of Increases in Liver Biochemistry and Evaluation of Hy’s 
Law) for clarification. 
Section 8. 8(Mobile Software 
Applications[s])Rem oved the section on software applications because the study will 
no lo nger use a digital support system. 
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 124of 129Section # and Name [CONTACT_601102] 9.3 (Populations for 
Analy ses), Section 9.4.3 (Safety)Changed the definition of the Safety Population to majority of 
estimated usage to minimize potential bias in estimated rates of AEs 
based on exposure, w hile rely ing on objective and programmable 
criteria. Participants receiving the wrong treatment will be analyzed 
according to the actual trea tment (majority treatment received) and 
randomized dose level (to avoid bias in assigning participants with 
tolerability issues prior to reaching a 400 μg dose to the 300 μg 
analy sis arm).
Section [IP_ADDRESS] (Secondary 
Endpoint[s])• Primary  analy sis of progre ssion to cirrhosis will use multiple 
imputation (placebo washout) to provide more realistic estimates 
of cirrhosis progression rates by [CONTACT_601100]. Because progression 
to cirrhosis may not be very common (especially compared to the 
degree of missing data), results using non -responder imputation 
for missing data would be difficult to interpret for this endpoint, 
while multiple imputation will better estimate the progression 
rates.
• Clarified that binary endpoints will utilize a composite strategy 
for intercurrent events of liver outcomes. 
Section [IP_ADDRESS] (Multiplicity Plan) Multiplicity strategy for Part B was changed to allow for the possibility 
of reaching statistical significance in 600 μg se condary endpoint 
analy ses without necessarily reaching significance for the 300 μg 
primary endpoint analy ses, while still controlling the familywise Type 
I erro r. 
Appendix A1 (Regulatory and 
Ethical Considerations), Appendix 
A6 (Dissemination of Clinical
Study Data)Updated sections on regulatory reporting requirements for serious 
breaches and dissemination of clinical study data to align with sponsor 
template language. 
Nonsubstant ial changes to the protocol are summarized below.
Section # and Name [CONTACT_601102] 1.1 (Synopsis) The number of evaluable participants was removed for clarity because 
it is the same as the number of randomized participants. 
Section 1.1 (Synopsis), Section 4.1 
(Overall Design)Corrected the description of the study population to include the upper 
limit of the age range. 
Section 1.1 (Synopsis), Section 3.1 
(Objectives and Endpoints: Part A), 
Section 3.2 (Objectives and 
Endpoints: Part B)Minor clarifications to the safety endpo ints to align with planned 
analy ses. 
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 125of 129Section # and Name [CONTACT_601102] 1.3 (Schedule of Activities: 
Screening), Table 5 (Part A 
Schedule of Activities), Table 6 
(Part B Schedule of Activities), 
Section 8.2.4 (Electrocardiograms)• ECG -related footnote was added to the schedule of activities for 
the treatment period of Part B for consistency with the schedule 
of activities for the treatment period of Part A. 
• The rest period was updated to 10 minutes in the footnotes and in 
Section 8 .2.4 (Electrocardiograms) to correct an administrative 
error.
• Greater detail regarding triplicate ECG procedures in Part A was 
added. 
• Guidance for ECG device malfunction was added. 
Table 5 (Part A Schedule of 
Activities)Clarification to note that V11 i s also the EOT visit for Part A.
Section 2.1 (Study Rationale) • Changed the length of the PROXYMO study treatment period 
from [ADDRESS_796046] an administrative error. 
• Changed ALT to AST to correct a typographical error.
Table 5 (Part A Schedule of 
Activities), Table 6 (Part B 
Schedule of Activities), Section 
[IP_ADDRESS] (Rationale for Exploratory 
Endpoints), Section 8.1 (Efficacy 
Assessments)Added controlled attenuation parameter to the schedule of activities 
and the description of efficacy assessm ents to align with the endpoint 
related to FibroScan for Part A and Part B.
Section 3.1 (Objectives and 
Endpoints: Part A), Section 3.2 
(Objectives and Endpoints: Part B), 
Section [IP_ADDRESS] (Rationale for 
Explo ratory  Endpoints)Added C -Peptide to the explo ratory  biomarker endpoints to correct an 
administrative error.  
Section 3.3 (Estimands) Added a description of the estimands to Section 3 (Objectives and 
Endpoints) to align with sponsor template. 
Section 4.1.2 (Part B Overall 
Design)Clarified that pa rticipants will remain on study intervention until the 
end of treatment visit ,not the common study end date. 
Section 5.1 (Inclusion Criteria) • Clarified that there are no contraceptive requirements for male 
participants. 
• Original protocol stated that women must use one highly effective 
form of birth control. Clarified that women must use at least one 
highly  effective method of birth control.
Section 5.2 (Exclusion Criteria) Added the albumin cut -off value in units (g/L) used by [CONTACT_328501]. 
Section 6.1.1 (Investigational 
Products)Additions were made to the description of the investigational products 
to improve clarity on number of doses and instructions for use.
Section 6.1.2 (Medical Devices) Updated the ECG device model.
Section 6.2 
(Preparation/Handling/Storage/ 
Accountability)• Updated the location of the guidance for final disposition of 
unused study intervention to correct an administrative error.
• Rem oved sharps containers from list of supplies provided to 
participants that need to be returned. Clarified that sharps 
containers are provided to participants for safe needle disposal.
• Added cooling bags to the list of items supplied by [CONTACT_456].
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 126of 129Section # and Name [CONTACT_601102] 6.5.3 (Management of 
Nausea and Vomiting)Added the class of medication (anti -histamine) for cyclizine for 
consistency with other medications listed. 
Section 7.2 (Participant Withdrawal 
from the Study)• For clarity, removed text on early discontinuation t hat was 
inconsistent with other sections of the protocol. 
Section 8.1.1 (Liver Biopsy -based 
Histopathology)• Added the early discontinuation visit as a timepoint for biopsy for 
consistency with the Schedule of Activities. 
Section 8.1.2 (Artificial 
Intelligence -based Histopathology)• Added literature references for AI histopathology read. 
• Rem oved reference to the Histopathology Manual in Section 
8.1.2 (Artificial Intelligence -based Histopathology) because the 
manual does not have information on artif icial intelligence -based 
read.
Section 8.2.3 (Vital Signs) Corrected the timing of the initial blood pressure from baseline to 
screening and clarified that the selection of the arm to use for readings 
through the study should be based on the systolic bloo d pressure. 
Appendix A6 (Dissemination of 
Clinical Study Data)Edited for clarity and consistency with terminology used elsewhere in 
the protocol. 
Clinical Study Protocol -3.[ADDRESS_796047], in obese or overweight patients with ty pe 2 
diabetes: a randomised, controlled, double- blind, ascending dose and phase 2a study . Lancet. 
2018;391([ZIP_CODE]):2607-18.
Angulo 2007
Angulo P . GI epi [INVESTIGATOR_82331]: Non -alcoho lic fatty liver disease. Aliment Pharmaco l Ther .
2007;25(8):883 -9.
Angulo et al 2015
Angulo P , Kleiner DE, Dam -Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P , et 
al. Liver fibrosis, but no other histologic features, associates w ith long-term outcomes of 
patients wi th nonalcoholic fatty  liver disease. Gastroenterology .2015;149(2):389 -97.
Armstrong et al 2016
Armstrong MJ, Gaunt P , Aithal GP , Barton D, Hull D, Parker R ,et al. Liraglutide safet y and 
efficacy in pat ients with non-alcoho lic steatohepatitis (LEAN): a mult icentre, double -blind, 
rando mised, placebo -controlled phase 2 study . Lancet. 2016;387([ZIP_CODE]):679 -90.
Bellentani et al 2010
Bellentani S, Scaglio ni F, Marino M, Bedogni G. Epi[INVESTIGATOR_601041]-alcoho lic fatty liver 
disease. Di g Dis. 2010;28(1):155-61.
Boland et al 2020
Boland ML, Laker RC, Mather K, Nawrocki A, Oldham S, Boland BB, et al. Resolut ion of 
NASH and hepatic fibrosis by  [CONTACT_17978] -1R/GcgR dual -agonist cotaduti de via modulat ing 
mitochondrial funct ion and lipogenes is. Nat Metab. 2020;2(5):413 -31. 
Bosch et al 2021
Bosche J, Chung C, Carrasco -Zevallo s OM, Harrison SA, Abdelmalek MF , et al . A machine 
learning approach to liver histo logical evaluation predicts clinically significant portal 
hypertensio n in NASH cirrhosi s. Hepatol . 2021;74(6):3146 -60. 
Cholankeril et al 2017
Cholankeril G, Patel  R, Khurana S, Satapathy  SK. Hepatocellular carcino ma in non-alcoho lic 
steatohepatit is: Current knowledge and implicat ions for m anagement. W orld J Hepatol . 
2017;9(11):533 -43.
Dulai et al 2017
Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Y ounossi Z, et al. Increased risk o f mortalit y 
by [CONTACT_601057] s stage in non -alcoho lic fatty liver di sease: System atic review and meta -analysis. 
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 128of 129Hepatology . 2017;65(5):1557- 65. 
Estes et al 2018
Estes C , Razavi H, Loomba R, Y ounossi  Z, Sanyal AJ. Modeling the epi[INVESTIGATOR_601042] o f disease. Hepatol ogy. 
2018;67(1):123 -133.
Inker et al 2021
Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y . New creatinine -and 
cystati n c-based equations to estimate GFR without race. N Eng J Med. 
2021;385(19):1737 -49. 
Harrison et al 2019
Harrison SA, Bashir MR, Guy  CD, Zhou R, Moylan CA, Frias JP , et al . Resmet irom (MGL -
3196) for the treatmen t of non-alcoho lic steatohepatit is: a mult icentre, randomised, double -
blind, pl acebo -controlled, phase 2 trial. Lancet. 2019;394([ZIP_CODE]):2012-24.
Marra et al 2013
Marra F1, Lotersztajn S. Pathophysio logy of NASH: perspectives for a targeted treatment. 
Curr Pharm Des. 2013;19(29):5250-69.
Mishra and Younossi 2012
Mishra A, Younossi  ZM. Epi [INVESTIGATOR_601043]-alcoho lic fatty liver 
disease. J Clin Exp Hepatol. 2012;2(2):135 -44.
Nahra et al 2021
Nahra R, W ang T , Gadde KM, Oscarsson J, Stumvoll M, Jermutus L, et al. Effects of 
cotaduti de on m etabo lic and hepat ic parameters in adults with overweight or obesit y and ty pe 
2 diabetes: A 54-week rando mized phase 2b study . Diabetes Care. 2021;44(6):1433 -42. 
Nalbantoglu and Brunt 2014
Nalbantoglu I, Brunt EM. Role of liver biopsy in nonalcoho lic fatty liver di sease. W orld J 
Gastroenterol. 2014;20(27):9026 -37. 
Neuschwander -Tetri 2017
Neuschwander -Tetri. Non -alcoho lic fatty liver di sease. BMC Med. 2017;15:45.
Newsome et al 2021
Newso me PH, Buchho ltz K, Cusi K, Linder M, Okanoue T , Ratziu V , et al . A placebo -
controlled trial o f subcutaneous semaglut ide in nonalcoho lic steatohepatit is. N Engl J Med. 
2021;384(12):1113 -24.
Pais et al 2016
Pais R, Barri tt AS 4th, Calmus Y , Scatton O, Runge T , et al. NAFLD and liver transplantation: 
Clinical Study Protocol -3.0 [COMPANY_008]
Cotadutide -D5671C00006 15 May  2023
CONFIDENTIAL AND PROPRIETARY 129of 129Current burden and expected challenges. J Hepatol. 2016;65(6):1245- 1257.
Petit et al [ADDRESS_796048] of 
liraglutide therapy  on liver fat content in patients with inadequately  controlled ty pe 2 diabetes: 
The Lira -NAFLD study . J Clin Endocrinol  Metab. 2017;102(2):407-15.
Regev et al 2019
Regev A, Palmer M, A vigan MI, Dimick -Santos L, Treem WR, Marcinak JF ,et al. Conse nsus: 
guidelines: best practices for detection, assessment and management of suspected acute drug -
induced liver injury  during clinical tri als in pat ients with nonalcoholic steatohepatit is. Aliment 
Pharmaco l Ther . 2019;49:702-13.
Taylor -Weiner et al 2021
Taylor-Weiner A, Pokkalla H, Han L, Jia C, Huss R, et al. A machine learning approach 
enables quantitative measurement of liver histology and disease monitoring in NASH. 
Hepatol. 2021;74(1):[ADDRESS_796049] rapi [INVESTIGATOR_601044] U.S. 
Hepatology . 2014;59(6):2188-95.
Younossi et al 2016
Younossi ZM, Koenig AB, Abdelat if D, Fazel Y , Henry  L, Wymer M. Gl obal epi[INVESTIGATOR_601045] -Meta -analyt ic assessment of prevalence, incidence, and 
outcom es. Hepatol ogy. 2016;64(1):73 -84.
6,*1$785(3$*(
7KLVLVDUHSUHVHQWDWLRQRIDQHOHFWURQLFUHFRUGWKDWZDVVLJQH G
HOHFWURQLFDOO\DQGWKLVSDJHLVWKHPDQLIHVWDWLRQRIWKHHOHFWU RQLFVLJQDWXUH
'RFXPHQW1DPH GFFVSY
'RFXPHQW7LWOH '&&OLQLFDO6WXG\3URWRFROYHUVLRQ
'RFXPHQW,' 'RF,'
9HUVLRQ/DEHO &855(17/$7(67$[ZIP_CODE]('
6HUYHU'DWH
GG000\\\\++PPµ87&¶=6LJQHGE\ 0HDQLQJRI6LJQDWXUH
&RQWHQW$SSURYDO
&RQWHQW$SSURYDO
0DQDJHPHQW$SSURYDO
1RWHV'RFXPHQWGHWDLOVDVVWRUHGLQ$1*(/DQ$VWUD=HQHFD GRFXPHQWPDQDJHPHQWV\VWHP[COMPANY_003]
[COMPANY_003]
[COMPANY_003][COMPANY_003]
[COMPANY_003]
[COMPANY_003]